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ABSTRACT 
Immunoglobulins are large multi-domain and multi-functional proteins that are increasingly 
being developed as biologic drugs to bind to a wide variety of therapeutic targets. The 
immunoglobulin G1 class of molecules represents the largest class of therapeutic monoclonal 
antibodies (mAbs) currently under preclinical and clinical development. One of the major 
challenges in developing antibodies as drugs is their physical instability caused by various 
processing, storage and handling related stresses which can lead to aggregation and loss of 
efficacy.  Immunoglobulins are dynamic molecules whose motions are important for their 
biological function and stability. It is currently difficult to predict the effects of minor process or 
formulation changes on the higher order structure and dynamics of mAbs using currently 
available analytical techniques. Hence new analytical techniques are needed to better understand 
the effects of such changes on the structure and dynamics of mAbs, especially within 
pharmaceutical dosage forms containing excipients. This dissertation work explored the effects 
of certain pharmaceutical excipients and three sodium salts from the Hofmeister series on the 
changes in thermal stability, storage stability and local dynamics of an IgG1 mAb. Changes in 
local dynamics of the mAb were explored at peptide level resolution using hydrogen-deuterium 
exchange mass spectrometry. Preliminary correlations were established between changes in 
dynamics of particular segments in the CH2 domain of the IgG1 mAb and decreased thermal 
stability as well as higher aggregation propensity of the IgG1 mAb in presence of destabilizing 
excipients and salts. This dissertation work also explored the mechanism behind the relative 
decrease in physical stability due to YTE (M255Y/S257T/T259E) triple mutation in the CH2 
domain of a different IgG1 mAb (that was shown in previous work to result in extended in-vivo 
half-life due to changes in interaction with FcRn receptors). The YTE mutation induced 
iv 
 
decreases in physical stability of the IgG1 mAb which correlated with changes in local dynamics 
of the same particular segment in the CH2 domain described above in the presence of 
destabilizing excipients and salts. Hence, changes in dynamics of specific local segments within 
the CH2 domain of IgG1 mAbs identified in this work may serve as a general indicator for 
changes in physical stability for other IgG mAb drug products. By better understanding the root 
causes of mAb physical destabilization, more rational design of antibody formulations and/or 
protein engineering approaches are now possible to improve the pharmaceutical stability 
properties of mAbs. 
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Chapter 1 
 
Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for 
stabilization and formulation development of therapeutic monoclonal antibodies 
 
  
2 
 
1.1 Introduction 
The IgG class of monoclonal antibodies (mAbs) represents the largest category of 
therapeutic protein candidates under clinical development.
1,2
  Antibodies are dynamic molecules 
with internal motions that are important for their biological function and stability. Monoclonal 
antibodies (mAbs) are large, multi-domain and multi-functional proteins that can be engineered 
to bind to a variety of therapeutic targets. An IgG molecule consists of two antigen binding (Fab) 
regions, each containing a constant and variable domain from both the light and heavy chain, in 
the form of two arms attached by a proline-rich hinge region to the constant (Fc) region. The Fc 
region contains two constant Ig domains from each of two heavy chains including an N-linked 
glycosylation site. The Fc region is responsible for non-antigen binding biological activity and 
maintaining in vivo half-life. These regions are potentially flexible structures that lead to a wide 
range of possible conformations for IgG molecules. Dynamic motions of antibodies include 
whole molecule tumbling, rocking and breathing motions along with bending, flexing and 
rotational motions of the Fab arms around the hinge region.
3-6
 However, the inter-relationships 
between regional and local dynamic motions and protein conformational stability are complex 
and is an active area of research.
7
  
Therapeutic proteins such as mAbs are exposed to various environmental stresses during 
manufacturing, storage, and administration that can cause physical and chemical degradation. 
Hence, robust formulation strategies are needed to impart maximal stability to these proteins and 
to minimize degradation during long term storage (e.g., across the shelf life).  From a 
pharmaceutical development perspective, it is also a major challenge to predict the effects of 
product or process changes on the higher-order structure and long term stability of mAb drug 
products as part of comparability assessments.
8
  One recent trend in the formulation development 
3 
 
field is to explore the interrelationships between antibody dynamics, conformational stability, 
and pharmaceutical stability.
7,9-13
 If direct relationships can be established between these 
variables, these relationships can lead to a better understanding of the implications of process 
and product changes on protein stability.  This, in turn, would inform the design of improved 
mAb proteins and their formulations. 
The global dynamics of monoclonal antibodies have been studied by various techniques 
such as high resolution ultrasonic spectroscopy, pressure perturbation calorimetry, red edge 
excitation shifts and time correlated single photon counting.
7,9,14
 Data visualization tools such as 
empirical phase diagrams have been used to compare changes to the dynamic states of antibodies 
as a function of solution pH and temperature.
10
  In addition, classical biophysical techniques such 
as circular dichroism, fluorescence spectroscopy, ultraviolet absorption spectroscopy, Fourier 
transform infrared spectroscopy and light scattering have been widely used to characterize the 
higher-order structural integrity and conformational stability of proteins.
15
 These biophysical 
methods provide global information about the overall dynamics and conformational stability of 
proteins.  
One disadvantage of measuring global dynamics of antibodies is that there can be small-
scale, local changes in dynamics due to a variety of factors that may go undetected when 
averaged across the entire molecule.
12
 However, one or a few such local changes in dynamics 
may be important for the stability or biological functions of an antibody. Hence, higher 
resolution analytical techniques capable of detecting and localizing small scale changes in 
dynamics in an antibody are important for a more comprehensive assessment of changes in 
protein dynamics and stability. Two well-established high resolution techniques that have 
previously been used to investigate local structural changes in smaller therapeutic proteins are 
4 
 
nuclear magnetic resonance (NMR) spectroscopy
16,17
 and X-ray crystallography
18,19
.  Although 
great advances have been made in terms of applicability of these techniques to pharmaceutical 
development, practical limitations remain for the analysis of structural dynamics of an entire 
monoclonal antibody molecule under formulation conditions.  For example, some of the 
challenges in NMR analysis of mAbs are the requirement for isotopic labelling (
15
N, 
13
C, or 
19
F) 
of the mAb and the difficulty of spectral crowding due to the large size of mAbs. X-ray 
crystallography data may not necessarily reflect antibody dynamics in complex solution buffers 
and the technique requires the generation of antibody crystals, which can sometimes be difficult 
to produce. Temperature factors for individual residues can be obtained as a measure of 
flexibility but are again limited to the solid state. Thus, there is a need for faster and more 
practical, higher resolution analytical techniques that are sensitive enough to detect changes in 
local structural dynamics in antibody molecules formulated in pharmaceutical dosage forms 
containing a wide range of protein concentrations and stabilizing excipients.  
Hydrogen-deuterium exchange coupled to mass spectrometry (H/D-MS) potentially 
addresses this need.
20
 This method utilizes the variable exchange rates of amide hydrogens along 
the protein backbone to provide information about the local dynamics of a protein. 
Hydrogen/deuterium exchange in proteins was first studied using gravimetric techniques by 
Hvidt and Linderstrom-Lang in the 1950s.
21
 Since then molecular sieve chromatography in 
tritiated water as well as several spectroscopic techniques such as infrared spectroscopy,
22
 
NMR,
23,24
 and most recently mass spectrometry
25,26
 have been used to measure hydrogen 
exchange kinetics in proteins.  H/D-MS has shown promising results for analysis of dynamics of 
large proteins such as IgG antibodies with high sensitivity, low sample requirements and the 
ability to analyze proteins in complex formulation buffers.
12,13,20,27
 Protease digestion using an 
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acid resistant protease such as pepsin along with reduction of disulfide bonds at low pH has 
enabled peptide level analysis of mAb structure at a resolution of 5-20 amino acids.
26
  
There has been a steady growth in the last five years in the number of reports describing 
the use of H/D-MS to explore dynamics of monoclonal antibodies and antibody fragments. For 
example, H/D-MS has recently been used to assess changes in higher order structure of mAbs as 
a result of deglycosylation,
20
 freeze-thaw and thermal processing,
28
 chemical modifications,
29,30
 
post-translational modifications,
27
 formulating with pharmaceutical excipients and salts from the 
Hofmeister series,
12,13
 targeted mutations,
31,32
 and drug conjugation to free inter-chain cysteine 
residues
33
. This chapter summarizes the use of H/D-MS technique in advancing our 
understanding of the role of local dynamics in modulating antibody physical stability and 
implications for stabilization and formulation development of therapeutic mAbs. 
1.2 Fundamentals of amide hydrogen exchange in proteins 
When a protein is incubated in D2O, its labile hydrogens will exchange with the solvent 
deuterium.  There is nearly instantaneous exchange with deuterium by amine, carboxyl, and 
hydroxyl groups of amino acid residues, but these sites readily revert to hydrogen upon exposure 
to H2O during LC separation (see below).  In contrast, the amide hydrogens of the polypeptide 
backbone exchange much more slowly at rates strongly influenced by the folded structure of the 
protein.
21,34-37
 Amide hydrogens within the folded β-sandwich structure of Ig domains that are 
solvent shielded and strongly hydrogen bonded to neighboring hydrogen bond acceptors are 
expected to exchange slowly. In contrast, the amide hydrogens on the surface or in the 
unstructured loop regions of an antibody that are solvent exposed and weakly hydrogen bonded 
are expected to exchange faster. The fastest exchanging amide hydrogens in a mAb can 
exchange in milliseconds at physiological pH
38,39
 while the slowest exchanging amide hydrogen 
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may take many months to exchange because the central domain regions of mAbs are known to 
have a tightly folded and stable structure. Hence the difference in observed rates of deuterium 
exchange can provide valuable information about the local structure and dynamics of proteins 
such as mAbs.  
Amide H/D exchange in the absence of any higher order structure is referred to as 
intrinsic or chemical exchange (i.e., kch in equations 1-4). The rate of intrinsic exchange
40-42
 can 
be expressed as  
ch 3 2[H O ] [OH ] [H O]A B Wk k k k
                                                                                (1) 
where kA, kB and kW are the rate constants for acid-, base- and water-catalyzed amide deuterium 
exchange reactions. The rate of intrinsic exchange is strongly influenced by solution pH, 
temperature, neighboring side chains and solution components such as salts.
38,39
 The intrinsic 
exchange rate is predominantly base-catalyzed above pH 3.0 and predominantly acid-catalyzed 
below pH 2.3. Moving away from the minimum at a pH of approximately 2.5, the rate increases 
ten-fold for every unit of pH increase.  A temperature increase of ~ 22 °C has a similar effect.
43
 
Proteins are known to exist as an ensemble of interconverting conformations in 
solution,
44-46
 and each amide hydrogen may therefore exist in folded and unfolded conformations 
at any point in time. Amide hydrogen exchange by folded proteins can be described by one of 
two distinct models:  the two-process model and the local unfolding model. The two-process 
model,
37
 proposes that amides in both folded and unfolded states can exchange.  Amides in the 
folded state exchange due to very small-scale fluctuations in the protein’s native state. These 
fluctuations, though small, are sufficient to bring solvent and catalyst (OD
-
 under physiological 
conditions) to the amide. Amides in globally unfolded states can also exchange. Hence, under the 
two-process model, the observed exchange rate (kobs) for individual amide hydrogens in a protein 
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would be a sum of the exchange rate contributions from its folded (kf) and unfolded (ku) forms
47
 
as shown in Equation 2.  
 obs f u u chk k k K k                                                                                            (2) 
Here  represent the probability of exchange from the folded state that is influenced by the 
strength of hydrogen bonding and solvent accessibility. Ku is the equilibrium rate constant for 
unfolding. kch is the chemical exchange rate constant for the particular amide hydrogen in the 
absence of any form of higher order protein structure (equation 1).  
In contrast, the local unfolding model
48
 proposes that the protein transiently occupies a locally 
unfolded state that fully exposes the amide to solvent and catalyst. The mechanism is illustrated 
in Equation 3. Breathing motions in proteins can transiently break amide hydrogen bonds in the 
folded state (NHcl) allowing access of the catalyst (OD
–
 under physiological conditions) to the 
open backbone amide hydrogens in a locally unfolded conformation (NHop).    
1 1ch
1 1
cl op op clOD
NH NH ND ND
k kk
k k

 
                                 (3) 
1
obs ch op ch
1
k
k k K k
k
                                                                       (4) 
The observed rate of exchange, as illustrated in Equation 3, depends on the dynamic equilibrium 
(Kop) between the open and closed H-bonded states and on the rate of intrinsic exchange (kch). 
The mechanism for exchange may not be universal for all amide hydrogens in a protein and can 
vary for individual amide hydrogens depending upon local fluctuation or unfolding reactions that 
present the individual amide hydrogen in the exchange competent state.
36
  Furthermore, the 
mechanisms described here apply to proteins that undergo two-state unfolding. If there are long-
lived unfolding intermediates in proteins, then their role would also need to be considered for a 
detailed mechanistic understanding of the observed deuterium exchange. 
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Under the local unfolding model, when kch>>k-1, the intrinsic exchange step is rate-
limiting.  This mechanism is referred to as the EX1 limit. EX1 exchange is often interpreted as 
evidence that deuterium exchange proceeds through global or subglobal unfolding of the protein. 
Although only a few proteins exchange by an EX1 mechanism under native conditions,
49
 many 
proteins can be induced to undergo deuterium exchange by an EX1 mechanism by exposing the 
protein to denaturants.
50
  Under native conditions, most proteins undergo exchange under the 
limit k-1>>kch, known as the EX2 limit.  This kinetic limit implies that the opening and closing of 
a H-bond occurs many times before a successful deuterium chemical exchange. Deuterium 
exchange under the two types of kinetic regimes can easily be distinguished experimentally by 
their unique peptide mass spectral signatures.
51
 Under the EX2 exchange regime, a gradual 
increase in m/z of a peptide segment can be seen with increasing deuterium exposure. Upon EX1 
exchange, two distinct spectral envelopes can be seen on the m/z scale. 
49
 
1.3 Description of the H/D-MS method applied to monoclonal antibodies 
H/D exchange experiments are typically performed to compare the effects of two or more 
conditions that can alter the local conformational dynamics of mAbs (e.g., physicochemical 
modifications, addition of perturbants, alteration of solution conditions, protein-protein or 
protein-ligand interactions, etc.). Protein amide hydrogen exchange reactions are typically 
performed at neutral or near-neutral pH for different lengths of time in either a continuous 
labeling protocol or for a single interval of time in a pulsed labeling experiment.  In either case, a 
stock solution of protein, in H2O solution, is rapidly diluted with a large excess of a D2O solution 
to initiate exchange. After a predefined period of exchange, the H/D exchange reaction is 
quenched by reducing the pH to around 2.5 and lowering the temperature to ~0 ºC where the 
intrinsic exchange rate is at a minimum. The half-life of intrinsic exchange under these quench 
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conditions is approximately 5000-fold slower than typical labeling conditions, pH 6.5 at 22 °C. 
In a continuous labeling experiment, the incorporation of deuterium into the protein is followed 
as a function of time by measuring deuterium uptake intervals in response to external 
perturbants.
52
  In a pulsed labeling experiment, the interval of exposure to D2O is fixed. In the 
case of a rapid pulse (μsec – msec), such as in a protein refolding experiment, two or more 
distinct protein populations that are either folded, unfolded, or partially folded in response to the 
perturbant can be detected.
53
 Continuous labeling experiments are used more widely than pulsed 
labeling primarily because the labeling time where differences will be most apparent between 
protein states can be difficult to predict a priori.  Thus, casting a broad net of widely-spaced 
labeling times, typically spanning a range between ~10
1
 and ~10
5
 seconds (i.e., over ~1 day), 
maximizes the probability of detecting differences between two protein states. When another 
experimental parameter such as ligand or perturbant concentration is varied, pulsed labeling is 
often used. 
1.3.1 Automated sample preparation and data acquisition  
A schematic representation of a typical H/D-MS experimental workflow to analyze the 
local dynamics of a mAb is shown in Figure 1.1. In the first step, the H/D exchange reaction is 
initiated by mixing mAb stock solution (panel A) in an excess of deuterated formulation buffer at 
a precisely regulated temperature (ideally ± 0.1 °C). The deuterated solution can contain 
excipients whose concentrations should be adjusted such that the mixed mAb-labeling buffer 
solution contains the same formulation composition that is used in parallel for mAb 
conformational and pharmaceutical stability studies. The only difference is that D2O has replaced 
H2O. Excipients containing exchangeable hydrogens such as sugars or amino acids either need to 
be deuterated beforehand, or the number of exchangeable hydrogens needs to be accounted for 
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while preparing deuterated buffers to maintain uniform deuterium content across all conditions 
being compared.
13
 Moreover, the pH of all deuterated buffers should be carefully checked and 
reported either directly from a pH meter or after correction for the deuterium isotope effect.
54
 
Since the formulation components are subsequently washed out during LC-MS analysis, there is 
no limitation on their use with a few notable exceptions. For example, surfactants such 
polysorbates should not be included in the deuterium labeling buffer, or ideally even the protein 
stock solution, since they are difficult to remove from reversed-phase columns and traps and 
even trace amounts tend to suppress ionization at the ESI source of mass spectrometers. A recent 
report, however, describes a removal technique for non-ionic surfactants prior to MS analysis 
that is compatible with H/D-MS workflow.
55
  
The deuterium labeling continues for various times usually ranging from a few tens of 
seconds to many hours. Since mAbs are well-folded proteins, some regions of a mAb may not be 
fully deuterated even after a day of incubation in deuterated buffers at room temperature.
12,13
 In 
the second step of Figure 1.1, mAb H/D exchange labeling (panel B) is quenched by reducing the 
pH of the final mixture to 2.5 by addition of concentrated acid such as hydrochloric, 
trifluoroacetic, or formic acids or a strong buffer such as phosphate. The temperature of the 
mixture is also lowered to ~ 0 °C. A denaturing agent (ex. guanidine HCl ~ 4 M for mAbs) and a 
reducing agent (ex. TCEP ~ 0.5 M for mAbs) are also included in the acidic quench buffer to 
unfold the mAb and rapidly reduce the disulfide bonds.  
All of these steps are best accomplished with robotic autosamplers (such as the HDX-
PAL from LEAP Technologies, NC) now widely used for protein H/D exchange sample 
preparation. These devices feature at least two independently temperature-controlled drawers, 
one for labeling (variable temperature) and the other for quenching (usually held just above 0 
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°C).  Typically, each drawer can hold several trays containing 50-100 individual 0.5-2 mL 
autosampler vials. One tray each is used to hold vials containing the mAb stock solution, the 
deuterated labeling buffers, the labeling vials, and the quench buffer. Precise mixing and transfer 
of solutions from one vial to another are achieved by robotically controlled syringes. The 
quenched mAb solution is injected into a sample loop housed inside a refrigerated column 
compartment. The software that handles such autosamplers is capable of precisely performing 
any sequence of events for sample preparation such as syringe cleaning, dispensing protein into a 
vial, adding D2O label, mixing, waiting for preset amounts of labeling time, transferring solution 
to a different vial containing quench solution, injection into the LC loop, and sending the signal 
to the LC-MS to start sample analysis. A schedule is built by the software that optimizes the time 
management during various steps of sample preparation thereby ensuring that the labeling for a 
comparatively long deuteration time point is started before initiating the labeling of a much 
shorter time point.   
In the third step of Figure 1.1, the quenched, reduced, and denatured mAb (panel C) is 
digested using an acid resistant protease with high activity, the most popular being pepsin. This 
is achieved using a loading pump to carry the mAb sample from the sample loop, through an 
immobilized protease column
56,57
 , and then onto a reversed-phase peptide trap for concentration 
and desalting. Digestion with an immobilized pepsin column offers higher efficiency of digestion 
than in-solution digestion.
56
 Typically, mAbs are completely digested during an approximately 
one minute passage through an immobilized pepsin column. A disadvantage of non-specific 
proteases is that they tend to produce many more peptides than specific proteases; the resulting 
peptides often have overlapping cleavage sites. However, reproducible digestion conditions yield 
reproducible peptide maps.
58
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In the fourth step of Figure 1.1, a gradient pump (HPLC or UHPLC) is used to elute the 
peptides (panel D) from the trap, through a reversed phase column for peptide separation, and 
into a mass spectrometer for peptide mass analysis. The valves, columns, and tubing are housed 
inside a refrigerated compartment maintained at ~ 0 °C. The mAb sample digestion, trapping, 
separation and elution are achieved using precooled (~ 0 °C) mobile phase at pH ~ 2.5 (e.g., 0.1 
vol% formic acid has a pH of 2.5). The low temperature and pH ~ 2.5 throughout pepsin 
digestion, peptide trapping, and separation minimize peptide back-exchange, i.e. amide D to H 
conversion, during sample analysis. Following data acquisition by the mass spectrometer, the 
raw data for all peptides, as shown in the representative example in panel E, are provided in the 
form of a total ion chromatogram (TIC) which is a plot of ion count vs. retention time and mass 
spectra in the form of ion counts vs. mass to charge ratio (m/z). 
Several experimental challenges are commonly faced during method development for the 
third and fourth steps.  One such problem is resistance of a particular mAb towards pepsin 
digestion at 0 °C. In such cases, mAb digestion efficiency can be increased by increasing the 
temperature of the immobilized pepsin column either by placing it outside the refrigerated box at 
room temperature or placing it inside a protease column oven inside the refrigerated box.
59
 
However, increasing the temperature of the solution during pepsin digestion will lead to faster 
peptide back-exchange.  
Another common challenge is carry-over of peptic peptides. Carry-over here refers to 
appearance of peptic peptides in subsequent blank LC runs following a sample injection.  Carry-
over is particularly problematic in H/D-MS measurements because the carried-over peptides 
undergo nearly complete back-exchange between LC-MS injections. Thus these carried-over 
peptides will appear as undeuterated features in subsequent LC-MS runs.
60
  Carry-over can arise 
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from either the pepsin column
61
 or the reversed-phase trap and column.
60
 Although an 
immobilized pepsin column offers better digestion efficiency than in-solution digestion, pepsin 
columns can also give rise to carry-over problems.
61
 Wash cocktails may be required to 
minimize carry-over originating from mAb digestion using an immobilized protease column; 
these solutions are designed to remove retained peptides while not degrading the enzymatic 
activity of the pepsin enzyme.
61
 In the fourth step, as shown in Figure 1.1, reversed-phase HPLC 
separation of hundreds of mAb peptic peptides is typically carried out using a steep gradient of 
acetonitrile over 5-10 min to minimize back-exchange. This type of gradient is unlike routine 
peptide mapping used for mAbs, where gradients are much shallower. Steep gradients increase 
the chance of carry-over on the trap and column.  Hence, the chromatography cycle might 
require additional wash cycles at the end of the gradient to clean the reversed phase column to 
minimize carry-over.
60
  
Several experimental parameters discussed earlier determine the total amount of back-
exchange after quenching the H/D exchange reaction and during LC-MS analysis. Back-
exchange levels, when reported, usually vary between 5 and 40% depending on the peptide 
sequence.
12,27,59
 Higher deuterium loss may be unacceptable because valuable information about 
protein dynamics embedded in the amount of deuterium attached to amide nitrogen atoms may 
be lost. Back-exchange correction to normalize exchange to 100% can be applied by measuring 
back-exchange levels of fully deuterated mAb peptides under identical experimental conditions 
to the mAb H/D-MS experiments. The corrected average number of deuterons (D0) gained by a 
peptide segment during an H/D exchange experiment is  
0%
0
100% 0%
m m
D X N
m m



                      (5) 
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where m0%, m, and m100% denote the centroid m/z values of the undeuterated, partially deuterated, 
and fully deuterated peptide segment, respectively, and N denotes the number of exchangeable 
amide hydrogens.
26
 Other approaches to correct for back-exchange include the use of reference 
peptides or internal standards to correct for deuterium loss.
62
 Correcting for back exchange, 
however, seems to offer only modest benefit.  In practice, back-exchange is often monitored but 
not corrected for if the levels are within an acceptable range, since many H/D-MS experiments 
with mAbs compare two or more conditions “head to head”.  Thus, the compared peptides 
generated from the mAb will have the same back-exchange levels and relative comparisons can 
be made without corrections.  
1.3.2 H/D-MS Data Analysis  
H/D exchange data analysis is illustrated schematically in Figure 1.2. In the first step, the raw 
LC-MS data (panel A) is processed to develop a peptic peptide map (panel B) for the mAb, 
ideally with high sequence coverage across all regions. The peptides from pepsin digestion are 
generally identified using a combination of accurate mass measurements and peptide 
fragmentation-based tandem MS measurements. Medium and high resolution mass spectrometers 
such as time-of-flight, quadrupole-time-of-flight, ion cyclotron resonance (ICR), or orbitrap 
mass spectrometers are beneficial for H/D exchange measurements because of their ability to 
resolve the isotopic structure of highly-charged ions and because of their high mass accuracy. It 
should be noted that the spectra of peptides that elute at nearly identical retention time and very 
close m/z values tend to partly or fully overlap upon deuteration. An additional benefit of high-
resolution mass analyzers is their ability to resolve partially overlapping isotope profiles.   
Some peptides may lose MS signal intensity due to ion suppression. If spectral quality is 
poor, such peptides get excluded from later steps of H/D-MS data processing. It is therefore 
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beneficial to have a fairly large number of redundant peptides (e.g., greater than 200 peptides for 
a mAb) with overlapping sequence and high total primary sequence coverage (> 95%) when 
constructing the initial peptide map in the first step. This helps to preserve relatively high 
primary sequence coverage across all regions at the end of H/D-MS data processing (for 
example, >85-90% coverage with ~100-200 peptides). High sequence coverage allows analysis 
of H/D exchange data for the majority of the protein’s primary sequence. Moreover, it is typical 
to have peptides spanning 3 to 25 residues in the peptide map. Peptides larger than ~30 residues 
are less useful because the spatial resolution is poor. At the end of the first step (shown in Panel 
B), peptide retention time, mass and/or sequence are tabulated for all of the peptic peptides of the 
mAb that will be used in the peptide map. 
The second step of data processing involves identification of deuterated peptides based 
on the retention time of the undeuterated peptide and range of possible m/z values. As shown in 
panel C of Figure 1.2, individual peptide spectra stacked with increasing deuterium exposure 
times show EX2 kinetics, i.e., a gradual shift of the spectral envelop towards higher m/z values 
(peptides that exhibit EX1 kinetics will have a biomodal profile.)
49
 In the third step, the average 
masses of the deuterated peptide segments are calculated after peak picking (as shown by red 
dots in panel D) across the expected m/z range and retention time window. The second and third 
steps are generally accomplished using software specifically designed for H/D exchange mass 
spectrometry. Available software options include commercial products such as HDExaminer 
(Sierra Analytics) and DynamX (Waters), and free software such as HDX-Analyzer
63
, HX-
Express,
64
 Hydra
65
 and HDX WorkBench
66
, some of which are also open-source. Programs such 
as DynamX are compatible with LC-MS data from one vendor only.  Programs such as 
HDExaminer read all common vendor formats and other programs like Hydra read open-source 
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data formats such as mzXML, making all of these compatible with data from multiple types of 
instruments. In general, the information required for processing H/D-MS data are a list of 
peptides, retention times, and the sequence of the protein. The LC-MS data files need to be 
uploaded to the software along with assignment of labeling times for each data file.  While most 
MS measurements of peptides focus on the monoisotopic peak, incorporation of deuterium 
obscures this feature, as shown in panel C of Figure 1.2.  For this reason, the average or centroid 
m/z value of peptide isotopic clusters is measured:  
i
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                                                                                                                                  (6) 
where    represents the spectral intensity of the ith channel in the peptide spectrum, averaged 
across the chromatographic band.  
 Although the peak picking feature is fully automated in most software packages, all of 
them allow some level of manual peak picking or manual adjustment of the retention time 
window and isotopic envelope used for centroid m/z calculation. These features allow an analyst 
to correct processing errors. In a typical H/D-MS workflow, a large number of peptides are 
separated chromatographically in a relatively short time window (usually 5-10 min). Hence there 
is always a possibility that two or more peptides with similar m/z will co-elute. The result is 
totally or partially overlapped mass spectra. Although software can usually identify such cases of 
spectral overlap using a scoring algorithm, they are in practice not completely reliable. Hence, as 
shown in the fourth step of Figure 1.2, the data must be inspected and curated by experts in order 
to have full confidence in peak picking and centroid m/z calculation for all peptides. Curating the 
data generally involves peptide retention time alignment to get better matching of calculated and 
observed mass spectra and exclusion of peptides that have spectral overlap or poor spectral 
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quality. It should be noted that many of the peptides that are excluded during manual curation of 
the data can be detected reliably and reproducibly in the undeuterated sample. Exclusion of 
peptides from the data set during H/D exchange data processing may lead to lower mAb 
sequence coverage compared to the initial peptide map of the mAb. The mass increase values 
(panel E) for each peptide segment are automatically calculated. In the fifth step, the mass 
increase values for each peptide are plotted (panel F) corresponding to predefined deuterium 
exposure times or displayed as a deuteration percent heat map using the protein sequence. 
Ultimately, the goal in most H/D exchange efforts is to identify specific peptides that 
exhibit altered H/D exchange in response to some change in the protein or its solution conditions.  
To identify significant changes, statistical analysis usually needs to be performed.  A complete 
review of all the statistical approaches used is beyond the scope of this chapter.  Some examples 
include the use of pair-wise t tests,
67
  analysis of covariance, 
63
 and Tukey’s test for multiple 
comparisons.
68
 The method outlined by Houde et. al.
67
 to assess comparability of mAb local 
dynamics in multiple formulations or different processing conditions is illustrated in Figure 1.3. 
In the first step, variances in replicate measurements of deuterium uptake (Panel A) are pooled to 
define a confidence interval at the desired level (e.g., 99%) for significant differences in 
deuterium incorporation in a specific peptide segment at a certain deuterium exposure time. First, 
the 99
th
 percentile (or another confidence level) of variance is determined (s99%
2
).  Next, random 
error propagation is applied to estimate the 99% confidence interval for a deuterium uptake 
difference between two conditions, for example one test formulation and a control formulation:  
sCI
2
 = s99%
2
 + s99%
2
 .  This method was used in our laboratories to compare the effects of different 
excipients and salts on the local dynamics of an IgG1 mAb.
12,13
 Panel B in Figure 1.3 shows the 
deuterium uptake differences between two conditions plotted as bar charts and the 99% 
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confidence interval as dotted lines. Mass difference values exceeding the 99% confidence 
interval are regarded as significant. 
To better visualize differences in deuterium uptake across the ~100-200 individual 
peptides from the mAb, the significant differences can be qualitatively mapped (third step in 
Figure 1.3) onto a homology model (Panel C in Figure 1.3) based on a known X-ray crystal 
structure.  A simple mAb homology model can be obtained by simply aligning the mAb 
sequence against the solved mAb structure.  Homology models for mAbs can also be prepared 
using software such as Modeller
69
 (freely available) or Discovery Studio (commercially available 
from Accelrys, San Diego, CA). In case of significant differences between the sequence of the 
specific mAb being analyzed and the sequence of the antibody in the homology model, structure 
prediction features available in these programs can be used to address the gaps. These programs 
first thread the primary sequence of the mAb onto the structure of a homologous mAb or 
structures of separated Fab and Fc domains that can then be ligated. The programs then use some 
form of energy minimization to optimize the structure of the homology model.  Readjustments 
can be made to correct for missing sequence or secondary structure.
13
 Homology models may be 
displayed in PyMOL or similar modeling software to denote segments that exhibit changes in 
deuterium uptake.  
1.4 Case studies of the application of H/D-MS to formulation development of mAbs  
Monoclonal antibodies share high sequence similarity within an immunoglobulin 
subclass, yet they can have dramatically different physical and chemical stability properties 
unique to a specific mAb. Hence individual formulation strategies are needed to address different 
types of physical and chemical instabilities observed for different mAbs formulated in various 
dosage forms.
70
 Stabilization strategies depend on an assessment of the impact of degradation 
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pathways on the structural integrity, stability and biological activity of a mAb.  Experimentally, 
this often includes forced degradation studies as well as accelerated and long-term stability 
studies. However, standard quality control assays and lower resolution biophysical techniques 
are not always capable of detecting subtle changes in the higher order structure and local 
dynamics of mAbs, and hence may be limited in their ability to monitor and predict the ability of 
different formulations to provide long-term stability of therapeutic mAbs.  
H/D-MS is emerging as a promising new analytical tool to explore the effect of chemical 
and physical modifications on the local structural dynamics of mAbs. Changes in local dynamics 
may better correlate with the short-term or long-term pharmaceutical stability of some or perhaps 
many different mAbs than data obtained from other biophysical measurements. Alterations in 
mAb local dynamics can therefore be of interest during many aspects of pharmaceutical 
development including elucidating degradation pathways, designing stable formulations, 
assessing biopharmaceutical comparability due to process or product changes,
67
 and potentially 
assessing mechanisms of self-association and high viscosity in certain mAbs.
71
 Here we review 
the application of H/D-MS to formulation development of mAbs by exploring the effects of 
chemical modifications, environmental stresses, and formulation additives on the local dynamics 
of IgG1 mAbs and their interrelationships with conformational and pharmaceutical stability.  
1.4.1 Impact of chemical modifications on mAb local dynamics.  
A typical IgG1 monoclonal antibody is made up of approximately 1300 amino acid 
residues, along with post translational modifications such as glycans attached at a specific 
asparagine in the CH2 domain. The result is a heterogeneous mixture of glycoforms with an 
average molecular weight around 150 kDa. Only a few of the twenty naturally-occurring amino 
acid residues are commonly prone to chemical modifications under conditions routinely 
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encountered during protein production, purification, long-term storage and administration.
72
 The 
effects of methionine oxidation, asparagine deamidation, and aspartic acid isomerization on mAb 
higher order structure and dynamics have been studied using H/D-MS and are discussed in the 
following paragraphs. Many other chemical modifications are possible in mAbs and need to be 
considered including light and free radical induced tryptophan and histidine oxidations (and their 
related byproducts),
73
 C-terminal lysine cleavage, N-terminal pyroglumate formation, hinge 
region fragmentation, and proteolysis.
72
 However, these modifications are not the focus of this 
chapter as we are not aware of any published literature to-date studying the effect of these 
modifications on mAb’s higher order structure and dynamics using H/D-MS. While the impact 
of other chemical modifications such as deglycosylation,
20
 cytotoxic drug conjugation to free 
cysteines,
33
 and amino acid substitutions
31,32
 on the higher order structure and dynamics of mAbs 
have been explored using H/D-MS, they are also outside the scope of this chapter which focuses 
on stabilization and formulation development of “standard” therapeutic mAbs. 
For Met oxidation, Asn deamidation and Asp isomerization, the probability and extent of 
occurrence of these chemical modifications can be dependent on the presence of specific 
neighboring amino acids (e.g., NG motif for deamidation and DG motif for Asp isomerization), 
location within the protein’s higher order structure, solution pH and temperature as well as 
formulation composition. It is common to accumulate small fractions of these modifications in 
mAb drug products during manufacturing and long-term storage. The impact of these 
modifications on the higher order structure, conformational dynamics, and pharmaceutical 
properties (stability as well as functional attributes such as antigen binding or Fc effector 
functions) of the mAb drug product varies with the specific antibody, its mechanism of action, 
and the location of the modified amino acid residue within the mAb. For example, two specific 
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methionine residues, Met 257 in the CH2 domain and Met 433 in the CH3 domain, located in the 
Fc region and conserved across all human IgG1 and IgG2 mAbs, have been found to have a 
much higher propensity towards oxidation compared to other methionine residues located in 
other regions of mAbs.
29,30
 Furthermore, oxidation of these two methionine residues has been 
shown to result in decreased FcRn binding,
74,75
 protein A binding,
74
 in vivo half-life,
76
 thermal 
stability,
77
 and increased aggregation propensity.
27
  
For experimental purposes, methionine oxidation can be induced under accelerated 
conditions by adding a molar excess of hydrogen peroxide followed by incubation for a few 
hours.
77
 The impact of methionine oxidation on the conformational dynamics of six different 
IgG1 mAbs has been studied by H/D-MS in three different laboratories.
27,30,77
 All the studies 
reported increased deuterium uptake in an eleven residue segment (FLFPPKPKDTL) located 
immediately before Met 257. The numbering of the residues varies slightly across studies due to 
differences in total number of amino acids in the specific IgG1 mAbs used in these studies.
27,30,77
 
Figure 1.4 A shows increased deuterium uptake in this peptide segment (HC 246-256) in the 
form of the H/D exchange mass difference plots for the mAb heavy chain as described in the 
previous section of this chapter.
77
 The mAb light chain did not show any difference in H/D 
exchange kinetics (Figure 1.4 B). Similar results for the HC 246-256 segment due to methionine 
oxidation were also reported for five other IgG1 mAbs by Zhang et. al.,
77
 Houde et. al.
27
 and 
Burkitt et. al.
30
  In one of these studies, Zhang et. al.
77
 used structural modeling to better 
understand local environments of Met 257 and Met 433. As illustrated in Figure 1.4 C, D, and E, 
it was found that these two methionine residues are closely packed in 3D space allowing 
hydrophobic interactions between the two methionine residues thereby stabilizing the local 
conformation as well as the CH2-CH3 interface.
77
 Oxidation increases the distance between the 
22 
 
two sulfur atoms of the methionine residues, thereby disrupting the hydrophobic packing and 
increasing local dynamics. Segments in the CH2-CH3 interface also exchanged faster in oxidized 
mAbs, although the extent of exchange was lower than the segment adjacent to Met 257. Hence 
H/D-MS was successfully used to identify perturbations in local dynamics due to methionine 
oxidation in IgG1 mAbs that may be the underlying mechanism behind changes in mAb physical 
stability or receptor binding.  
Asn deamidation and Asp isomerization can result in formation of aspartate and 
isoaspartate through a succinimide intermediate, and in contrast to methionine oxidation, have 
been found to occur at multiple locations within mAbs.
78
  Deamidation and isomerization in two 
CDR locations within the variable domains of certain mAbs, i.e. Asn 55
79
 and Asp 102
80
, 
respectively, have been shown to decrease antigen binding depending on the location of the 
amino acid residue in the CDR. However, deamidation of Asn residues located in constant 
domains (Asn 389 and Asn 434) did not affect Fc receptor binding.
81
 The impact of these 
modifications on local dynamics of an IgG1 mAb was studied by H/D-MS recently by Zhang et. 
al.
77
 Various pH and temperature stresses were used to initiate deamidation and isomerization 
reactions in mAb samples which were then analyzed by H/D-MS experiments. Significant 
deamidation was detected at Asn 389 and isomerization was detected at Asp 55 and Asp 104. 
The mAb used in this work had Asp 55
77
 in CDR 2 as opposed to Asn 55 residue.
79
  H/D-MS 
experiments revealed no significant differences in local dynamics between the native mAb and 
either deamidated or isomerized mAb samples, likely because only a small fraction of mAbs 
underwent deamidation and isomerization at these sites. Since the observed kinetics of H/D 
exchange are essentially a weighted average of all protein forms present in solution, enriched 
fractions of deamidated and isomerized species of a mAb would need to be generated and/or 
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isolated to more fully assess the effects of these modifications on mAb structural dynamics. 
However, subtle changes in deuterium uptake compared to the control were observed in peptide 
segments covering Asp 55 and Asp 104 where the succinimide intermediate formed. 
1.4.2 Impact of environmental stresses on mAb local dynamics. 
Antibody drugs may be exposed to a variety of environmental stresses during processing 
such as freeze-thaw, elevated temperatures, pH changes, and agitation. These stresses may 
generate variable amounts and types of protein aggregates. For example, elevated temperature or 
agitation stress have been shown to induce aggregation by Fab-Fab interaction
82,83
 while pH 
changes may induce aggregation by Fc-Fc interaction.
82
 The aggregates formed by different 
conditions may thus contain protein molecules which have different types of structures which in 
turn may affect their immunogenic potential.
84
 High-resolution analytical techniques such as 
H/D-MS may be valuable tools for deciphering the alterations in higher-order structure and 
dynamics of protein molecules found in process-induced mAb aggregates.  For example, H/D-
MS has been used to explore changes in the structural dynamics of Bevacizumab (Avastin) 
aggregates induced by both freeze/thaw cycles and by exposure to high temperature.
28
   
Thermally-induced Bevacizumab aggregates were produced by incubation at 70 °C for 10 
min and then isolated by centrifugation. The thermally induced aggregates showed widely 
different dynamics by HD-MS analysis, primarily in the Fab region compared to the control. 
Figure 1.5 shows a summary of the deuterium incorporation kinetics in the light chain (A) and 
the heavy chain (B) of both thermally-induced mAb aggregates and in the native mAb. Widely 
different deuteration rates were observed in the Fab region of aggregated IgG, primarily showing 
increased deuterium uptake across most regions of the Fab, but resulting in decreased deuteration 
in three segments of the CDRs (LC 48-54, HC 27-35, and HC 54-64). Only one segment in the 
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Fc region of the aggregated mAb (HC 430-452) had increased deuteration while the rest of the 
peptide segments from the Fc region were unaffected. Previous studies indicated the critical role 
of the Fab region in thermally-induced mAb aggregation by correlating Fab thermal stability with 
molecular aggregation propensity
85
 and by correlating similarities observed in aggregation 
behavior between intact mAbs and isolated Fab fragments.
82,83
 The H/D exchange data in this 
case study revealed substantial changes in local structural dynamics of the Fab portion only in 
mAb aggregates, thereby demonstrating the critical role of the Fab in thermally-induced mAb 
aggregation. Furthermore, the exchange protected segments in the CDRs of aggregated 
Bevacizumab are probably the locations of intermolecular contacts in the thermally-induced 
aggregates.
86
 Extensive structural perturbations in thermally-induced aggregates detected by 
H/D-MS are consistent with a dramatic increase in the intensity and red-shift of intrinsic 
tryptophan fluorescence and by increased intensity and blue-shift of ANS fluorescence in the 
same mAb aggregates.
28
 
In contrast to thermally induced aggregates, isolated aggregates of Bevacizumab 
produced by up to 30 freeze/thaw cycles showed little change in H/D kinetics.
28
  In this case, 
there was also no appreciable change in intrinsic tryptophan fluorescence or ANS fluorescence 
between the freeze-thaw induced aggregate and the control mAb. Results from H/D-MS analysis 
in this study correlated well with fluorescence measurements, and the fluorescence results were 
consistent with observations in a complementary freeze-thaw and thermally-induced aggregate 
study with another mAb.
83
 
As an additional example, dimers produced during production and storage of two 
different IgG1 mAbs were analyzed using H/D-MS and complimentary biophysical tools.
87
  One 
of the mAb dimers showed no difference in local structural dynamics by H/D-MS but differential 
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scanning calorimetry (DSC) analysis indicated a decrease in thermal stability of the CH2 domain 
and small angle x-ray solution scattering (SAXS) analysis indicated a heterogeneous mixture of 
dimer species in solution. Since H/D-MS did not detect differences in the mAb aggregate, the 
authors concluded that the structural changes were mediated by the amino acid side chains. In the 
other mAb dimer, H/D-MS detected significant differences in the CH2 domain where more 
protection against exchange in the hinge region as well as less protection in a segment adjacent 
to the hinge region were observed in the dimer compared to native mAb. Biophysical 
measurements suggested that a collection of mechanisms including disulfide scrambling, domain 
swapping and surface interactions can play important roles in dimerization of the mAb. Hence 
complimentary biophysical tools may be valuable to help interpret or extrapolate the results 
obtained from H/D-MS experiments to better understand the degradation pathways leading to 
formation of aggregated mAbs. 
1.4.3 Impact of formulation additives on mAb local dynamics, conformational stability and 
aggregation. 
Since mAbs are prone to physical and/or chemical degradation due to various stress 
conditions, a variety of pharmaceutical excipients (such as buffering agents, sugars, sugar 
alcohols, surfactants, amino acids, salts, etc.) are routinely introduced into protein formulations 
to increase the solubility and/or stability during manufacturing, storage, distribution and 
administration.
88
 The various mechanisms by which these excipients and salts interact with 
and/or stabilize proteins at the molecular level are an area of active investigation.
88-91
 The 
identification of pharmaceutical excipients to stabilize mAb drugs during long term storage is 
often empirically determined. This is reflected in the wide spread interest in using high 
throughput screening technologies to identify stabilizing agents as part of protein formulation 
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development.
92,93
 Each class and type of excipient, along with their combinations, are generally 
evaluated for their ability to protect a mAb against physicochemical degradation pathways 
leading to inactivation and loss of potency specific to each mAb. By utilizing higher resolution 
analytical techniques, an improved mechanistic understanding of how different excipients can 
affect the pharmaceutical stability of multi-domain proteins such as mAbs is expected, and thus, 
more rationale strategies can be developed to design excipient mixtures to provide stable mAb 
formulations.  
To this end, recent work in our laboratories has explored the inter-relationships of 
pharmaceutical excipients, physical stability and local dynamics in an IgG1 mAb.
12,13
 Arginine 
and sucrose were used as model excipients, while salts from the Hofmeister series (sodium salts 
of sulfate, chloride and thiocyanate) were also examined. The conformational stability of the 
mAb in different formulations was monitored using the thermal melting onset temperature and 
three different melting transitions obtained from DSC. The rate of aggregate formation was 
measured by size exclusion chromatography (SEC) following incubation at various temperatures. 
While both sucrose (0.5 M) and sodium sulfate (0.5 M) increased the conformational stability of 
the mAb as evidenced by DSC (Tm values), sucrose increased the Tonset temperature and sulfate 
decreased it.  Both sucrose and sulfate slowed the rate of mAb monomer loss during storage as 
measured by SEC. Sucrose addition resulted in formation of soluble aggregates while sulfate led 
to formation of both soluble and insoluble aggregates. In contrast, arginine (0.5 M) moderately 
and sodium thiocyanate (0.5 M) substantially decreased the mAb's conformational stability as is 
evident from the decrease in Tm and Tonset values. The largest effects were observed for Tm1 
which corresponds to thermal unfolding of the CH2 domain.
94
  Both arginine and thiocyanate 
increased the rate of mAb aggregation as measured by monomer loss including elevated levels of 
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predominantly insoluble aggregate formation over time.  These destabilizing effects on the IgG1 
mAb were much more prominent in the presence of thiocyanate than arginine. 
H/D-MS analysis of the IgG1 mAb in the presence of these additives was then 
performed. Figure 1.6 A is a summary of the changes in deuterium uptake observed by various 
peptide segments across the IgG1 mAb in the presence of the five different additives compared 
to the control (0.1 M NaCl in 20 mM citrate phosphate at pH 6.0) at four deuterium exchange 
times (120, 10
3
, 10
4
, and 10
5
 s). The vertical axes in these plots indicate deuterium uptake 
differences for each peptide segment when the mAb was labeled in the presence of an excipient 
compared to the control condition. The horizontal axes indicate the ordinal peptide number 
arranged in ascending order from the N to C terminus of the protein based on the peptide 
midpoint. The domain locations of the peptides are indicated at the top of the plots. A positive 
difference in Figure 1.6 A indicates increased H/D exchange while a negative difference 
indicates decreased exchange by a peptide in the presence of the two excipients or three different 
salts. Only differences that exceed the 99% confidence interval indicated by the dotted lines in 
the difference charts are considered to be significant. These significant changes in dynamics are 
colored in yellow, for faster exchange, or blue, for slower exchange, in each of the corresponding 
mAb homology models shown in Figure 1.6 B.  
Deuterium exchange experiments in the presence of 0.5 M sucrose revealed a global 
trend of small decreases in local dynamics across most regions of the mAb as shown in the mass 
difference charts for sucrose in Figure 1.6 A. Individually, the small decreases in dynamics were 
generally not statistically significant vs. the 99% CI, but collectively show a global trend which 
supports the preferential exclusion mechanism by which certain additives are believed to 
stabilize proteins in solution.
95,96
 For example, sugars have been shown to be preferentially 
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excluded from a protein’s surface thus increasing the chemical potential of the solution. In 
response to this thermodynamically unfavorable condition, proteins adopt smaller, more compact 
structures to decrease the relative surface area exposure (compared to unfolded forms of the 
protein). The H/D exchange results in this work with 0.5 M sucrose and 0.5 M NaCl are 
consistent with this model of global protein structural rigidification caused by preferential 
hydration due to addition of certain excipients to the protein solution. Sodium sulfate, on the 
other hand, even though it was observed to physically stabilize the mAb, increased the dynamics 
of local segments in the CH1, CL, VH and VL domains of the mAb (Figure 1.6 A and B). Thus its 
stabilizing effects on the mAb are likely due to a different mechanism. These two stabilizers did 
not cause any consensus change in any segment of the IgG1 mAb in terms of local dynamics of 
the amide backbone which points to the varying mechanisms by which sucrose and sulfate 
interact with and stabilize proteins. However, both sulfate and sucrose shared a common feature 
in terms of their effects on the local dynamics of this IgG1: both additives did not affect the local 
flexibility of the CH2 domain of the mAb. The importance of this observation is described below.     
The destabilizing additives, arginine and thiocyanate, significantly increased the local 
dynamics of specific segments of the mAb. Effects of arginine on local dynamics were found to 
be limited to only a few segments of the mAb, while thiocyanate increased dynamics of several 
segments from all domains. Although arginine and thiocyanate seemed to have differential 
effects at various regions of the mAb, both substantially increased the dynamics of the 241-251 
segment of the heavy chain in the CH2 domain. This effect is evident from the mass increase of 
several overlapping peptide segments representing this common segment (Figure 1.6 A and B). 
These results indicate that local dynamics of key regions within the CH2 domain correlate well 
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with the observed overall physical stability of this IgG1 mAb in the presence of the excipients 
and salts used in these studies.
12,13
  
1.5 Aggregation hotspot identification in mAbs using H/D-MS 
Antibody aggregation is a complex, multi-step process that results in formation of soluble 
or insoluble aggregates of varying sizes containing protein with varying levels of structural 
alterations.
97
 Aggregation of mAbs can proceed via several different mechanisms depending on 
factors such as the structural integrity of the protein, effective charge of the protein, nature of 
protein-protein interactions, colloidal properties of the protein solution, and the type of 
environmental stress (e.g., heat, agitation, freeze-thaw).
98
  While each mAb has its unique CDRs 
that can contribute to aggregation, the sequence of the constant domains in the Fab and Fc regions 
are highly similar across one source and class of antibody (e.g., human IgG1). Hence there could 
be more “universal” aggregation-prone sequences in the constant domains that affect mAb 
stability across one source and class of antibodies, e.g., human IgG1 mAbs.
99
   
Despite the heterogeneous nature of protein aggregates, their formation proceeds via 
some common steps as illustrated in Figure 1.7 A (from Roberts and Sahin, 2011). These steps 
are (i) a certain degree of structural alteration of the protein monomer (F) to reversible 
intermediate (R), (ii) reversible self-association of the partially unfolded monomers (R) to an 
oligomeric Rx species, and (iii) conformational rearrangement of reversible species to form 
irreversible intermolecular associations that act as the aggregating nucleus (Ax).
98,100
 Detection 
of these reversibly conformationally altered species remains an important analytical challenge 
for the better understanding of aggregation pathways. Recent work with the molecular chaperone 
protein GroEL linked to biolayer interferometry biosensors has shown the capability to trap 
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structurally altered pre-aggregate and early aggregated species (schematically shown in Figure 
1.7 A) of several pharmaceutically relevant proteins including an IgG1 mAb.
101
  
Recent results have indicated that H/D-MS may also be capable of detecting these pre-
aggregate species in mAbs by localizing unfolding to particular sequence locations that act as 
hotspots to trigger aggregation under stressed conditions. For example, significant increases in 
flexibility of a highly conserved sequence in the CH2 domain of IgG1 monoclonal antibodies 
have been identified in response to a variety of stress conditions such as the presence of 
destabilizing additives  (thiocyanate and arginine),
12,13
 methionine oxidation,
27,30,77
 
deglycosylation,
20
 as well as point mutations in the CH2 domain introduced to modulate the 
pharmacokinetic profile of a mAb.
31
 The shapes of the deuterium uptake curves for this segment 
in the CH2 domain across a variety of mAbs measured by H/D-MS in many different labs, are 
remarkably similar as shown in Figure 1.7 B to G.  Hence this segment not only appears to 
exhibit similar local dynamics in many IgG1 mAbs, but shows similar increases in local 
flexibility when exposed to a variety of stresses and alterations (although the sequence 
numbering differs in each plot due to amino acid differences between the mAbs, all of the plots 
correspond to the same peptide segment). This segment has two aliphatic side-chains (valine and 
leucine) and two phenylalanine residues.  The phenyl rings pack tightly with the glycans in the 
crystal structure of an IgG1 mAb.
102
 Stress conditions accelerate H/D exchange in this region 
suggesting that stress causes an increase in the flexibility of this hydrophobic segment.  The 
resulting increase in flexibility disrupts the packing of the hydrophobic side-chains with the 
glycans, thereby transiently unfolding this particular segment. The exposure of this hydrophobic 
patch could then trigger conformational instability and aggregation.
99,103
 The similarity of 
deuterium uptake kinetic profiles of this segment across multiple studies and IgG1 mAbs also 
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points to the high inter-laboratory reproducibility in analyzing this aspect of local dynamics by 
H/D-MS.   
1.6 Challenges and opportunities for the H/D-MS technique as applied to mAb formulation 
development 
The technology for H/D-MS both, hardware and software, has seen revolutionary 
improvements in the last decade allowing for more wide spread use with larger, more complex 
protein molecules.
104,105
 The utility of this technique for assessing higher order protein structural 
and dynamic changes of mAbs has been established by numerous publications in recent years. 
As a result, the technique is becoming widely-adopted in both academic and industrial 
laboratories. In spite of all this recent progress, there still remain more challenges to overcome to 
make this technique more widely available and acceptable especially in the biopharmaceutical 
industry. First, we examine some of the current challenges with the analytical technology, and 
then evaluate some of remaining hurdles to implement H/D-MS technology as part of standard 
formulation development activities. 
1.6.1 Analytical technology challenges 
Advances in both hardware and software to control robotic autosamplers designed 
especially for H/D-MS experiments have made the technology amenable to customization for a 
wide variety of experiments. It is possible to do the entire H/D exchange reaction, liquid 
handling, mixing and moving, and sample analysis by LC-MS for hundreds of samples in a fully 
automated manner. Robotic liquid handling allows high accuracy and precision in deuterium 
labeling experiments that is difficult to achieve in long, labor-intensive manual labeling 
experiments. To-date, however, commercial solutions for automated H/D exchange are not 
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seamlessly integrated with LC-MS platforms. Typically, experiments need to be set up in parallel 
on both platforms with limited communication between the instrument platforms to handle 
errors. 
While there is the promise of fully-automated data analysis, the current reality is that 
considerable user review and correction is still required.  Hence, data processing is still the rate-
limiting step in bottom up H/D-MS analysis of large proteins such as mAbs. This is primarily 
because no perfect scoring algorithm exists so far that can predict the match of calculated 
isotopic envelopes with experimentally observed envelopes with 100% accuracy for every 
peptide and every exchange time point in a large H/D-MS data set. In our hands using 
HDExaminer, for example, to process H/D-MS data for a mAb, only ~ 10% of the peptide mass 
spectra need to be manually corrected. To date, there is no completely reliable algorithm to 
identify data that requires manual correction. Hence, manual review and correction to correctly 
identify the peaks in a peptide isotopic cluster is still necessary to improve accuracy. Thus, there 
is currently no satisfactory alternative available to avoid manually reviewing and correcting at 
least some of the data.  
Because of the subjective nature of data processing and because different levels of back-
exchange are obtained using different H/D-MS instrumental setups, some more formal 
assessment of inter-laboratory comparison of H/D-MS data would be highly beneficial to gain 
more confidence in the reproducibility of H/D-MS results. This may be achieved by performing 
H/D-MS experiments using the same protein under similar experimental conditions in multiple 
laboratories.  To meet this need, the US National Institute of Standards and Technology recently 
announced a round-robin H/D-MS study of a reference protein. 
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Finally, H/D-MS data have been summarized and presented in various ways such as 
deuterium incorporation heat maps, bar charts, line diagrams, scatter plots, etc. Some of these 
different modes of data visualization are shown in Figures 1.4, 1.5, and 1.6 of this chapter. A 
consensus mode of data presentation that will be informative for most types of experiments has 
the potential for better comprehension and comparison of H/D-MS data generated across 
laboratories. 
1.6.2 MAb formulation development challenges 
There are several challenges in implementing bottom up H/D exchange experiments for 
more routine formulation development of mAbs.  First, excipients can potentially change 
intrinsic exchange rates.  Zhang et al. 
62
 described the use of a poly-proline and isoleucine 
peptide as an internal standard in a protein stock solution to track and correct for changes in 
intrinsic exchange during deuterium labeling due to the presence of various amounts of 
guanidine salt in solution. However, introducing such control peptides in solution requires testing 
to establish that no form of interaction occurs between the control peptide and the protein. 
Second, as described below, although H/D-MS has the potential to provide better mechanistic 
understanding of mAb pharmaceutical stability profiles, some additional challenges remain as 
discussed below.   
The effects of chemical degradation on local flexibility of IgG mAbs as measured by 
H/D-MS has now been investigated by several groups including studies of methionine oxidation, 
asparagine deamidation, and aspartic acid isomerization.
27,30,77
 In these studies, methionine 
oxidation caused significant changes in H/D exchange kinetics in some regions and peptide 
segments of the mAb, but no significant effects were detected for asparagine deamidation or 
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aspartic acid isomerization.
27,30,77
 The absence of effects as detected by H/D-MS, however, may 
have been due to the small fraction of chemically-modified protein present in solution. The 
observed kinetics of H/D exchange are the weighted average of all protein forms present in 
solution. Hence, H/D-MS analysis may be more useful for detailed characterization of enriched, 
isolated fractions of such chemically altered samples, but less useful for probing their nature 
directly in protein formulations when present at low levels. H/D-MS experiments planned at 
different concentrations of chemically modified mAb species may be required to establish 
whether H/D-MS is sufficiently sensitive to detect changes in higher order structure, if present, 
due to the minor amounts of chemically modified mAb species present in solution.  
In terms of characterization of mAb aggregates by H/D-MS, the impact of freeze-thaw 
and heating on the nature of the higher order structure and dynamics of protein within the mAb 
aggregate has been explored using H/D-MS.
28
 It will be interesting to explore the impact of 
similar stresses on different IgG1 molecules as well as other classes of IgG molecules. In 
addition, the impact of other types of processing stresses such as shaking, stirring, and 
lyophilization/reconstitution on the local dynamics of mAb molecules may also potentially be 
explored by H/D-MS. 
The work reviewed in the preceding section suggests that H/D-MS could be used to 
screen excipients and additives for their effects on dynamics of specific aggregation-prone 
regions in mAbs. For example, it was shown that changes in the local dynamics of specific 
sequences in the CH2 domain caused by destabilizing excipients and salts correlated with 
decreased storage stability and conformational stability of an IgG1 mAb.
12,13
 Hence, a large 
number of different formulations could be screened using H/D-MS for their effects on specific 
peptides that have been identified as markers of instability.  By focusing on a subset of peptide 
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segments, H/D-MS experiments including data analysis could be performed more rapidly 
offering the possibility of a high-throughput excipient screening H/D-MS assay to identify 
stabilizing excipients. Such changes in dynamics could potentially serve as indicators of long-
term stability of different mAbs in different formulations.  Results from such experiments may 
also improve our basic understanding of the relationships between changes in protein flexibility 
and stability. Such experiments are currently underway in our laboratories.  
Therapeutic mAbs are more frequently being formulated in high concentration solution 
dosage forms to facilitate subcutaneous self-administration by patients. Some mAbs however 
undergo reversible self-association
71,106
 in a concentration dependent manner resulting in high 
viscosity,
107,108
 opalescence
109
 or liquid-liquid phase separation
110
.  High viscosity, for example, 
can pose major problems for manufacturing (filtration), stability (aggregation) and 
administration (syringeability).
111
 The interfacial contacts involved in self-association of such 
mAb candidates could potentially be identified using H/D-MS to gain mechanistic insights into 
the molecular origin of self-association of mAbs. Such insights may guide design of appropriate 
strategies to minimize or mitigate self-association behavior of specific mAbs using selected 
excipients or protein engineering. Such experiments are also currently underway in our 
laboratories. 
1.7 Conclusions 
H/D-MS is a promising technique for more expanded use in formulation development  of 
mAbs, especially in terms of analysis of higher order structure and dynamics of mAbs in 
response to various external stress conditions, changes in formulation composition, or specific 
physicochemical modifications. This chapter not only presented an overview of the method as 
applied to mAb formulation development (i.e.,sample preparation, sample analysis, data 
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acquition, and data processing), but also presented illustrative case studies using the of H/D-MS 
technique to analyze mAbs as part of formulation development. Furthermore, the utility of using 
H/D-MS in identifying transient locally unfolded mAb monomeric species that can act as 
aggregation hotspots under stress conditions has been demonstrated with the example of a 
specific sequence in the CH2 domain of IgG1 mAbs. This chapter also highlights the current 
challenges in using this technique, opportunities for further advances in H/D-MS technology and 
potential future applications during formulation development of mAb biotherapeutics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
1.8 References 
1. Reichert JM 2011. Antibody-based therapeutics to watch in 2011. mAbs  3(1):76-99. 
2. Reichert JM 2014. Antibodies to watch in 2014. mAbs  6(1):5-14. 
3. Saphire EO, Stanfield RL, Max Crispin MD, Parren PWHI, Rudd PM, Dwek RA, Burton 
DR, Wilson IA 2002. Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility. J 
Mol Biol  319(1):9-18. 
4. Hanson DC, Yguerabide J, Schumaker VN 1985. Rotational dynamics of 
immunoglobulin G antibodies anchored in protein A soluble complexes. Mol Immunol  
22(3):237-244. 
5. Bongini L, Fanelli D, Piazza F, De Los Rios P, Sandin S, Skoglund U 2005. Dynamics of 
antibodies from cryo-electron tomography. Biophys Chem  115(2-3):235-240. 
6. Roux KH, Strelets L, Michaelsen TE 1997. Flexibility of human IgG subclasses. J 
Immunol  159(7):3372-3382. 
7. Kamerzell TJ, Ramsey JD, Middaugh CR 2008. Immunoglobulin Dynamics, 
Conformational Fluctuations, and Nonlinear Elasticity and Their Effects on Stability. The 
Journal of Physical Chemistry B  112(10):3240-3250. 
8. Alsenaidy MA, Jain NK, Kim JH, Middaugh CR, Volkin DB 2014. Protein comparability 
assessments and potential applicability of high throughput biophysical methods and data 
visualization tools to compare physical stability profiles. Frontiers in pharmacology  5:39. 
9. Kamerzell TJ, Middaugh CR 2007. Two-Dimensional Correlation Spectroscopy Reveals 
Coupled Immunoglobulin Regions of Differential Flexibility that Influence Stability. 
Biochemistry  46(34):9762-9773. 
38 
 
10. Ramsey JD, Gill ML, Kamerzell TJ, Price ES, Joshi SB, Bishop SM, Oliver CN, 
Middaugh CR 2009. Using empirical phase diagrams to understand the role of intramolecular 
dynamics in immunoglobulin G stability. J Pharm Sci  98(7):2432-2447. 
11. Thakkar SV, Kim JH, Samra HS, Sathish HA, Bishop SM, Joshi SB, Volkin DB, 
Middaugh CR 2012. Local dynamics and their alteration by excipients modulate the global 
conformational stability of an lgG1 monoclonal antibody. J Pharm Sci  101(12):4444-4457. 
12. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh 
CR, Volkin DB, Weis DD 2013. Effects of salts from the Hofmeister series on the 
conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal 
antibody. Biochemistry  52(19):3376-3389. 
13. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, Bishop SM, 
Middaugh CR, Weis DD, Volkin DB 2013. Correlating excipient effects on conformational and 
storage stability of an IgG1 monoclonal antibody with local dynamics as measured by 
hydrogen/deuterium-exchange mass spectrometry. J Pharm Sci  102(7):2136-2151. 
14. Thakkar SV, Joshi SB, Jones ME, Sathish HA, Bishop SM, Volkin DB, Middaugh CR 
2012. Excipients differentially influence the conformational stability and pretransition dynamics 
of two IgG1 monoclonal antibodies. J Pharm Sci  101(9):3062-3077. 
15. Alsenaidy MA, Kim JH, Majumdar R, Weis DD, Joshi SB, Tolbert TJ, Middaugh CR, 
Volkin DB 2013. High-throughput biophysical analysis and data visualization of conformational 
stability of an IgG1 monoclonal antibody after deglycosylation. J Pharm Sci  102(11):3942-3956. 
16. Panjwani N, Hodgson DJ, Sauve S, Aubin Y 2010. Assessment of the effects of pH, 
formulation and deformulation on the conformation of interferon alpha-2 by NMR. J Pharm Sci  
99(8):3334-3342. 
39 
 
17. Amezcua CA, Szabo CM 2013. Assessment of higher order structure comparability in 
therapeutic proteins using nuclear magnetic resonance spectroscopy. J Pharm Sci  102(6):1724-
1733. 
18. Favero-Retto MP, Palmieri LC, Souza TA, Almeida FC, Lima LM 2013. Structural meta-
analysis of regular human insulin in pharmaceutical formulations. Eur J Pharm Biopharm  85(3 
Pt B):1112-1121. 
19. Norrman M, Schluckebier G 2007. Crystallographic characterization of two novel crystal 
forms of human insulin induced by chaotropic agents and a shift in pH. BMC Struct Biol  7:83. 
20. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR 2009. Characterization of IgG1 
Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass 
Spectrometry. Anal Chem  81(7):2644-2651. 
21. Hvidt A, Linderstrom-Lang K 1954. Exchange of hydrogen atoms in insulin with 
deuterium atoms in aqueous solutions. Biochim Biophys Acta  14(4):574-575. 
22. Kim YS, Randolph TW, Manning MC, Stevens FJ, Carpenter JF 2003. Congo red 
populates partially unfolded states of an amyloidogenic protein to enhance aggregation and 
amyloid fibril formation. J Biol Chem  278(12):10842-10850. 
23. Paterson Y, Englander SW, Roder H 1990. An antibody binding site on cytochrome c 
defined by hydrogen exchange and two-dimensional NMR. Science  249(4970):755-759. 
24. Jeng MF, Englander SW, Elove GA, Wand AJ, Roder H 1990. Structural description of 
acid-denatured cytochrome c by hydrogen exchange and 2D NMR. Biochemistry  29(46):10433-
10437. 
40 
 
25. Katta V, Chait BT, Carr S 1991. Conformational changes in proteins probed by hydrogen 
exchange electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom  5(4):214-
217. 
26. Zhang Z, Smith DL 1993. Determination of amide hydrogen exchange by mass 
spectrometry: A new tool for protein structure elucidation. Protein Sci  2(4):522-531. 
27. Houde D, Peng Y, Berkowitz SA, Engen JR 2010. Post-translational Modifications 
Differentially Affect IgG1 Conformation and Receptor Binding. Molecular & Cellular 
Proteomics  9(8):1716-1728. 
28. Zhang A, Singh S, Shirts M, Kumar S, Fernandez E 2012. Distinct Aggregation 
Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by 
Hydrogen Exchange. Pharm Res  29(1):236-250. 
29. Zhang A, Hu P, MacGregor P, Xue Y, Fan H, Suchecki P, Olszewski L, Liu A 2014. 
Understanding the conformational impact of chemical modifications on monoclonal antibodies 
with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and 
structural modeling. Anal Chem  86(7):3468-3475. 
30. Burkitt W, Domann P, O'Connor G 2010. Conformational changes in oxidatively stressed 
monoclonal antibodies studied by hydrogen exchange mass spectrometry. Protein Sci  19(4):826-
835. 
31. Majumdar R, Esfandiary R, Bishop SM, Middaugh CR, Volkin DB, Weis DD 2014. 
Correlations between changes in conformational dynamics and physical stability in a mutant 
IgG1 mAb engineered for extended serum half-life. mAbs (Submitted). 
41 
 
32. Rose RJ, van Berkel PHC, van den Bremer ETJ, Labrijn AF, Vink T, Schuurman J, Heck 
AJR, Parren PWHI 2013. Mutation of Y407 in the CH3 domain dramatically alters glycosylation 
and structure of human IgG. mAbs  5(2):219-228. 
33. Pan LY, Salas-Solano O, Valliere-Douglass JF 2014. Conformation and dynamics of 
interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium 
exchange mass spectrometry. Anal Chem  86(5):2657-2664. 
34. Englander SW, Kallenbach NR 1983. Hydrogen exchange and structural dynamics of 
proteins and nucleic acids. Q Rev Biophys  16(04):521-655. 
35. Skinner JJ, Lim WK, Bédard S, Black BE, Englander SW 2012. Protein dynamics viewed 
by hydrogen exchange. Protein Sci:n/a-n/a. 
36. Skinner JJ, Lim WK, Bédard S, Black BE, Englander SW 2012. Protein hydrogen 
exchange: testing current models. Protein Sci:n/a-n/a. 
37. Woodward C, Carulla N, Barany G. 2004. Native State Hydrogen-Exchange Analysis of 
Protein Folding and Protein Motional Domains. In Jo M. Holt MLJ, Gary KA, editors. Methods 
Enzymol, ed.: Academic Press. p 379-400. 
38. Molday RS, Englander SW, Kallen RG 1972. Primary structure effects on peptide group 
hydrogen exchange. Biochemistry  11(2):150-158. 
39. Bai Y, Milne JS, Mayne L, Englander SW 1993. Primary structure effects on peptide 
group hydrogen exchange. Proteins: Structure, Function, and Bioinformatics  17(1):75-86. 
40. Berger A, Loewenstein A, Meiboom S 1959. Nuclear Magnetic Resonance Study of the 
Protolysis and Ionization of N-Methylacetamide1. J Am Chem Soc  81(1):62-67. 
42 
 
41. Englander JJ, Calhoun DB, Englander SW 1979. Measurement and calibration of peptide 
group hydrogen-deuterium exchange by ultraviolet spectrophotometry. Anal Biochem  
92(2):517-524. 
42. Gregory RB, Crabo L, Percy AJ, Rosenberg A 1983. Water catalysis of peptide hydrogen 
isotope exchange. Biochemistry  22(4):910-917. 
43. Englander SW 2006. Hydrogen Exchange and Mass Spectrometry: A Historical 
Perspective. J Am Soc Mass Spectrom  17(11):1481-1489. 
44. Henzler-Wildman K, Kern D 2007. Dynamic personalities of proteins. Nature  
450(7172):964-972. 
45. Tokuriki N, Tawfik DS 2009. Protein Dynamism and Evolvability. Science  
324(5924):203-207. 
46. Bryan PN, Orban J 2010. Proteins that switch folds. Curr Opin Struct Biol  20(4):482-
488. 
47. Kim KS, Woodward C 1993. Protein internal flexibility and global stability: effect of 
urea on hydrogen exchange rates of bovine pancreatic trypsin inhibitor. Biochemistry  
32(37):9609-9613. 
48. Hvidt A, Nielsen SO 1966. Hydrogen exchange in proteins. Adv Protein Chem  21:287-
386. 
49. Engen JR, Wales TE, Chen S, Marzluff EM, Hassell KM, Weis DD, Smithgall TE 2013. 
Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry. 
Int Rev Phys Chem  32(1):96-127. 
50. Deng Y, Smith DL 1998. Identification of unfolding domains in large proteins by their 
unfolding rates. Biochemistry  37(18):6256-6262. 
43 
 
51. Miranker A, Robinson CV, Radford SE, Aplin RT, Dobson CM 1993. Detection of 
transient protein folding populations by mass spectrometry. Science  262(5135):896-900. 
52. Wales TE, Engen JR 2006. Hydrogen exchange mass spectrometry for the analysis of 
protein dynamics. Mass Spectrom Rev  25(1):158-170. 
53. Deng Y, Zhang Z, Smith DL 1999. Comparison of continuous and pulsed labeling amide 
hydrogen exchange/mass spectrometry for studies of protein dynamics. J Am Soc Mass 
Spectrom  10(8):675-684. 
54. Glasoe P, Long F 1960. Use of glass electrodes to measure acidities in deuterium oxide. 
Journal of Physical Chemistry (US)  64. 
55. Rey M, Mrazek H, Pompach P, Novak P, Pelosi L, Brandolin G, Forest E, Havlicek V, 
Man P 2010. Effective Removal of Nonionic Detergents in Protein Mass Spectrometry, 
Hydrogen/Deuterium Exchange, and Proteomics. Anal Chem  82(12):5107-5116. 
56. Wang L, Pan H, Smith DL 2002. Hydrogen Exchange-Mass Spectrometry: optimization 
of digestion conditions. Molecular & Cellular Proteomics  1(2):132-138. 
57. Busby SA, Chalmers MJ, Griffin PR 2007. Improving digestion efficiency under H/D 
exchange conditions with activated pepsinogen coupled columns. Int J Mass spectrom  259(1-
3):130-139. 
58. Ahn J, Cao M-J, Yu YQ, Engen JR 2013. Accessing the reproducibility and specificity of 
pepsin and other aspartic proteases. Biochimica et Biophysica Acta (BBA) - Proteins and 
Proteomics  1834(6):1222-1229. 
59. Keppel T, Jacques M, Young R, Ratzlaff K, Weis D 2011. An Efficient and Inexpensive 
Refrigerated LC System for H/D Exchange Mass Spectrometry. J Am Soc Mass Spectrom  
22(8):1472-1476. 
44 
 
60. Fang J, Rand KD, Beuning PJ, Engen JR 2011. False EX1 signatures caused by sample 
carryover during HX MS analyses. Int J Mass Spectrom  302(1-3):19-25. 
61. Majumdar R, Manikwar P, Hickey JM, Arora J, Middaugh CR, Volkin DB, Weis DD 
2012. Minimizing Carry-Over in an Online Pepsin Digestion System used for the H/D Exchange 
Mass Spectrometric Analysis of an IgG1 Monoclonal Antibody. J Am Soc Mass Spectrom  
23(12):2140-2148. 
62. Zhang Z, Zhang A, Xiao G 2012. Improved Protein Hydrogen/Deuterium Exchange Mass 
Spectrometry Platform with Fully Automated Data Processing. Anal Chem. 
63. Liu S, Liu L, Uzuner U, Zhou X, Gu M, Shi W, Zhang Y, Dai S, Yuan J 2011. HDX-
Analyzer: a novel package for statistical analysis of protein structure dynamics. BMC 
Bioinformatics  12(Suppl 1):S43. 
64. Weis DD, Engen JR, Kass IJ 2006. Semi-automated data processing of hydrogen 
exchange mass spectra using HX-Express. J Am Soc Mass Spectrom  17(12):1700-1703. 
65. Slysz GW, Baker CA, Bozsa BM, Dang A, Percy AJ, Bennett M, Schriemer DC 2009. 
Hydra: software for tailored processing of H/D exchange data from MS or tandem MS analyses. 
BMC Bioinformatics  10:162. 
66. Pascal BD, Willis S, Lauer JL, Landgraf RR, West GM, Marciano D, Novick S, 
Goswami D, Chalmers MJ, Griffin PR 2012. HDX workbench: software for the analysis of H/D 
exchange MS data. J Am Soc Mass Spectrom  23(9):1512-1521. 
67. Houde D, Berkowitz SA, Engen JR 2011. The utility of hydrogen/deuterium exchange 
mass spectrometry in biopharmaceutical comparability studies. J Pharm Sci  100(6):2071-2086. 
45 
 
68. Chalmers MJ, Pascal BD, Willis S, Zhang J, Iturria SJ, Dodge JA, Griffin PR 2011. 
Methods for the Analysis of High Precision Differential Hydrogen Deuterium Exchange Data. 
Int J Mass Spectrom  302(1-3):59-68. 
69. Šali A, Blundell TL 1993. Comparative Protein Modelling by Satisfaction of Spatial 
Restraints. J Mol Biol  234(3):779-815. 
70. Wang W, Singh S, Zeng DL, King K, Nema S 2007. Antibody structure, instability, and 
formulation. J Pharm Sci  96(1):1-26. 
71. Esfandiary R, Hayes DB, Parupudi A, Casas-Finet J, Bai S, Samra HS, Shah AU, Sathish 
HA 2013. A systematic multitechnique approach for detection and characterization of reversible 
self-association during formulation development of therapeutic antibodies. J Pharm Sci  
102(9):3089-3099. 
72. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS 2010. Stability of 
protein pharmaceuticals: an update. Pharm Res  27(4):544-575. 
73. Torosantucci R, Schoneich C, Jiskoot W 2014. Oxidation of therapeutic proteins and 
peptides: structural and biological consequences. Pharm Res  31(3):541-553. 
74. Pan H, Chen K, Chu L, Kinderman F, Apostol I, Huang G 2009. Methionine oxidation in 
human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci  18(2):424-433. 
75. Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, 
Drummond J, Prueksaritanont T, Vlasak J 2009. Impact of methionine oxidation on the binding 
of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol  46(8-9):1878-1882. 
76. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, 
Prueksaritanont T, Ionescu R 2011. Impact of methionine oxidation in human IgG1 Fc on serum 
half-life of monoclonal antibodies. Mol Immunol  48(6-7):860-866. 
46 
 
77. Zhang A, Hu P, Macgregor P, Xue Y, Fan H, Suchecki P, Olszewski L, Liu A 2014. 
Understanding the conformational impact of chemical modifications on monoclonal antibodies 
with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and 
structural modeling. Anal Chem  86(7):3468-3475. 
78. Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H 2012. Chromatographic analysis of the 
acidic and basic species of recombinant monoclonal antibodies. mAbs  4(5):578-585. 
79. Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, 
Arroll T, Han Y, Gadgil H, Latypov RF, Wallace A, Lim A, Kleemann GR, Wang W, Balland A 
2009. Succinimide formation at Asn 55 in the complementarity determining region of a 
recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci  98(10):3509-3521. 
80. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, 
Totpal K, Chen AB 2001. Identification of multiple sources of charge heterogeneity in a 
recombinant antibody. J Chromatogr B Biomed Sci Appl  752(2):233-245. 
81. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara 
A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, 
Motchnik P 2010. Charge variants in IgG1: Isolation, characterization, in vitro binding properties 
and pharmacokinetics in rats. mAbs  2(6):613-624. 
82. Chen S, Lau H, Brodsky Y, Kleemann GR, Latypov RF 2010. The use of native cation-
exchange chromatography to study aggregation and phase separation of monoclonal antibodies. 
Protein Sci  19(6):1191-1204. 
83. Hawe A, Kasper JC, Friess W, Jiskoot W 2009. Structural properties of monoclonal 
antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci  38(2):79-87. 
47 
 
84. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W 2004. Structure-immunogenicity 
relationships of therapeutic proteins. Pharm Res  21(6):897-903. 
85. Garber E, Demarest SJ 2007. A broad range of Fab stabilities within a host of therapeutic 
IgGs. Biochem Biophys Res Commun  355(3):751-757. 
86. Kheterpal I, Cook KD, Wetzel R. 2006. Hydrogen/Deuterium Exchange Mass 
Spectrometry Analysis of Protein Aggregates. In Indu K, Ronald W, editors. Methods Enzymol, 
ed.: Academic Press. p 140-166. 
87. Iacob RE, Bou-Assaf GM, Makowski L, Engen JR, Berkowitz SA, Houde D 2013. 
Investigating Monoclonal Antibody Aggregation Using a Combination of H/DX-MS and Other 
Biophysical Measurements. J Pharm Sci  102(12):4315-4329. 
88. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB 2011. Protein-excipient 
interactions: mechanisms and biophysical characterization applied to protein formulation 
development. Adv Drug Deliv Rev  63(13):1118-1159. 
89. Baldwin RL 1996. How Hofmeister ion interactions affect protein stability. Biophys J  
71(4):2056-2063. 
90. Zhang Y, Cremer PS 2006. Interactions between macromolecules and ions: the 
Hofmeister series. Current Opinion in Chemical Biology  10(6):658-663. 
91. Mason BD, Zhang-van Enk J, Zhang L, Remmele RL, Zhang J 2010. Liquid-Liquid 
Phase Separation of a Monoclonal Antibody and Nonmonotonic Influence of Hofmeister Anions. 
Biophys J  99(11):3792-3800. 
92. He F, Woods CE, Becker GW, Narhi LO, Razinkov VI 2011. High-throughput 
assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. J 
Pharm Sci  100(12):5126-5141. 
48 
 
93. Gibson TJ, McCarty K, McFadyen IJ, Cash E, Dalmonte P, Hinds KD, Dinerman AA, 
Alvarez JC, Volkin DB 2011. Application of a high-throughput screening procedure with PEG-
induced precipitation to compare relative protein solubility during formulation development with 
IgG1 monoclonal antibodies. J Pharm Sci  100(3):1009-1021. 
94. Feige MJ, Walter S, Buchner J 2004. Folding mechanism of the CH2 antibody domain. J 
Mol Biol  344(1):107-118. 
95. Lee JC, Timasheff SN 1981. The stabilization of proteins by sucrose. J Biol Chem  
256(14):7193-7201. 
96. Arakawa T, Timasheff SN 1982. Stabilization of protein structure by sugars. 
Biochemistry  21(25):6536-6544. 
97. Telikepalli SN, Kumru OS, Kalonia C, Esfandiary R, Joshi SB, Middaugh CR, Volkin 
DB 2014. Structural characterization of IgG1 mAb aggregates and particles generated under 
various stress conditions. J Pharm Sci  103(3):796-809. 
98. Roberts CJ, Das TK, Sahin E 2011. Predicting solution aggregation rates for therapeutic 
proteins: Approaches and challenges. Int J Pharm  418(2):318-333. 
99. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL 2009. Aggregation-Prone 
Motifs in Human Immunoglobulin G. J Mol Biol  391(2):404-413. 
100. Li Y, Roberts CJ 2009. Lumry-Eyring nucleated-polymerization model of protein 
aggregation kinetics. 2. Competing growth via condensation and chain polymerization. J Phys 
Chem B  113(19):7020-7032. 
101. Naik S, Kumru OS, Cullom M, Telikepalli SN, Lindboe E, Roop TL, Joshi SB, Amin D, 
Gao P, Middaugh CR, Volkin DB, Fisher MT 2014. Probing structurally altered and aggregated 
49 
 
states of therapeutically relevant proteins using GroEL coupled to bio-layer Interferometry. 
Protein Sci:n/a-n/a. 
102. Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, 
Stanfield RL, Burton DR, Wilson IA 2001. Crystal Structure of a Neutralizing Human IgG 
Against HIV-1: A Template for Vaccine Design. Science  293(5532):1155-1159. 
103. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL 2009. Design of therapeutic 
proteins with enhanced stability. Proc Natl Acad Sci U S A  106(29):11937-11942. 
104. Engen JR 2009. Analysis of Protein Conformation and Dynamics by 
Hydrogen/Deuterium Exchange MS. Anal Chem  81(19):7870-7875. 
105. Iacob RE, Engen JR 2012. Hydrogen exchange mass spectrometry: are we out of the 
quicksand? J Am Soc Mass Spectrom  23(6):1003-1010. 
106. Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ 2012. The influence of charge 
distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol 
Pharm  9(4):791-802. 
107. Liu J, Nguyen MD, Andya JD, Shire SJ 2005. Reversible self-association increases the 
viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci  94(9):1928-
1940. 
108. Yadav S, Liu J, Shire SJ, Kalonia DS 2010. Specific interactions in high concentration 
antibody solutions resulting in high viscosity. J Pharm Sci  99(3):1152-1168. 
109. Mason BD, Zhang L, Remmele RL, Jr., Zhang J 2011. Opalescence of an IgG2 
monoclonal antibody solution as it relates to liquid-liquid phase separation. J Pharm Sci  
100(11):4587-4596. 
50 
 
110. Nishi H, Miyajima M, Nakagami H, Noda M, Uchiyama S, Fukui K 2010. Phase 
separation of an IgG1 antibody solution under a low ionic strength condition. Pharm Res  
27(7):1348-1360. 
111. Shire SJ, Shahrokh Z, Liu J 2004. Challenges in the development of high protein 
concentration formulations. J Pharm Sci  93(6):1390-1402. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
Figure 1.1 
 
 
Schematic representation of the H/D-MS experimental workflow for a typical IgG mAb. In the 
first step, the concentrated mAb stock (panel A) is diluted ~ 20-fold with deuterated formulation 
buffer to initiate deuterium exchange of backbone amide hydrogens (panel B). In the second 
step, the exchange is quenched after various pre-defined times by mixing with an ice-cold acidic 
quench buffer to lower the pH to 2.5 and the temperature to 0 °C.  The antibody is denatured and 
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reduced during the quench step as well. In the third step, the quenched antibody solution (panel 
C) is injected into the sample loop of the LC where a loading pump carries the antibody through 
an immobilized pepsin column and the resultant peptides (panel D) are trapped by a reversed-
phase trap. In the fourth step, the peptides are eluted from the trap by a gradient pump (HPLC or 
UPLC), separated by a reversed-phase column held at 0 °C, and then analyzed by a mass 
spectrometer.  The data (panel E) obtained from the LC-MS contains the total ion 
chromatograms and mass spectra for all peptides from each deuterium exchange time point. 
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Figure 1.2 
 
 
Schematic representation of the H/D-MS data processing workflow for a typical IgG mAb. In the 
first step, the LC-MS data (panel A) are processed to find peptides that match particular 
sequences of the mAb to obtain an initial peptide map (panel B). All peptides are identified 
based on accurate mass measurements and/or fragmentation-based tandem mass measurements 
of undeuterated peptides.  In the second step, the sequence and retention time of peptides are fed 
into the H/D-MS data processing software along with the mAb primary sequence. The H/D-MS 
data processing software searches for peptides in the deuterated sample (panel C) based on 
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retention time and m/z of the peptides in the non-deuterated sample. In the third step, the 
software matches observed and calculated m/z values of deuterated peptides in the experiment in 
fully automated way.  When a match is established (as indicated by the red dots in panel D), the 
centroid m/z value of the peptide isotopic cluster is calculated by the software. In the fourth step, 
the peptide spectra are manually inspected (and corrected if required) for the accurate matching 
of observed and calculated mass spectra. The deuterium uptake (in Da or percentage) (panel E) 
for each peptide segment is calculated from the mass difference values between a deuterated 
mAb sample and the corresponding undeuterated sample automatically. In the fifth step, the 
kinetic profile of deuterium uptake for a mAb peptide segment is generally plotted as a graph 
(panel F) and also used to compare two or more conditions.  This analysis is then repeated for 
each peptide. 
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Figure 1.3 
 
 
Statistical analysis of H/D-MS data to identify significant changes in local dynamics of a mAb. 
At the first step, deuterium uptake differences for each peptide segment are calculated for each 
exchange time point (Δm) (as shown in panel A) and plotted, for example, as bars (panel B). The 
99% confidence interval for a significant difference is calculated by pooling variance values of 
all deuterium uptake measurements and by propagating the error for two measurements. The 
significant differences are then shown as colored regions in a homology map of the mAb (panel 
C). The homology model was created from an antibody X-ray crystal structure (PDB 1HZH).
102
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Figure 1.4 
 
 
H/D exchange differential plots for mAb1 heavy chain (HC, Panel A) and light chain (LC, Panel 
B). The two protein states compared are Met oxidized and control sample. Deuterium labeling 
was measured at 10 s (red), 1 min (orange), 5 min (cyan), 30 min (blue), and 180 min (green). 
Vertical sticks represent the sum total of H/D exchange differences for each peptide from the 
five labeling times. The gray and orange dotted lines represent the criteria for a significant H/D 
exchange difference for one single labeling time and for the total exchange difference, 
respectively. The regions with significant differences are labeled accordingly. Molecular 
modeling illustrating the effect of Met oxidation on mAb1 conformation (Panel C).  Regions 
246−256 and 324−353 are highlighted in red and pink, respectively, to represent different levels 
of conformational changes caused by Met oxidation. Zoomed-in view of the local conformation 
at the CH2−CH3 interface is shown for native (Panel D) and Met oxidized (Panel E) mAb1. The 
distance between two sulfur atoms of Met257 and Met433 is labeled in green. This figure is 
reproduced from Zhang and Liu, 2014
29
 by permission from American Chemical Society. 
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Figure 1.5 
 
 
Representation of H/D exchange data mapped onto primary sequence of a mAb. Peptide level 
H/D exchange labeling patterns of LC (A) and HC (B) of native Bevacizumab and thermally-
induced aggregates. The labeling for each peptide is shown by two sets of five colored bars 
underneath the corresponding portion of the primary sequence. For each peptide, the labeling of 
native protein is shown by the top five bars, and the labeling of aggregates is shown by the 
bottom five bars. Each set of bars represents the labeling at five different labeling times (from 
top to bottom, 10 s, 1 min, 10 min, 60 min and 180 min). The percentage of deuterium labeling 
in each peptide at each labeling time is color-coded using the scale shown (A). The regions with 
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dramatic increases and decreases in deuterium labeling after thermally induced aggregation are 
circled in red and blue, respectively. The gray block in (B) indicates a peptide that was not 
detectable in the analysis of the aggregate. (C) Three-dimensional representation of regions of 
Bevacizumab showing significant increases and decreases in labeling. The peptides from (A) and 
(B) that showed significant increases (red) and decreases (blue) in deuterium labeling after 
thermally induced aggregation are indicated. The Bevacizumab structure was created by 
homology modeling using 1IGY as a template. This figure is reproduced from Zhang and 
Fernandez, 2012
28
 with permission from Springer. 
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Figure 1.6 
 
60 
 
(A) Relative deuterium uptake differences for all peptide segments of an IgG1 mAb in the 
presence of two pharmaceutical excipients and sodium salts from the Hofmeister series as 
measured by H/D–MS at each deuterium exposure time.  Samples contained 0.5 M sucrose, 
sodium sulfate, sodium chloride, arginine, and sodium thiocyanate in 20 mM citrate-phosphate 
buffer at pH 6.0 and were compared relative to the control solution (0.1 M sodium chloride in the 
same buffer). The dashed lines at ±0.59 Da represent the 99% confidence interval. The 
horizontal axis denotes the ordinal peptide numbers, sorted in ascending order from the N-
terminus of the heavy chain to the C-terminus of the light chain based on the midpoint of their 
sequences. Positive values in these plots represent increased H/D exchange by a peptide in the 
presence of the additive relative to the control.  Negative values represent decreased H/D 
exchange. Locations of the mAb domains shown in the figure are approximate since some 
peptide segments span two different domains. (B) Effects of additives on the H/D exchange of 
the mAb plotted onto a homology model of the IgG1 mAb. Changes in flexibility are colored 
according to the legend. These figures have been redrawn and adapted from data presented in 
Majumdar et al, 2013 
12
, and Manikwar et al, 2013
13
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61 
 
Figure 1.7 
 
Potential aggregation hotspot in the CH2 domain of IgG mAbs as identified by H/D-MS. (A) 
Schematic representation of some of the key steps in protein aggregation pathway (see text for 
explanation). This figure is reproduced from  Roberts and Sahin, 2011
98
 with permission from 
Elsevier. (B) Arginine increased and sucrose did not affect the deuterium uptake in the CH2 
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segment HC 241-252.
13
 (C) Thiocyanate increased the deuterium uptake in the CH2 segment HC 
241-252
12
 while chloride and sulfate had no effect. (D) Methionine oxidation increased the 
deuterium uptake of the CH2 segment HC 242-252 (FLFPPKPKDTL). 
30
 (E) Deglycosylation 
increased the deuterium uptake of the CH2 segment 242-253 (FLFPPKPKDTLM).
20
 The black 
line represents data from the glycosylated form and the dotted line represent data from 
deglycosylated form of the mAb. (F) Post-translational modifications alter the deuterium uptake 
in the CH2 segment HC 242-253.
27
 Solid black, native IgG1; solid gray, degalactosylated IgG1; 
dotted black, hypergalactosylated IgG1; solid red, deglycosylated IgG1; solid blue, methionine 
oxidized IgG1; dotted blue, hypergalactosylated-methionine-oxidized IgG1. (G) Dimerization of 
mAb increased the deuterium uptake of the CH2 segment HC 249-259 (FLFPPKPKDTL).
87
  The 
sequence numbers mentioned here are slightly different for each graph due to slightly different 
number of residues present in IgG1 mAbs used in these different studies, but they correspond to 
the same segment in the CH2 domain. The deuterium uptake curves marked as (B) to (G) have 
been redrawn from data presented in Majumdar et al, 2013 
12
, Manikwar et al, 2013
13
, Burkitt et 
al, 2010,
30
 Houde et al. 2009,
20
 Houde et al. 2010,
27
 and Iacob et al. 2013.
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Chapter 2  
Minimizing carry-over in an online pepsin digestion system used for the H/D exchange 
mass spectrometric analysis of an IgG1 monoclonal antibody 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(“Minimizing carry-over in an online pepsin digestion system used for the H/D exchange mass 
spectrometric analysis of an IgG1 monoclonal antibody.”, Majumdar R., Manikwar P., Hickey 
J.M., Arora J., Middaugh C.R., Volkin D.B., Weis D.D., J. Am. Soc. Mass Spectrom. 2012 Dec; 
23(12): 2140-8.) 
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2.1 Introduction 
Over the past two decades, amide H/D exchange coupled with MS-based detection has 
matured into a valuable tool in the analysis of protein structure in solution.
1, 2, 3, 4
 When a protein 
is placed in a large excess of D2O, the backbone amide hydrogens undergo exchange with 
deuterium at rates that are characteristic of protein conformation and dynamics.  Mass analysis 
reveals the kinetics of deuterium incorporation, usually expressed in the form of a deuterium 
uptake curve.  The technique is widely used to detect ligand binding
5
 and to understand ligand-
induced conformational changes
6
, to define the effects of protein-protein interactions
7, 8
,  to 
understand the effects of post-translational modifications or other chemical changes
9
, to 
characterize the dynamics of intrinsically disordered proteins
10, 11
, to map protein-protein 
interfaces
12
, and to evaluate therapeutic proteins as part of biopharmaceutical comparability 
studies
9
.  
Localized information, at a resolution of ~10 amino acid residues, can be achieved by 
subjecting deuterated proteins to proteolysis under slow-exchange conditions (so-called 
quenched conditions, pH ~2, 0 °C)
1, 13
.  Acid-tolerant proteases such as pepsin are required for 
this digestion step.  Even under quenched exchange conditions, the slow deuterium loss during 
digestion in H2O-based solutions demands rapid proteolysis.  For this reason early H/D-MS work 
employed high concentrations of solution-phase pepsin.  The high protease concentration can 
interfere with the subsequent LC-MS analysis, and even at high concentrations, digestion is often 
inadequate.  The development of online systems using immobilized pepsin columns for H/D-
MS
14
 greatly improved digestion efficiency and eliminated pepsin from the downstream analysis.  
The abundance of the peptides generated by rapid proteolysis with immobilized protease 
columns can lead to carry-over artifacts.  The problem of carry-over is particularly vexing in H/D 
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exchange experiments because the retained peptide undergoes extensive back-exchange during 
the delay between sample injections.  Such back-exchanged carry-over will manifest itself in the 
mass spectral data as isotopic profile doublets consisting of both a deuterated peptide feature and 
a corresponding undeuterated feature left over from the previous injection (for example, see 
figure 2.4 in work of the Fang et al.
15
).  Such carry-over can produce a mass spectral profile that 
can be mistaken for exchange via the EX1 mechanism
15
.  In this same study, mitigation of carry-
over of a collection of so-called sticky peptic peptides in reversed-phase column and trap of a 
UHPLC was systematically explored
15
.  The potential for the immobilized pepsin column to also 
contribute to carry-over artifacts in H/D exchange MS experiments was suggested but not 
investigated by Fang et al, presumably since the wash protocols identified in their work (for 
minimizing carry-over in the reversed-phase column and trap) were not expected to be 
compatible with maintaining pepsin’s enzymatic activity.   
In the course of recent method development for the H/D-MS analysis of an IgG1 monoclonal 
antibody in our laboratories, we encountered excessive carry-over of peptic peptides in our 
online digestion system.  Given the recent interest in the potential utility of hydrogen/deuterium 
exchange mass spectrometry for analysis of IgG monoclonal antibodies (mAbs),
9, 16, 17, 18
 it is 
important to assess the nature and extent of peptide carry-over issues with each mAb, especially 
given the large number of peptides generated with these ~150 kDa proteins.  In this paper, we 
show that the primary source for carry-over for our system arose not from the reversed-phase 
columns, but from the online pepsin digestion process.  We further demonstrate that a simple 
two-step washing procedure can be used to substantially decrease this carry-over and that 100 
cycles of the washing process does not adversely affect the activity and specificity of the 
immobilized pepsin column.  Since previous H/D-MS studies with mAbs have not mentioned 
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this aspect of method development, this work serves as a case study to raise awareness and 
provide a protocol that minimized carryover during H/D-MS studies with a particular IgG1 mAb. 
2.2 Materials and Methods 
2.2.1 Reagents and materials 
LC mobile phases were prepared from LC/MS grade acetonitrile and water (Fisher Optima) 
and formic acid (Thermo Scientific, 99+ % LC/MS grade).  Phosphoric acid solution and acetic 
acid (both HPLC grade, > 98.5 %) were obtained from Fluka.  Isopropanol (Optima LC/MS 
grade) was obtained from Fisher Scientific.  Guanidine hydrochloride, tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), porcine pepsin were obtained from Sigma-
Aldrich.  The IgG1 monoclonal antibody stock contained 50 mg ml
–1
 protein containing 0.005 % 
polysorbate 80 in 10 mM sodium-histidine buffer at pH 6. 
2.2.2 Sample preparation 
The antibody sample was diluted to 10 mg ml
–1
 working concentration with 10 mM sodium 
histidine buffer at pH 6.0.  For a typical mAb digest run, 5 µl of antibody sample at working 
concentration was diluted with 95 µl of 0.1 % formic acid.  This solution was mixed with a 
reducing quench buffer containing 500 mM TCEP, 4 M guanidine hydrochloride and 200 mM 
sodium phosphate buffer at pH 2.5 in a 1:1 ratio by volume.  The antibody sample was incubated 
at 0 ºC for one minute for disulfide bond reduction and then 10 µL of this solution 
(approximately 16 pmol of antibody) was injected into sample loop of the LC.  The short 
incubation time, low temperature, and low pH mimic typical quenching conditions for H/D 
exchange. 
2.2.3 Chromatography and mass spectrometry 
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A single-valve, two-pump system for H/D exchange with a refrigerated valve and column 
compartment was used to maintain 0 °C throughout the online digestion and separation, as 
described previously (see Fig 2.1)
19
.  Following sample injection, a loading pump carried the 
sample through a 50 mm × 2.1 mm immobilized pepsin column, prepared in-house
14
, using 0.1 
% formic acid at a flow rate of 200 μL min
–1
.  The resultant peptides were captured and desalted 
on a reversed-phase trap (Peptide Concentration & Desalting microtrap, Bruker-Michrom, 
Auburn, CA) for 5 minutes at the same flow rate.  For gradient elution the mobile phases were 
0.1 % formic acid (A) and 90 % acetonitrile/10 % water/0.1 % formic acid (B).  The peptides 
were eluted from the trap and separated on a revered-phase analytical column (ZORBAX 
300SB-C18, 50 mm × 1 mm, 3.5 μm particle diameter, Agilent Technologies, Santa Clara, CA) 
using a 15-40 %B gradient over 5 min.  Following the shallow gradient, the trap and column 
were cleaned using a 40-90 %B gradient followed by a 5-90 %B gradient in 1 min each with 1 
min of equilibration at the highest and lowest organic content. The needle port and sample loop 
were cleaned between injections by overfilling with mobile phase B followed by mobile phase 
A.  Following positive electrospray ionization (3.5 kV capillary), mass spectra were acquired 
with a time of flight mass spectrometer (model 6220, Agilent Technologies, Santa Clara, CA) 
operating in 2 GHz extended dynamic range mode with the fragmentor set to 150 V.  The 
desolvation gas flow was 10 L min
–1
 at 325 °C with a nebulizer pressure of 20 psig.    
Following the completion of a protein digest run, blanks were run to evaluate carry-over.  An 
LC blank was run first to evaluate carry-over in the peptide trap and the reversed phase column.  
For the LC blank, the valve was kept in the load position (see Fig 2.1); there was no injection of 
the contents of the loop.  One or two digestion blanks followed the LC blank.  For the digestion 
68 
 
blanks, 10 µL of 10 mM sodium histidine buffer diluted 1:1 with the reducing quench buffer was 
injected.  The same gradient was used for all blanks and digests.  
2.2.4 Peptide identification 
Preliminary peptide identities were assigned on the basis of accurate mass (± 20 ppm) using 
the known antibody sequence.  Peptides that could not be unambiguously assigned by mass 
mapping were assigned in separate MS/MS measurements.  The antibody sample was diluted 
with quench buffer as described in the Sample Preparation section.  The sample was infused 
through an immobilized pepsin column at 200 μL min
–1
 at 4 °C using a syringe pump.  The 
eluate was collected and flash frozen with liquid nitrogen.  The resulting peptide mixture was 
then analyzed by tandem mass spectrometry by a linear quadrupole ion trap mass spectrometer 
(LTQ-XL, Thermo Scientific).  The peptides were separated by HPLC (Shimadzu) through a 
reversed-phase C18 column (ZORBAX SB300-C18, 2.1 × 100 mm, Agilent) with a 120 min 0-
60% B gradient (A: 99% H2O, 1% ACN, 0.1% formic acid; B: 99 % ACN, 1% H2O, 0.1 % 
formic acid; 200 μl min
–1
 flow rate).  The capillary temperature and voltage were set to 275 °C 
and 48 V, respectively.  The source current was set to 100 μA, the tube lens was set to 115 V, 
and the sheath gas flow rate was set to 40.  Data-dependent MS/MS analysis was performed 
using the Xcalibur 2.0 software (Thermo Scientific).  Survey mass spectra were acquired in the 
LTQ over an m/z range of 300-2000.  The three most intense ions in each spectrum were selected 
for fragmentation by collision-induced dissociation using normalized collision energy of 35 V.  
Ion selection threshold was 1,000 counts and the dynamic exclusion duration was 30 s.  After the 
initial MS/MS run, inclusion and exclusion mass lists were included during additional runs to 
increase the number of confirmed peptides from the consensus list.  Raw data was processed 
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using the Proteome Discoverer 1.3 software (Thermo Scientific).  Only MS/MS spectra with 
XCorr score of ≥ 2 were used to validate peptide assignments.   
2.2.5 Pepsin column washing 
The pepsin column wash process consisted of two injections of 100 µL of wash cocktail.  
Wash cocktail 1 was 5% acetonitrile/5% isopropanol/20% acetic acid in water and wash cocktail 
2 was 2 M guanidine hydrochloride / 100 mM sodium phosphate at pH 2.5.  Three different 
washing processes were evaluated:  2 × wash cocktail 1, 2 × wash cocktail 2, and wash cocktail 1 
+ wash cocktail 2.  The loading pump was used to carry each injection through the pepsin 
column and trap at a flow rate of 200 μL min
–1
 for 7.5 min (see Fig 2.1, middle panel).  The 
injection port and sample loop were flushed between injections as described in the previous 
section.   
2.2.6 Pepsin column stress test 
To determine if the pepsin column remained stable after extensive washing, an immobilized 
pepsin column was subjected to 200 wash injections, alternating between wash cocktails 1 and 2, 
for a total of 100 cycles of the two-step washing process.  This test was performed using an HDX 
PAL robot (LEAP Technologies, Carrboro, NC) with a refrigerated compartment held at 0 °C 
housing the trap, columns and valves.  The HDX PAL system is comprised of two valves and 
features a back-flush of the pepsin column to waste during the gradient elution step.  In other 
respects, the configuration of the pumps and columns is the same.  The pepsin column stress test 
began with an online antibody digest run.  The digest run was followed by 100 wash cycles, as 
described above.  After the 100 wash cycles, the online digestion of the antibody was repeated.  
2.2.7 Data processing 
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Peptide mass spectral features from digestions were extracted using the Find by Molecular 
Feature algorithm in MassHunter Qualitative Analysis with BioConfirm (Agilent Technologies, 
Santa Clara, CA).  The peptides were quantified using the MS intensity from spectra averaged 
across the chromatographic band.  Peptides were initially assigned by mapping them onto the 
antibody sequence by mass-matching (± 10 ppm) using Protein Prospector (MS-Product, 
http://prospector.ucsf.edu).  An exclusion list, developed from online digest blanks run before 
antibody digestion, was used to eliminate pepsin autodigestion peptides.  The list of extracted 
antibody peptides was filtered to exclude peptides with low MS response (< 3000 counts) and to 
remove peptides with fewer than 5 residues or more than 25 residues.  To account for variability 
across the digest runs obtained on different days, a consensus list of 169 peptides found in all 
digest runs (Figs 2.2, 2.3, and pre-stress digest of Fig 2.4) was constructed.  Consensus peptides 
were those peptides that matched mass within ± 10 ppm across all runs and had a retention time 
standard deviation of less than 0.2 min.  Since the pepsin column stress test was run using a 
different LC system, only the 10 ppm mass match criterion was imposed for the pre-stress list.  
For carry-over detection, a signal threshold of 750 counts, the approximate chemical noise level, 
was imposed.  101 of the 169 consensus peptide assignments were confirmed using MS/MS; 57 
of which were not carried-over and 44 of which were carried over in blank digestions.  The pI 
and hydrophobicity for each identified peptide was determined using ProtParam
20, 21
 on the 
ExPASy server (http://web.expasy.org/protparam/). 
2.3 Results and Discussion 
Because carry-over can introduce serious artifacts into H/D exchange measurements, we 
routinely undertake a carry-over study at the beginning of LC method development for H/D 
exchange studies of proteins.  Recently, method development work in our laboratories with an 
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IgG1 monoclonal antibody revealed substantial carry-over in blanks following online pepsin 
digestion of the protein.  Some level of carry-over can usually be found in LC/MS data if one 
looks hard enough.  For quantitative analysis, rigorous definitions of carry-over can be derived 
that can be used to set thresholds for identifying significant carry-over effects
22, 23
. In the case of 
qualitative analyses, such as proteomic studies, however, any amount of carry-over can 
potentially result in false-positives
24
.  In H/D-MS, carry-over can produce a so-called false EX1 
MS signature that can skew the average mass determination
15
.  
2.3.1 Online digestion is the major source of peptide carry-over  
The flow path for our online digestion system
19
 at different stages in the analysis process is 
shown in Fig 2.1.  The system consists of a two-position twelve port valve.  In the A position, the 
loop was loaded with sample, the immobilized pepsin column was in-line with the loading pump 
and the reversed-phase trap and separation column are in-line with the gradient pump.  Switching 
to the B position puts the loop and peptide trap in-line with the pepsin column and loading pump 
(0.1% formic acid).  During this stage, the contents of the loop are carried through the pepsin 
column and then pass through the trap.  Following a suitable digestion interval, the valve was 
switched back to the A position.  In this position, the reversed-phase trap and separation columns 
are in-line with the gradient pump; a water-acetonitrile gradient was then used to elute and 
separate the peptides. 
Representative chromatographic and mass spectral data illustrating the carry-over problem are 
shown in Figures 2.2(a) and 2.2(b), respectively. The top panels (labeled mAb digest) show a 
well-defined chromatographic peak in the extracted ion chromatogram for a selected mAb 
peptide.  To isolate sources of the carry-over in the chromatographic system, we used a series of 
blank runs following an antibody digestion run.  First, an LC blank followed each injection of the 
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antibody for online digestion.  The LC blank was simply a second gradient cycle run while the 
valve was held in the A position (see Fig 2.1); the reversed-phase trap and separation column 
were not re-exposed to eluate from the immobilized pepsin column.  The second set of panels in 
Figures 2.2(a) and 2.2(b) (labeled LC blank) show a minimal MS response for the peptide (<1% 
carry-over, quantified by the MS intensity).  As the next set of panels show, however, the peptide 
was readily detected in a subsequent blank digestion (an injection of sample buffer without 
protein) with a mass spectral response 26% of its original value. Hence, the major source of 
carry-over for this peptide was the immobilized pepsin column, not the reversed-phase trap and 
column.   
To account for the inherent variability in digestion across the numerous LC/MS runs in this 
study, a consensus list of 169 peptides found in common across all digests was employed.  For 
this reason, the reported number of peptides detected in the antibody digests is always 169.  The 
number of consensus peptides detected in the antibody digest and in the blanks are shown in Fig 
2.2(c).  For the LC blank, out of 169 peptides detected in the digestion of the antibody, only 8 ± 
5 peptides were carried over.  This result shows that only ~5% of the peptides could be detected 
as carry-over in the trap and the reversed phase column. On average, the peptides carried-over in 
the LC blank had an MS intensity of 3.4% of their intensities in the digest.  In contrast, blank 
digestions, showed significantly more carry-over (44 ± 12 peptides) that persisted through a 
second blank digest (21 ± 14 peptides) and the average intensity was 9%. These results show that 
most of the carry-over from this antibody digestion arose from the immobilized pepsin digestion 
process, not from peptides retained on the reversed-phase column and trap. Similar results were 
obtained when these studies were performed using both a different in-house column and a 
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commercial column (Applied Biosystems) (data not shown).  We have also observed that the 
number of carried-over peptides increased as the mAb load was increased (data not shown).  
2.3.2 Pepsin column washing decreases peptide carry-over 
Having established that online digestion was the major source of carry-over, we developed a 
pepsin column wash procedure.  A wide variety of washing reagents and washing cocktails to 
mitigate peptide carry-over have been described in the literature (for example 
15, 24
) for the 
reversed-phase column and trap.  In the case of the online pepsin column, however, it is essential 
that the washing reagents do not irreversibly perturb the immobilized enzyme.  The 
manufacturer’s literature indicated that immobilized pepsin would tolerate low concentrations of 
organic co-solvents and moderate concentrations of denaturants.  We thus evaluated two 
different wash solutions:  “Wash 1” consisted of acetonitrile (5 vol%) / isopropanol (5 vol%) / 
acetic acid (20 vol%) in water, and  “Wash 2” contained 2 M guanidine hydrochloride and 100 
mM sodium phosphate buffer at pH 2.5.  Two sequential loop volumes of the wash cocktails 
were injected onto the pepsin column (see Fig 2.1). Figures 2.2(a) and 2.2(b) (bottom panels) 
show that there was a significant decrease in MS response for the representative peptide in both 
the mass spectrum and the corresponding extracted ion chromatogram (~4% carry-over).  The 
effects of different combinations of the two washes on peptide carry-over in digestion blanks are 
shown in Fig 2.3.  For example, Wash1 + Wash2 was equally effective at minimizing carry-over 
as 2 × Wash2 (9 ± 5 and 12 ± 3 carried-over peptides, respectively).  In contrast, injection of two 
loop volumes of Wash 1 was significantly less effective than the other two combinations (26 ± 3 
carried-over peptides), yet still decreased carry-over in the digest blank relative to carry-over 
observed without washing (44 ± 12 carried-over peptides). These results demonstrate that for this 
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IgG1 mAb, peptide carry-over can be substantially decreased by post-digest injection of the wash 
cocktails through the online immobilized pepsin column. 
2.3.3 Pepsin column washing does not degrade pepsin column performance 
To determine if the washes would have a detrimental effect on the performance of the pepsin 
column, we subjected a pepsin column to a stress test consisting of 200 alternating injections of 
Wash 1 and Wash 2.  The pepsin column was used to digest the antibody before and after the 
stress test.  After the stress test, 151 of the 169 peptides were detected (Fig 2.4), indicating that 
the pepsin column retains most of its specificity. To determine if enzymatic activity was lost, we 
compared the MS response of each of the 151 individual peptides before and after the stress test.  
Figure 2.5 shows a plot of peptide MS response after the stress test vs. MS response before the 
stress test.  The figure shows a near-unity slope (0.97) with an excellent linear correlation (r
2
 = 
0.92) indicating that there was little loss in peptide abundance following the pepsin column stress 
test.  To further examine the effects of wash protocols on pepsin activity, we examined the mass 
distribution of all abundant peptides that could be mapped onto the mAb sequence (see Table 
2.1).  The average peptide mass and standard deviations of the distributions were essentially the 
same before and after the stress test (1697 ± 1250 Da vs. 1769 ± 1366 Da), although there was an 
18% decrease in the total number of peptides.  (This analysis relies on peptide mass rather than 
length, since not all peptide assignments in this expanded list of peptides were confirmed by 
MS/MS.)   The results indicate that the stress test had little effect on the selectivity of the 
immobilized pepsin.  Taken together these results demonstrate that extensive washing of the 
pepsin column does not lead to a pronounced decrease in either specificity or activity. 
2.3.4 Basis of the carry-over 
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A variety of hydrodynamic and chemical effects can cause carry-over
24
.  Regions of unswept 
volume caused by tubing diameter mismatches, scratches in valve components, or inadequate 
flushing of a needle port are examples of mechanical sources of carry-over.  In the experimental 
setup employed here, the digestion flow-path was flushed continuously by the loading pump (see 
Fig 2.1) for 12 min during the gradient step and an additional 17 min during the LC blank shown 
in Fig 2.2.  Despite this long washout period, significant carry-over persisted, as shown in Fig 
2.2.  In addition, the needle port was thoroughly flushed between injections.  Finally, only a 
limited sub-set of the peptic peptides from the antibody digest were found to carry over.  Taken 
together, these observations suggest that the observed carry-over is not attributable to 
hydrodynamic effects, rather it appears to be chemical in nature.  If undigested protein were 
carried over, then all peptides would exhibit the effect.  Thus we conclude that it is carry-over of 
peptides or partially digested protein, rather than intact protein. 
The observed carry-over has been shown to be primarily due to the immobilized pepsin 
column digestion process (Figs 2.2 and 2.3).   Carry-over could potentially arise from the binding 
to the immobilized pepsin itself, the column stationary phase substrate, or chromatographic 
system components (frits, tubing, etc.).  According to the manufacturer’s literature, the POROS 
substrate for pepsin immobilization is a cross-linked poly(styrene-divinylbenzene).  Carry-over 
could therefore arise from slow release of hydrophobic or aromatic peptides from the stationary 
phase.  Carry-over could also potentially arise from specific binding between pepsin and certain 
amino acid sequences found in the antibody.  For example, pepsin inhibitor-3 (PI-3) from 
Ascaris suum is a protein that reversibly inhibits pepsin through the tight binding of short linear 
segment into the pepsin active site
25
.  Alternatively, carry-over could also arise from non-specific 
associations with the pepsin.   
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To determine if there were any chemical characteristics that could distinguish between 
peptides exhibiting carry-over from peptides that were not carried over, we compared the two 
sets of peptides with respect to mass, MS response, pI, and hydrophobicity
20
 (see Fig 2.6).  We 
are unable to distinguish between peptides that were carried-over from peptides that were not 
carried-over on the basis of mass, pI, or hydrophobicity.  This result suggests that there may in 
fact be several different mechanisms that contribute to carry-over.  Our results suggest that 
carried-over peptides have a greater MS response, but this is attributable to carry-over becoming 
undetectable in peptides that had low MS response in the digest.  
2.4 Conclusions 
In this paper we have demonstrated that significant amounts of carry-over can arise from the 
digestion of an IgG1 monoclonal antibody with an immobilized pepsin column under conditions 
used in H/D exchange mass spectrometry measurements.  Further, we have shown that the online 
digestion itself was the major source of the observed carry-over.  It remains to be determined 
whether similar carry-over would arise from other proteases
26, 27, 28
 or whether similar results will 
be observed with different monoclonal antibodies (e.g., IgG2, IgG4). We have developed a two-
step washing process for the immobilized pepsin column that greatly diminished the amount of 
carry-over for the IgG1 mAb being examined in our laboratory.  Finally, we have shown with a 
pepsin column stress test that extensive washing (100 cycles) does not adversely affect either the 
specificity or activity of the pepsin column.  Based on our analysis of chemical properties of the 
carried-over peptides, there was no single distinctive property of the peptic peptides that can 
simply explain the basis for the observed carry-over. 
The immobilized pepsin column washing procedure described in this work is not easily 
implemented on single valve systems
19
 because injection interrupts the elution step (see Fig 2.1).  
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This setup requires that the pepsin column wash must be delayed until the end of the gradient 
run.  In contrast, with two-valve in-line systems
14
, such as the robotic system we used for the 
pepsin column stress test, the wash process can be run in parallel with the elution and reversed-
phase separation of the peptides. 
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Table 2.1   
 
 before stress test after stress test 
n 565 461 
mean mass (Da) 1769 1697 
median mass (Da) 1312 1292 
standard deviation (Da) 1367 1249 
 
Size distribution and number of IgG1 mAb peptic peptides
1
 before and after stress test of 
immobilized pepsin column.   Stress test consisted of 200 alternating injections of Wash 1 and 
Wash 2; see text). 
 
1
MS features that mapped onto the mAb sequence with better than ±10 ppm mass accuracy and 
had an MS base-peak response greater than 10
4
 cps at the chromatographic peak maximum.
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 Figure 2.1   
 
 
Flow diagram of the LC/MS system for online digestion with an immobilized pepsin column 
used for carry-over studies.  The system is comprised of a two-position, twelve port valve
19
.  The 
red regions of the flow path denote the location of sample at the different stages of analysis.  In 
the first step, sample is loaded through the needle port with the valve in the A position.  In the 
second step, the valve is switched to the B position.  The loading pump carries sample through 
the pepsin column where the resulting peptides are captured by the reversed-phase peptide trap.  
In the third step, the valve is switched back to the A position and a water-acetonitrile gradient 
elutes the peptides from the trap onto a reversed-phase column for separation and then to the 
mass spectrometer for analysis. 
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Figure 2.2 
 
 
 
 
 
 
 
Carry-over from the online digestion of an IgG1 monoclonal antibody with an immobilized 
pepsin column arises from online digestion.  Extracted ion chromatograms (a) and mass spectra 
(b) of the peptide PEVTCVVVDVSHEDPEVK show that carry-over of this peptide was 
insignificant in the LC blank compared with the carry-over in the digestion blank.  A digest 
blank following a pepsin column wash (see text for details) shows that washing eliminated the 
observed carry-over. (c) A list of 169 consensus peptides found in all digestion runs was used to 
identify carried-over peptides.  Only a small number of these consensus peptides were found in 
the LC blank while a much larger number were detected in two subsequent digestion blanks.  
Based on flow diagram (see Fig. 2.1), the online pepsin digestion is thus the major source of 
peptide carry-over.  The error bars denote one standard deviation for three independent 
replicates.  (Since all 169 peptides were found in all digestions, no error bars are shown for the 
digest.) 
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Figure 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Injections of different combinations of two wash cocktails decreased the number of consensus 
peptides (see Fig 2.2c) detected as carry-over in the digestion blanks.  For comparison, the mAb 
digest and digest blank 1 values are duplicated from Fig 2.2c.  For the composition of the wash 
cocktails, see the Methods section.  The error bars denote one standard deviation for three 
independent replicates.  (Since all 169 peptides were found in all digestions, no error bars are 
shown for the digest).   
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Figure 2.4 
 
 
 
 
 
A pepsin column stress test consisting of 200 alternating injections of wash cocktails 1 and 2 did 
not cause a substantial decrease in the number of detected consensus peptides (see Fig 2.2c) in 
the online digestion of an IgG1 monoclonal antibody. 
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Figure 2.5 
 
 
 
 
 
A pepsin column stress test consisting of 200 alternating injections of wash cocktails 1 and 2 did 
not cause a substantial decrease in the MS response of the consensus peptides.  Each point 
corresponds to one of the 151 consensus peptides detected after the pepsin column stress test (see 
Fig 2.4).   
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Figure 2.6 
 
Carried-over peptides are indistinguishable from peptides that were not carried over on the basis 
of (a) mass, (b) MS response, (c) pI, and (d) hydrophobicity
20
.  In (d), negative values are 
hydrophilic and positive values are hydrophobic.  For each category, the median value is 
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designated by the horizontal band in the middle of the box; the box limits indicate the 25th and 
75th percentiles.  The bars denote the minimum and maximum values.  
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Chapter 3 
 
Correlating Excipient Effects on Conformational and Storage Stability of an IgG1 
Monoclonal Antibody with Local Dynamics as Measured by Hydrogen-Deuterium 
Exchange Mass Spectrometry  
 
 
 
 
 
 
 
 
 
 
(“Correlating Excipient Effects on Conformational and Storage Stability of an IgG1 Monoclonal 
Antibody with Local Dynamics as Measured by Hydrogen-Deuterium Exchange Mass 
Spectrometry.”, Manikwar P., Majumdar R., Hickey J.M., Thakkar S.V., Samra H.S., Hasige 
A.S, Bishop S.M., Middaugh C.R., Weis D.D., Volkin D.B., J. Pharm. Sci. 2013 
Jul;102(7):2136-51.) 
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3.1 Introduction 
Immunoglobulin G1s (IgG1s) are large, complex glycoproteins, belonging to a major class of 
therapeutic protein drug products approved for treatment of a wide range of human diseases.
1
 
The IgG1 protein consists of four polypeptide chains that are bridged by disulfide bonds.  Each 
of these polypeptide chains forms distinct globular-like domains (e.g., CH 1, 2, 3, VH for the 
heavy chain; CL and VL for the light chain) which in turn form the two antigen binging fragments 
(Fab) and one crystallizable fragment (Fc) that impart a Y-shaped structure to the molecule.  The 
Fabs are linked to the Fc by a proline-rich hinge region,
2
 which provides flexibility to the 
molecule.
2-4
  Due to these structurally independent fragments, IgG1s are considered to be highly 
dynamic proteins in solution, with motions ranging from small alterations of side chains and the 
peptide backbone to larger scale movement of structural domains relative to each other.
3-5
  IgG1 
molecules are thus not only an excellent model, but also an important therapeutic class of 
proteins for exploring the inter-relationships between protein stability and dynamics.  
A common approach to improve a therapeutic protein’s storage stability and protect it from 
various environmental stresses is adding pharmaceutical excipients to the formulation.  Some of 
the most widely used excipient categories for stabilizing proteins include sugars, polyols, amino 
acids, salts, and surfactants.
6
 Stabilizing excipients for protein drug candidates, including mAbs, 
can be identified by high-throughput screening methods that utilize multiple biophysical 
techniques.
7-12
  For example, a recent study using intrinsic Trp fluorescence spectroscopy 
examined various stabilizing excipients and identified specific sugars and polyols that increased 
the thermal unfolding temperature (Tm) of a mAb by ~6 C.  These results correlated well with 
their effects on aggregation behavior.
7
  Previous studies in our laboratories have shown that 
excipients such as sucrose and arginine affect both the conformational stability and the global 
92 
 
dynamics of mAbs.
13
  In fact, when two different IgG1 monoclonal antibodies (mAbs) were 
examined, differential effects of these two excipients on the mAb’s conformational stability and 
global dynamics were observed.
13,14
 
The evaluation of the various physicochemical mechanisms by which excipients interact with 
and stabilize proteins at the molecular level is an area of active investigation.
6,15-17
  Some 
excipients stabilize proteins by direct interaction, while others by indirect mechanisms such as 
preferential hydration.
6,16
  It has been shown that the flexibility of the amide backbone and side-
chain interactions can play a significant role in maintaining protein thermal stability.
18-20
  In 
addition, solution conditions such as pH and temperature can have profound effects on 
immunoglobulin dynamics and stability through alteration of solvent fluctuations.
21,22
  These 
studies suggest a complex relationship between differential flexibility and conformational 
stability of proteins.
21-25
   
While several biophysical techniques can provide information about the global dynamics of a 
protein, localized information is more difficult to obtain, especially for large proteins such as 
mAbs in solutions containing pharmaceutical excipients.  Amide H/D exchange analyzed by 
mass spectrometry (H/D-MS) has become widely used to measure local backbone dynamics of 
proteins in solution.
26-30
  H/D-MS in combination with proteolytic fragmentation using pepsin 
offers peptide-level structural resolution for proteins including mAbs.
29,31-34
  Previously, H/D-
MS was successfully applied to study the effect of excipients on protein conformational changes 
in both the solid state
35-37
 and frozen state.
29,30
  Here, we have adopted H/D-MS to identify 
regions in an IgG1 mAb with differential flexibility in the presence of stabilizing and 
destabilizing excipients under solution conditions.  
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A better mechanistic understanding of protein/excipient interactions as related to their effects 
on conformational stability, storage stability, and local dynamics may lead to new approaches to 
improve current protein formulation methodologies.  We hypothesize that stabilizing and 
destabilizing pharmaceutical excipients have differential effects on the local dynamics of certain 
regions within IgG1 molecules.  This, in turn, can be correlated with their effects on the overall 
conformational and storage stability of mAbs.  This work examines the effects of stabilizing 
(sucrose) and destabilizing (arginine) excipients on the conformational stability as well as the 
accelerated and long term storage stability of a model IgG1 mAb (mAb-B) at pH 6.0 using 
differential scanning calorimetry (DSC) and size-exclusion chromatography (SEC), respectively.  
Concomitantly, H/D-MS analysis was performed with mAb-B in the presence of sucrose and 
arginine to identify changes in the local flexibility of different regions within mAb-B.  Finally, 
the corresponding local structural flexibility alterations, especially in the CH2 domain, were 
correlated with mAb-B’s overall conformational and storage stability.   
3.2 Materials and methods 
3.2.1 Materials 
The IgG1 monoclonal antibody (mAb-B) was obtained at 50 mg/mL containing 0.005 % 
polysorbate 80 in 10 mM histidine buffer at pH 6.0 from MedImmune (Gaithersburg, MD). 
Protein concentration was determined with an Agilent 8453 UV-visible spectrophotometer (Palo 
Alto, CA) using an extinction coefficient 1.45 M
-1 
cm
-1
 after diluting the stock mAb-B solution.  
Liquid chromatography grade acetic acid and phosphoric acid, tris (2-carboxyethyl) phosphine 
hydrochloride (TCEP), arginine monohydrochloride, porcine pepsin, guanidine hydrochloride 
and deuterium oxide (99+%D) were purchased from Fluka/Sigma Aldrich (St Louis, MO).  
LC/MS grade formic acid (99+ %) was purchased from Thermo Scientific (Rockford, IL). 
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Sodium chloride and LC-MS grade water, acetonitrile and isopropanol were purchased from 
Fisher Scientific (Fair Lawn, NJ).  Sucrose (ultrapure, RNAse free) was purchased from MP 
Biomedicals LLC. (Solon, OH).  Anhydrous forms of sodium phosphate dibasic and citric acid 
(99.5%) were purchased from Acros Organics (NJ, USA).  
3.2.2 Differential scanning calorimetry (DSC)  
DSC thermograms were obtained using a Microcal VP-Capillary DSC with autosampler 
(MicroCal, Northampton, MA).  A scan rate of 60C/hr. was used over the temperature range 
10-100 C.  DSC thermograms of mAb-B in the presence of 0.1 M NaCl (control), and 0.1 M 
NaCl containing either 0.5 M sucrose, 1 M sucrose, 1.35 M sucrose, 0.5 M arginine, 1 M 
arginine or 1.35 M arginine in 20 mM citrate-phosphate buffer (pH 6.0) were compared to 
reference thermograms of buffer alone (sample containing excipients but no mAb-B).  Data 
analysis was performed using the MicroCal LLC DSC plug-in for the Origin 7.0 software 
package.  These results were fit to a multi-state model with three transitions to calculate the 
midpoint of thermal unfolding (Tm) values.  The onset temperature (Tonset) was determined by 
identifying the point where the heat capacity (Cp) value for the first thermal transition reached 
500 cal/mol/C. 
3.2.3 Storage stability study  
Samples of mAb-B containing 20 mM citrate-phosphate buffer (pH 6.0) with 0.1 M NaCl in 
the absence of additional excipients (control), or containing either 0.5 M sucrose or 0.5 M 
arginine were prepared at a concentration of 0.5 mg/mL.  Corresponding control solutions were 
also prepared without mAb-B.  All three mAb formulations were sterilized using a 0.22m filter 
(Millipore, Billerica, MA) in a pre-sterilized laminar flow hood and 0.5 mL aliquots were 
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dispensed into 1mL borosilicate glass type I vials (West Pharmaceutical Services, Exton, PA) 
and sealed with rubber stoppers (West Pharmaceutical Services, Exton, PA).  Samples were 
stored in duplicate at –70, 4, 25, and 40 C and analyzed by SEC at time zero and after storage 
for approximately 1, 2, 3, 6, 9, and 12 months.  For stressed storage, duplicate samples were 
incubated for 1 month for 55 C.  
3.2.4 Size exclusion high performance liquid chromatography  
Samples were analyzed using a Shimadzu HPLC system with photodiode array detector 
capable of recording 200400 nm UV absorbance spectra with a 7.8  30 cm Tosoh TSK-Gel 
BioAssist G3SWxL (TOSOH Biosciences, King of Prussia, PA) and a corresponding guard 
column.  Following preconditioning, the column was calibrated using molecular weight 
standards (Bio-Rad, Hercules, CA).
38
  To remove insoluble aggregates, all samples were 
centrifuged at 14,000  g for 5 min before injection.  To separate soluble mAb-B species based 
on size, a mobile phase containing 0.2 M sodium phosphate, pH 6.8 and a flow rate of 0.7 
mL/min were used.  The elution of mAb-B was monitored using the absorbance spectrum from 
200-400 nm.   
The peak areas for each resolved species (multimer, dimer, monomer, and fragments) were 
quantified using the dual wavelength quantification method.
38
  The peak areas for multimers and 
dimer were combined to obtain the total amount of soluble aggregates.  Since this SEC method is 
primarily used to determine the level of soluble aggregates, monomers and fragments, an indirect 
method was used to quantify the insoluble aggregates.
39
  The difference in the total area of mAb-
B (sum of all SEC peaks in a chromatogram) at any time point versus time zero was defined as 
the formation of insoluble aggregates.
39
  Then, the percentage of each of the species (insoluble 
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aggregate, soluble aggregate, monomer, and fragment) remaining relative to the total area at time 
zero was calculated and plotted against incubation time using the equation given below: 
            
 t
  
     
where at is the area of individual species on any given day (0 or 1 month), A0 is the total area 
(combined area) of all the species at time zero.  The error bars for soluble aggregate, monomer, 
and fragment represent standard deviation
40
 of single measurement of duplicate vials, while the 
error bars for insoluble aggregate were obtained by calculating propagation of uncertainty 
resulting from the errors in three different measurements (soluble aggregate, monomer, and 
fragment).  
3.2.5 Preparation of deuterated formulation buffers 
Deuterated formulation buffers containing 0.5, 1.0, and 1.35 M excipients (arginine or 
sucrose), 0.1 M sodium chloride and 20 mM citrate-phosphate at pH 6.0 were prepared for 
deuterium labeling mAb-B.  The molar percentage of exchangeable deuterium was fixed at 90 by 
accounting for exchangeable hydrogens in the excipients.  The procedures for preparing a fixed 
percent of deuterated excipient buffers are discussed below. 
The desired mole fraction of exchangeable deuterium in the buffer, F, is given by 
  
     
                
             (1) 
where n represents the number of moles of the subscripted substance, the subscript ex 
denotes the excipient, and λ is the number of exchangeable hydrogens in an excipient molecule. 
(Equation (1) is accurate to ±0.01% for a typical 20 mM buffer, such as citrate-phosphate. For 
strongly-buffered solutions, the equation would need to be modified to incorporate the 
contribution of buffer agents to the pool of total exchangeable hydrogens.) 
This equation can be re-arranged into a linear form: 
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              (   )                (2) 
The first step is to fix the number of moles of D2O by choosing a convenient nominal buffer 
volume (Vnom). This volume is arbitrary, but reduces the number of free parameters: 
     
        
    
                                                             (3) 
where ρ is the density of D2O and D2O M is the molar mass of D2O in kg mol–1. Because of 
changes in solution volume upon addition of solutes, this nominal buffer volume will not be 
achieved. Vnom is used to ensure that sufficient buffer is prepared to within perhaps 20%. Fixing 
the number of moles of D2O leaves two unknowns in equation (2). 
The molal concentration of the excipient (mol kg–1): 
    
   
                 
                      (4) 
can be fixed at the desired value. Rearranging into a linear form: 
                                               (5) 
leaves a system of two linear equations, (2) and (5), with two unknowns, nex and H2O n . 
Solving these equations provides the general recipe for the deuterated buffer: 
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We confirmed that λ = 8 for both arginine and sucrose by mass spectrometry as follows. About 1 
mg of each excipient was separately incubated in 1 mL of D2O for 24 hours at 25 °C. The 
solution was then diluted 103 fold in 80% acetonitrile/20% D2O/0.1% formic acid and directly 
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infused into the electrospray ionization source of a time of flight mass spectrometer (Agilent 
6220). The mass spectrometer was operated in positive ion mode for arginine and negative ion 
mode for sucrose. The number of exchangeable hydrogens was obtained by calculating the mass 
increase of arginine or the sucrose-formate adduct in the deuterated forms compared to their 
protonated forms. 
The buffers were prepared directly in a graduated cylinder so that the final volume of the 
solution could be measured. The excipient, D2O, and H2O were added according to their 
calculated weights from equation (6). Once the total solution volume was determined, sodium 
chloride was added to 0.10 M. Then solid anhydrous citric acid and anhydrous dibasic sodium 
phosphate (Na2HPO4) were added directly at 4.0 mM and 16.0 mM, respectively. The small 
amounts of buffering agents, < 2 g L–1, did not significantly change the total volume of the 
solution. The pH was then adjusted to 6.0 without any further correction for the isotope effect. 
The final molar concentrations of the excipients were within 4% of their targeted concentrations. 
3.2.6 Hydrogen/deuterium exchange mass spectrometry (H/D-MS) 
Sample handling for H/D exchange experiments was done using an H/DX PAL (LEAP 
Technologies, Carrboro, NC) robot. 2 µL of mAb-B (10mg/ml), held at 1 °C, was deuterium 
labeled with 38 µL of 90 atom% labeling buffer at 25 °C for 120, 10
3
, 10
4
 and 10
5
 s.  The 
exchange was quenched by 1:1 dilution in a quench buffer (0.5 M TCEP, 4 M guanidine HCl and 
0.2 M phosphate at pH 2.5) at 1 °C. 10 µL of the quenched solution (approximately 16 pmoles of 
mAb-B) was injected into the sample loop of a refrigerated compartment (attached to the H/D 
exchange PAL and the LC) housing the two valves, the immobilized pepsin column, the reversed 
phase trap and column.  The refrigerated compartment was maintained at 0 °C for our 
experiments. The LC-MS analysis of the mAb-B peptides were performed as described 
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previously.
41
  
3.2.7 MS data processing and analysis 
The peptides were identified using a combination of accurate mass data from the TOF and 
tandem mass spectrometry data from a linear ion-trap mass spectrometer (LTQ-XL; Thermo 
Scientific).
41
  A peptide map covering 85% of the primary sequence of mAb-B with a total of 
137 segments was created. H/D exchange data was processed and analyzed in the same manner 
as described elsewhere.
42
  Briefly, HDExaminer (Sierra Analytics, CA) was used to process the 
H/D exchange data.  All peptide mass spectra from three independent replicate experiments were 
processed by three different analysts to eliminate any potential bias in data processing.  The 99
th
 
percentile for a deuterium uptake difference for a peptide segment was ±0.59 Da in our 
experimental setup 
42
.  H/D exchange data were mapped onto a homology model of mAb-B 
based on human IgG1 b12 (PDB ID: 1HZH)
43
 as described in the Supporting Information.   
3.2.8 Construction of the homology map of mAb-B 
mAb-B and IgG1 B12 (PDB ID 1HZH)
1
 shared approximately 90% sequence homology with 
most differences located in the CDR region. Discovery Studio 3.0 (Accelrys, San Diego CA) was 
used to thread the primary sequence of mAb-B onto the 1HZH structure. Manual reassignment of 
secondary structures for mAb-B was done after correcting for gaps in the secondary structure 
assignment and renumbering the residues. Models were displayed using Pymol (Schrödinger, 
LLC, Portland, OR). 
3.3 Results 
3.3.1 Sucrose increases whereas arginine decreases the Tonset and Tm temperatures of mAb-
B 
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The conformational stability of mAb-B was examined in the presence and absence of 
excipients.  Sucrose and arginine were selected based on their previous recognition as stabilizers 
and destabilizers of immunoglobulins.  Figure 3.1A shows a representative DSC thermogram of 
mAb-B at pH 6.0 at 0.5 mg/mL which displays three thermal unfolding events with transition 
temperatures Tm1, Tm2, and Tm3.  The first transition (Tm1) is associated with the unfolding of 
the CH2 domain,
44,45
 and is more prominent in samples containing arginine than NaCl (control) 
and sucrose (see Figures 3.1B and 3.1C).  The second (Tm2) and third (Tm3) transitions are 
associated with the unfolding of the Fab and CH3 domains.
44-48
  A decrease in Tm1, Tm2, was 
observed, while Tm3 increased slightly, with increasing concentrations of arginine compared to 
control (Figure 3.1B and Table 3.1).  In contrast, an increase in all three unfolding temperatures 
was observed with sucrose in a concentration dependent manner (Figure 3.1C and Table 3.1).  
The observed changes in conformational stability of mAb-B at pH 6.0, indicated by either 
increased or decreased Tm values, were consistent with previous results obtained at pH 4.5.
13
  To 
better understand the effects of arginine and sucrose on the thermal stability of mAb-B, the onset 
temperatures for unfolding (Tonset) were also determined from the same DSC thermograms.  As 
shown in Table 3.1, in the presence of arginine, the Tonset values decreased with increasing 
excipient concentrations.  In contrast, the Tonset values were delayed in a concentration dependent 
manner in the presence of sucrose.   
3.3.2 Arginine decreases whereas sucrose increases the accelerated storage stability of 
mAb-B 
To better understand the effects of arginine and sucrose on the accelerated and long-term 
storage stability of mAb-B, protein samples were stored in stoppered glass vials at different 
temperatures (–70, 4, 25, 40, and 55 C) for up to 12 months.  First, the total area, monomer, 
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aggregate, and fragment content of SEC chromatograms were compared at day 0; 
chromatograms of mAb-B at time zero in formulation buffer (20mM citrate-phosphate buffer at 
pH 6.0 containing 0.1 M NaCl) without additional excipients (control) and in the presence of 
0.5M arginine or 0.5M sucrose are shown in Figure 3.2A (dotted lines).  These three mAb-B 
samples contain primarily monomer with low levels of dimer and fragments, and the SEC 
chromatograms of mAb-B in the three buffers superimpose well with no notable differences 
(Figure 3.2A; dotted lines).  Figure 3.2A (solid lines) also shows an overlay of SEC 
chromatograms of mAb-B in the same formulation buffers after storage for 4 weeks at 55C.  It 
can be seen that these stressed mAb-B samples show an additional, earlier eluting peak 
(multimeric species), a decrease in monomer, and elevated levels of fragments (peak assignments 
are based on molecular weight).  The loss of monomer was more pronounced in mAb-B samples 
containing arginine than in NaCl and sucrose.  
To better evaluate the effects of arginine and sucrose on formation of different degradants 
(fragments, soluble, and insoluble aggregates) of mAb-B, SEC results are summarized in a bar 
chart format at time zero and compared to the same samples incubated for 1 month at 55 C 
(Figure 3.2B and 3.2C).  At time zero, there are no initial differences between the different forms 
of mAb-B formulated with either arginine or sucrose compared to control (Figure 3.2B).  
Samples of mAb-B incubated at 55 C for 4 weeks showed significant differences in the type and 
extent of aggregates formed (Fig. 3.2C).  For mAb-B samples containing NaCl only (control), 
both soluble aggregates (i.e., dimers and multimers, 7%) and insoluble aggregates (i.e., derived 
from total area of chromatograms, 23%) were formed.  In comparison, the addition of arginine 
induced formation of more soluble aggregates (42%) but less insoluble material (12%).  In 
contrast, sucrose essentially completely suppresses formation of insoluble aggregates (i.e., none 
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detected) with lower levels of soluble aggregates (10%) compared to the control.  Although 
sucrose containing mAb-B samples showed somewhat higher levels of fragmentation (17%) 
compared to control (13%) and arginine containing formulations (6%), this effect is probably due 
improved mAb-B solubility (i.e., less insoluble protein) in the presence of sucrose when stored at 
55 C for 4 weeks (Fig 2A). 
Figure 3.3 shows the accelerated and long-term storage stability of mAb-B, as quantified by 
monomer relative to time zero, in different formulations at different temperatures.  No significant 
difference in the rate of loss of monomer was observed in mAb-B samples containing different 
excipients stored at 4 C and 25 C over 12 months (Fig. 3).  In addition, no change in loss was 
observed for the same samples stored over 12 months at –70 °C (data not shown).  Samples of 
mAb-B incubated at 40 C showed a more rapid rate of loss of monomer compared to 25 and 4 
C (Fig. 3).  At 40 C, mAb-B samples formulated with arginine showed a faster monomer loss 
after 8 months than NaCl (control), whereas, samples formulated with sucrose manifested slower 
disappearance of monomer than control throughout the time course studied.   
3.3.3 Effect of excipients on the local flexibility of mAb-B in solution 
3.3.3.1 mAb-B in control sample (0.1 M NaCl) 
For H/D-MS analysis, mAb-B was incubated in 90% deuterated solutions containing 20 mM 
citrate-phosphate buffer (pH 6.0) and 0.1 M NaCl in the absence (control) and presence of 0.5 M 
excipients (arginine or sucrose).  The exchange reaction was quenched at various times over ~28 
hours at room temperature, and the mAb was then subjected to rapid proteolysis using pepsin, 
and the resulting peptides were separated and mass analyzed using LC-MS.  Deuterium uptake 
plots were generated by plotting the mass increase for each peptide as a function of incubation 
time.  Deuterium uptake plots for six out of 137 mAb-B peptides observed are shown in Figure 
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3.4. Plots for all 137 mAb-B peptides from mAb-B incubated in the three deuterated 
formulations are provided in the supporting information Figure 3.S1.  For the 0.1M NaCl control, 
the exchange processes in the various peptides can be classified as relatively fast or slow.  For 
example, the heavy chain 300-306 segment (peptide number 71) in the CH2 domain exchanges 
slowly while the HC 156-174 segment (peptide number 53) in the CH1 domain exchanges 
relatively rapidly (Fig. 3.4).  To assess the relative polypeptide backbone flexibility of the entire 
mAb-B molecule in the control formulation (0.1M NaCl), we reported in a separate study the 
percentage deuteration at 120 s relative to maximum theoretical deuteration possible (in a 
companion paper on the inherent flexibility of mAb-B and effects of salts from the Hofmeister 
series, Majumdar et al, manuscript submitted
42
, backbone dynamics of mAb-B formulated in 0.1 
M NaCl are also described; these data serve as a control in this work).  The results showed that 
the CH3 and CH1 domains of mAb-B are relatively more dynamic, while the CH2 domain is 
relatively rigid, under these solution conditions.
42
 
3.3.3.2 Identifying the effects of excipients on local backbone flexibility of mAb-B  
Changes in deuterium uptake for a peptide segment compared to the control (0.1 M sodium 
chloride in 20 mM citrate-phosphate buffer at pH 6.0) were also used to infer changes in local 
flexibility due to presence of excipients.  These effects are shown in the representative deuterium 
uptake plots from different regions of mAb-B in Figure 3.4.  In the presence of excipients, there 
can be either an increase or decrease in the rate of H/D exchange at one or more time points 
compared to the control.  For example, in the presence of arginine, the heavy chain 241-252 
segment (peptide number 66) in the CH2 domain exchanged more quickly with the largest 
difference, relative to the control, evident at 10
3
 s.  In contrast, samples containing sucrose 
showed slower exchange in the same region at two different time points, 10
3
 and 10
4
 s compared 
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to control.  As perhaps expected, the extent of exchange levels-off at later time points (e.g., after 
27.8 hr.).  As shown in Fig. 3.4, only minor differences in the H/D exchange rates were observed 
in the five other representative peptide segments of mAb-B across the three formulations.  The 
statistical significance of these observations is addressed below.  
To better quantify the effects of excipients on H/D exchange across the 137 peptide segments 
from mAb-B, we calculated the differential uptake of deuterium, ΔD(t) = mexcipient(t) – mcontrol(t), 
i.e., the difference in the average mass of a given peptide (in the presence of an excipient 
compared to the 0.1 M sodium chloride control).  The relative deuterium uptake differences for 
each peptide at each labeling time are plotted on the y-axis of Fig. 5 against the corresponding 
peptide number on the x-axis.  Peptide numbers were assigned to each peptide based on 
ascending order of the sequence midpoint from the N-terminus.  In cases where the mid points of 
two sequences were the same, the peptide sequence with a starting amino acid closer to the N-
terminus of the chain was given priority for a smaller peptide number, similar to plots described 
earlier.
31
  The peptide locations are listed in Table 3.S1.   
Following the procedure described by Houde et al.,
32 
a statistical analysis of the H/D 
exchange data set for mAb-B peptide segments was performed (Majumdar et al., submitted 
manuscript)
42
 which showed that the 99% confidence interval for relative uptake differences was 
± 0.59 Da.  Hence, results in which |ΔD(t)| > 0.59 Da are statistically significant (Figure 3.5, 
dotted lines).  Significant differences were either classified as an increase or decrease based on 
their corresponding deuterium uptake.  This classification was used to identify regions of mAb-B 
with significant changes in local backbone flexibility due to the presence of excipients.  The 
results are mapped onto a homology model of mAb-B in Figure 3.6.  Regions showing increases 
and decreases are colored red and blue, respectively and unaffected regions are shown in grey. 
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Regions not covered by H/D exchange measurements are colored yellow.  Based on this 
classification, the effects of 0.5 M excipient (arginine or sucrose) on the local flexibility of mAb-
B are discussed below relative to the control (0.1 M NaCl). 
3.3.3.3 Arginine alters the local flexibility of certain regions of mAb-B 
The effect of arginine on two peptides, HC 241-252 (peptide number 66) in the CH2 domain 
and HC 105-126 (peptide number 50) connecting the VH and CH1 domains, are classified as a 
significant increase in local flexibility at 10
3
s and 10
5
 s, respectively (Fig. 5), and thus are 
colored in red in the homology model (Figure 3.6A).  The segment LC 47-70 (peptide number 
106) in the VL domain is classified as a significant decrease in local flexibility (colored in blue in 
Figure 3.6A) at 120

s.  The differences in the other four representative segments shown in Figure 
3.4 were not significant.  As shown in Figure 3.5, only a few significant changes were observed 
in mAb-B local flexibility (across the 137 peptides) in the presence of arginine compared to the 
control.  Interestingly, the effect of arginine was localized to a few regions of mAb-B (Fig. 
3.6A); there were both significant increases, and in some cases decreases, in local flexibility of 
mAb-B due to the presence of arginine.  
3.3.3.4 Sucrose causes small global changes in the flexibility of the mAb-B 
As shown in Figure 3.5, the presence of sucrose caused a clear trend of slower rates of 
deuterium exchange for almost all of the 137 peptides of mAb-B compared to the control; 
however, many of these small differences were not statistically significant.  For example, 
although the HC 241-252 segment located in the CH2 domain experienced slower deuterium 
uptake compared to the control (Fig. 3.4), the relative mass differences for this segment (peptide 
number 66 in Figure 3.5) do not exceed the 0.59 Da threshold (Fig 3.5).  For the other peptide 
segments shown in Figure 3.4, no significant difference in deuterium uptake were noted except 
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the segment LC 47-70 (peptide number 106) located in the VL domain showed a significant 
negative relative mass difference at 120 and 10
4
 s (Fig. 5).  Although most of the differences for 
the remaining 131 peptides across mAb-B were not significant, the segments 36-65 (peptide 
number 12), 198-220 (peptide number 61), 47-70 (peptide number 106) and 186-212 (peptide 
number 137) located in VH, CH1, VL, and CL domains, respectively, showed significant decreases 
in deuterium uptake compared to the control (Fig. 3.5).  The regions of significant differences in 
local flexibility in the presence of sucrose are mapped onto the homology model of the mAb-B in 
Figure 3.6B.   
3.3.4 H/D exchange experiments in the presence of higher concentration of excipients 
To explore the effect of increasing concentrations of excipients on local flexibility 
measurements of mAb-B, H/D exchange experiments were performed in the presence of 1.0 and 
1.35 M arginine and sucrose at the 10
3
 s time point.  A total of 43 mAb-B segments, representing 
all of the domains of the mAb-B, were analyzed.  The mass increase of the 43 segments in the 
presence of the control, and the control containing either 1.0 or 1.35 M excipients are plotted 
against excipient concentration as shown in the Supporting Information Figure 3.S2.  Although 
there was generally an increase in deuterium uptake with concentration for arginine and sucrose, 
the differences, relative to 0.5 M, were not statistically significant.  In other words, relative mass 
differences that were insignificant at 0.5 M did not become significant changes at higher 
concentrations of arginine or sucrose.  These results not only suggest that the effect is fully 
saturated at a concentration less than 0.5 M, but also suggest sucrose and arginine have no 
notable effect on intrinsic H/D exchange kinetics (see discussion).  Similar studies performed at 
high concentrations of chloride, sulfate and thiocynate (1.0 to 1.5 M) also showed no significant 
differences in the deuterium uptake compared to 0.5 M salts for the same 43 peptides of mAb-
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B.
42
 
3.4 Discussion 
3.4.1 Physical stability of mAb-B in the presence of arginine and sucrose  
Differential scanning calorimetry (DSC) is a powerful and robust technique often used in 
formulation development for determining thermodynamic properties of macromolecules
46
.  DSC 
has been extensively used to probe the conformational stability of individual mAb domains as a 
result of environmental stress such as pH and temperature.
7,13,21,40,45,47
 Temperature-induced 
unfolding of mAbs has displayed either two or three distinct DSC transitions depending on the 
solution conditions and Fab sequence.
3,44,45,48
  In the case of a 2-peak distribution, each of these 
transitions corresponds to either CH2/Fab and CH3 or CH2 and Fab/CH3, respectively.  Typically 
the unfolding of the CH2 domain takes place at a lower temperature than the CH3 domain while 
the unfolding of the Fab region can occur at similar temperature comparable to that of the CH2 or 
CH3 domain depending on the stability of Fab.  In the case of a 3-peak distribution, the unfolding 
of the Fab takes place at an intermediate temperature between that of the CH2 and CH3 domains.   
Based on these studies, the DSC thermograms of mAb-B in the presence of NaCl (control), 
sucrose and arginine at pH 6.0 were evaluated and showed a three-peak distribution (Figure 
3.1A) including a major, large peak (Tm2) between 65 C and 85 C presumably arising from the 
unfolding of the Fab; a smaller shoulder (Tm1) between 57 C and 80 C associated with the 
unfolding of the CH2 domain; and a second, minor peak (Tm3) between 80 C and 90 C which 
can be assigned to the CH3 domain.  In the presence of sucrose (Fig 3.1B) and arginine (Fig. 
3.1C), the Tm1 peak moves to higher (between 60 and 80 C) and lower temperatures (between 
50 C and 80 C), respectively, probably primarily due to a structural changes in the CH2 region, 
followed by effects on the second and third transitions (Tm2 and Tm3) corresponding to the 
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thermal unfolding of the Fab and CH3 domains, respectively.  In the presence of sucrose and 
arginine, the Tonset values increased and decreased, respectively, in a concentration dependent 
manner (Table 3.1).  To further examine the effects of sucrose and arginine on the physical 
stability of mAb-B, accelerated and long term storage stability studies were then performed with 
mAb-B in the formulations containing sucrose or arginine at different temperatures to monitor 
the extent and type of protein aggregation occurring over time.   
Size-exclusion chromatography is commonly used to quantify monomer loss and, indirectly, 
the formation of insoluble aggregates.
38,39,49
 Aggregation is a major concern because it not only 
decreases product purity but also due to its link to immunogenicity.
50-52
 Aggregation of mAbs 
can arise from different environmental stresses such as temperature,
53
 agitation
8,54
 and freeze-
thaw
8,53
 and has recently been shown to involve, under certain conditions, decreases in solvent 
accessibility of the CDR region due to new intermolecular contacts.
30
 In this work, under 
accelerated temperature conditions (40 C over 12 months and 55 C over 1 month), sucrose 
slowed the rate of monomer loss and the rate of formation of soluble and insoluble aggregates 
(Figure 3.2 and 3.3).  Arginine had the opposite effect leading to increased loss of monomer and 
higher levels of soluble and insoluble aggregates.  At lower temperatures (4 and 25 C over 12 
months), no notable differences were observed in the rate of monomer loss in the presence or 
absence of sucrose and arginine compared to the control (citrate-phosphate buffer pH 6.0 with 
0.1 M NaCl).  Additional stability data over the next 12-24 month time period will be required to 
better determine the extent to which sucrose and arginine affect the long term storage stability of 
mAb-B, compared to storage at higher temperatures, as measured by SEC. 
3.4.2 Effects of excipients on intrinsic exchange 
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Changes in the rate of H/D exchange in the presence of an excipient can be caused either by 
the effect of the excipient on the protein or by the effect of the excipient on the chemical 
exchange process.  In the usual EX2 limit of the Linderstrøm-Lang mechanism,
55,56
 the rate of 
H/D exchange depends on both flexibility (kcl/kop) and intrinsic chemical exchange (kint).   
 
 
 
If the rate of intrinsic exchange was excipient-dependent, then the observed rate of H/D 
exchange could be altered even if the flexibility of mAb-B was not affected.   
Changes in intrinsic exchange by sucrose and arginine could potentially arise through 
different mechanisms.  For example, in the case of sucrose, solution viscosity and water activity 
could potentially affect intrinsic exchange.  Experimental data however, argue the presence of 
sucrose has no significant effect.  Exchange by poly-DL-alanine was unaltered in presence of 1 
M sucrose.
57
  Moreover, two independent studies have shown that the intrinsic exchange rates 
are unaffected by decreasing the water activity
58
 or by increasing the solution viscosity induced 
by osmolytes (such as sorbitol).
59
  It was proposed that viscosity has little influence on intrinsic 
exchange because of the anomalous migration mechanism of protons in liquid water.
59
  On this 
basis, we conclude that the changes in H/D exchange kinetics induced by sucrose are attributable 
to changes in the backbone flexibility of mAb-B, kcl/kop.  In this work, no significant differences 
in the magnitude of change in local flexibility with increasing sucrose concentration were noted 
across 43 peptides, covering all of the domains of mAb-B.  The absence of concentration 
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dependence further supports the conclusion that sucrose has no significant effect on the intrinsic 
H/D exchange rates.     
 Arginine could alter an intrinsic exchange either by changes in ionic strength or through 
interactions of arginine or its chloride counter-ion with mAb-B.  In a separate study with mAb-B, 
we found that increasing the NaCl concentration from 0.1 M to 0.5 M induced subtle decreases 
in the rate of H/D exchange across many regions of mAb-B (Majumdar et al, submitted 
manuscript).
42
  The pattern of altered H/D exchange of mAb-B in presence of 0.5M NaCl is not, 
however, consistent with the arginine-induced changes observed here.  On this basis, we 
conclude that it is the influence of arginine, not chloride, which dominates this effect.  While 
base-catalyzed intrinsic exchange by poly-DL-arginine shows a strong ionic strength 
dependence,
60
 in more realistic peptide models, these effects are much smaller.
61
  Exchange by 
alanine model peptides also has little dependence on ionic strength.
62
  If kint were sensitive to 
arginine, we would expect that altered exchange kinetics in mAb-B would be widespread and 
show concentration-dependence.  Instead, we have found that 0.5 M arginine significantly 
altered exchange for only a few regions of mAb-B (see Figs 5 and 6A) relative to a 0.1 M NaCl 
control.  Furthermore, the level of differential exchange was not significantly altered when the 
arginine concentration was increased to 1.0 M and 1.35 M.  Hence, we conclude that changes in 
the kinetics of amide H/D exchange in mAb-B under our experimental conditions are due to the 
effects of arginine on mAb-B internal mobility and not due to alterations in the intrinsic kinetics 
of exchange. 
3.4.3 Sucrose effects on mAb-B physical stability and local flexibility 
As monitored by DSC at pH 6.0, sucrose (0.5 M) increased the onset temperature and three 
thermal unfolding temperatures for mAb-B (Figure 3.1B and Table 3.1).  In addition, 0.5 M 
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sucrose at pH 6 resulted in slowed monomer loss and slowed soluble and insoluble aggregate 
formation compared to control when incubated at 55 C for 1 month and 40C for 12 months 
(Fig. 3.2C and Figure 3.3).  These observations are consistent with earlier reports that sucrose 
prevented formation of soluble aggregates and slowed the rate of monomer loss in two different 
mAbs
63,64
 and a recombinant human interferon-.
65
  Increases in the thermal stability of the 
native state were also associated with an increase in the free energy of unfolding in the presence 
of different sugars
66
 and in proportion to sucrose concentration
67
 in several different proteins.  
The stabilizing effects of sucrose in aqueous solution were first explained by Lee and 
Timasheff, more than three decades ago, by a mechanism known as “preferential exclusion”.
68
  
Based on this mechanism, sucrose is preferentially excluded from the surface of proteins, and as 
a result, there is an increase in solution chemical potential.  According to the Le Chatelier’s 
principle, to counteract the imposed changes in the chemical potential, a new equilibrium is 
established to minimize thermodynamically unfavorable states.  In such conditions, proteins 
adopt to a smaller surface area with more compact and rigid structure to overcome the 
thermodynamically unfavorable condition.
68,69
  Furthermore, addition of sugars results in an 
increase in free energy of unfolding and hence the native state is thermodynamically favored.
70
  
Bolen et al. studied the internal dynamics of ribonuclease A by following the hydrogen-
deuterium exchange rates of individual amide protons using NMR.
57
  They reported a shift in 
equilibrium to the smallest surface area in the presence of 1 M sucrose.  This effect was also 
associated with a decrease in hydrogen-deuterium exchange rates of amide protons because of 
preferential exclusion of sucrose from the protein.  Similarly, a decrease in H/D exchange rates, 
along with concomitant decreases cysteine reactivity, were observed for recombinant interleukin-
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1 receptor antagonist in the presence of 1 M sucrose as a result of restricted conformational 
fluctuations and solvent accessibility.
69
 
In the current study, a decrease in the local conformational fluctuations throughout mAb-B 
can be visualized in the differential plots shown in Figure 3.5.  Sucrose caused significant 
decreases in local flexibility in four separate segments of mAb-B, all located in the Fab region 
(VH, CH1, VL, and CL domains).  These changes in local flexibility were associated with 
improved thermal stability as measured by DSC and slowed aggregation as monitored by SEC.  
Flexibility changes in these regions of the Fab could be important for mAb stability since it was 
found recently that site specific mutations in the variable domains (VH and VL) of a human 
antibody resulted in an aggregation resistant protein.
71
  Although the significant changes in mAb-
B local flexibility defined in this work are based on 99% confidence limits, our H/D-MS studies 
clearly indicate a global trend in which sucrose causes an overall decrease in deuterium uptake 
across essentially all regions of mAb-B (Fig. 5).  These H/D-MS exchange results across the 137 
peptides of mAb-B are consistent with previous observations for H/D exchange in various intact 
proteins in presence of sucrose (1 M) and trehalose (0.5 and 1 M) monitored by NMR,
57
 FT-
IR,
67,69,72
 and H/D-MS.
73,74
  Each of these studies report similar effects of sugars in the form of a 
global decrease in deuterium uptake in the presence of sucrose and trehalose. 
3.4.4 Arginine effects on mAb-B physical stability and local flexibility  
In contrast to sucrose-induced stabilization, arginine causes conformational destabilization of 
mAb-B.  This effect is evident in DSC measurements where the appearance of the Tm1 peak 
(corresponding to the unfolding of CH2 domain) at lower temperatures, along with a significant 
decrease in the Tonset temperature, proportional to arginine concentration is present (Fig. 1C and 
Table 3.1).  Interestingly, decreases in thermal stability correlate well with faster monomer loss 
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(at 40 C and 55 C), and faster aggregation in the presence of 0.5 M arginine at pH 6.0 during 
storage as measured by SEC (Fig. 3.2C and 3.3B).  Similar decreases in thermal stability due to 
arginine have been reported with the same mAb-B at pH 4.5,
13
 in a different  mAb (IgG2)
7
 and in 
other proteins.
75,76
  The destabilization of RNase A with increasing concentrations of arginine 
(up to 1.5 M) was proposed to be due to extensive binding of arginine to the protein.
75
  A similar 
decrease in the thermal stability of cytochrome c was observed in the presence of arginine.
76
   
Arginine caused a significant increase in local flexibility in two particular regions of mAb-B: 
in the CH2 domain (HC 241-252) and in the region connecting the CH1 and VH domain (105-126) 
of mAb-B (Fig 3.4, 3.5, and 3.6A).  In addition, a significant decrease in local flexibility was 
also observed in the region LC 47-70 corresponding to the VL domain (Fig. 3.5 and 3.6A).  The 
effect of arginine was more prominent on the conformational stability of the CH2 domain of 
mAb-B as is evident from DSC results that show a decrease in Tm1 values as a function of 
arginine concentration (Table 3.1).  A relatively small decrease in the conformational stability of 
the Fab (Tm2), and no effect on CH3 (Tm3) is seen as measured by DSC under the same 
conditions.  These conformational stability changes correlate reasonably well with the extent of 
changes in local flexibility of the Fab (CH1-VH and VL domains) and lack of notable changes in 
the local flexibility of the CH3 domain.   
In the solution state, arginine is known to interact with a number of functional groups of 
proteins.  This can occur through interaction with charged residues via hydrogen bonding and 
electrostatic interactions (such as salt-bridge formation), and with aromatic residues through 
cation- interactions.
77-79
  The guanidinium group and methylene groups of arginine can interact 
directly with a protein’s backbone as well as apolar regions.
78,80
  Interactions of arginine with a 
protein’s surface can vary with concentration.  At lower concentrations (<0.5 M), arginine is 
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expected to be directly bound to protein’s surface.  At higher concentrations (0.5-1.5 M), 
arginine favors self-interaction forming clusters resulting in reduced interaction with a protein’s 
surface.
78,81
  In this study, we investigated the effect of arginine on thermal stability and local 
flexibility of mAb-B at three different concentrations of arginine (0.5 M, 1 M and 1.35 M).  The 
H/D-MS results with 43 peptides representing all regions of mAb-B do not show a significant 
titration effect on deuterium uptake; this result could potentially be due to the self-interaction of 
arginine at higher concentrations.  At such concentrations, even though self-interaction of 
arginine predominates, it is still possible that weak interactions of arginine with the protein 
surface may exist.  Recently, small angle X-ray scattering (SAXS) analysis of two IgG1s in the 
presence of arginine (0.1–0.6 M) revealed an increase in structural relaxation and size of two 
antibodies in a concentration dependent manner, and such changes were not observed in the 
presence of sulfate and thiocyanate.
82
  With arginine present, structural relaxation of the 
molecule may result in local conformation changes within mAb-B, resulting in either an increase 
or decrease in the backbone amide hydrogen bonding network in specific regions leading to 
altered deuterium uptake.  As described above, several studies report the possibility of such 
specific interactions of arginine with both aromatic side chain residues and the peptide 
backbone.
77-80
 
3.4.5 mAb-B physical stability and local flexibility of segments within the CH2 domain 
Arginine-induced physical destabilization of mAb-B correlates with an increase in local 
flexibility of HC 241-252 within the CH2 domain and a segment connecting CH1 and VH domain 
(105-126) of the Fab region.  When compared to the DSC results, a more notable decrease in 
thermal stability of the CH2 domain (Tm1) was observed compared to the Fab region (Tm2) (Table 
3.1) in the presence of varying amounts of arginine.  Furthermore, a companion study conducted 
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in our laboratories (Majumdar et al., submitted manuscript)
42
 showed a substantial increase in 
flexibility of two different regions in the CH2 domain (HC 241-252 and HC 300-306) in the 
presence of the destabilizing salt (chaotrope) NaSCN.  The increase in local flexibility was 
associated with conformational destabilization as measured by DSC and increased aggregation 
determined by SEC.
42
  Consistent with these results, two studies from different labs have 
reported similar regions within the CH2 domain to be least stable
83
 and more prone to 
aggregation.
83,84
  For example, the binding of protein A to residues in the from CH2 and CH3 
domain of an intact IgG resulted in inhibition of aggregation.
84
  In a separate study, this region 
(HC 243-247) of the CH2 domain in both oxidized and deglycosylated IgG1s was found to be 
associated with increased deuterium uptake.
83
  In addition, the oxidized IgG1 was found to be the 
least stable form of the antibody.  Moreover, the thermal stability of an engineered CH2 domain 
was increased by about 20 C by incorporating an additional non-native disulfide bond.
85,86
  One 
of the two Cys mutations (L242C) was performed within the 241-252 region of the CH2 domain 
and the other Cys (K334C) was inserted in a neighboring -sheet.  Often the introduction of a 
disulfide bond decreases the flexibility of the molecule.
87,88
  Together, these results further 
support the hypothesis that decreasing flexibility of key regions within the CH2 domain results in  
increasing the overall physical stability of an IgG molecule.  
Based on results from this work, combined with previous literature results with IgGs as 
described above, key regions within the CH2 domain may dictate the overall physical stability of 
the mAb-B.  The physical stability of mAb-B itself may therefore be further improved by either 
mutation,
86
 truncation,
89
 or masking the hydrophobic segments
84
 of these key regions of the CH2 
domain.  There are two phenylalanine residues in this region (Phe241 and Phe243) that pack 
against the glycans as observed in the crystal structure.
43
  It is possible that destabilizers like 
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arginine increase conformational fluctuations in this region which expose these aromatic side-
chains allowing them to interact with other apolar side-chains.  Arginine is often added to protein 
solutions to improve refolding efficiency and suppress aggregation.
90-92
  With mAb-B, however, 
the addition of arginine results in lowering of the Tonset temperature (Table 3.1) and an increase 
in both soluble and insoluble aggregate formation during storage at elevated temperatures (Fig 
3.2C and Figure 3.3).  This result may be due to increased local flexibility of the CH2 domain of 
mAb-B in the presence of arginine.  Finally, these data demonstrate the potential utility of H/D-
MS as a new analytical tool to identify stabilizing excipients as part of protein formulation 
development.  To further explore the utility of this approach, ongoing experiments are evaluating 
the effect of a variety of excipients on local flexibility changes in certain key regions of IgGs 
using H/D-MS along with their effects on mAb physical stability.   
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Table 3.1 
Excipient 
concentration 
T
onset
 (°C) T
m
1 (°C) T
m
2 (°C) T
m
3 (°C)  
Mean SD Tonset Mean SD ΔTm1 Mean SD ΔTm2 Mean SD ΔTm3 
Control 57.7 0.2 -  69.3 0.1 - 73.6 <0.1 - 82.4 <0.1 - 
 
0.5 M arginine 50.3 0.3 -7.4 67.4 0.1 -1.9 72.4 <0.1 -1.2 81.8 <0.1 -0.6 
1.0 M arginine 47.0 0.8 -10.7 65.7 0.2 -3.6 72.3 <0.1 -1.3 81.8 <0.1 -0.6 
1.35 M arginine 46.7 0.5 -11.0 64.9 0.1 -4.4 72.8 <0.1 -0.8 82.4 <0.1 0.0 
 
0.5 M sucrose 60.2 0.4 2.5 70.8 0.1 1.5 75.3 <0.1 1.7 84.6 <0.1 2.2 
1.0 M sucrose 63.9 0.1 6.2 73.4 <0.1 4.1 77.6 <0.1 4.0 87.3 <0.1 4.9 
1.35 M sucrose 66.2 0.2 8.5 75.3 <0.1 6.0 79.5 <0.1 5.9 89.7 <0.1 7.3 
 
Formulations contained 0.5 mg/mL protein in 20 mM citrate-phosphate buffer, 0.1 M NaCl, 
pH 6.0 and the indicated level of excipients. The difference in melting temperature (Tm) was 
obtained from Tm,excipient – Tm,control. The mean and standard deviation 
40 are based on three 
separate measurements. 
 
Effect of excipient concentration on thermal onset temperature (Tonset) and thermal melting 
temperatures (Tm1, Tm2, and Tm3) for mAb-B as measured by DSC.   
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Table 3.S1 
Peptide number Peptide_ID 
1 mAbB Heavy 4-17 (VH) 
2 mAbB Heavy 5-22 (VH) 
3 mAbB Heavy 30-35 (VH) 
4 mAbB Heavy 33-36 (VH) 
5 mAbB Heavy 36-47 (VH) 
6 mAbB Heavy 37-46 (VH) 
7 mAbB Heavy 36-49 (VH) 
8 mAbB Heavy 36-58 (VH) 
9 mAbB Heavy 36-59 (VH) 
10 mAbB Heavy 37-58 (VH) 
11 mAbB Heavy 37-59 (VH) 
12 mAbB Heavy 36-65 (VH) 
13 mAbB Heavy 47-58 (VH) 
14 mAbB Heavy 47-59 (VH) 
15 mAbB Heavy 47-60 (VH) 
16 mAbB Heavy 47-61 (VH) 
17 mAbB Heavy 47-62 (VH) 
18 mAbB Heavy 48-61 (VH) 
19 mAbB Heavy 47-63 (VH) 
20 mAbB Heavy 47-65 (VH) 
21 mAbB Heavy 47-68 (VH) 
22 mAbB Heavy 48-68 (VH) 
23 mAbB Heavy 50-68 (VH) 
24 mAbB Heavy 59-68 (VH) 
25 mAbB Heavy 60-68 (VH) 
26 mAbB Heavy 61-68 (VH) 
27 mAbB Heavy 62-68 (VH) 
28 mAbB Heavy 64-68 (VH) 
29 mAbB Heavy 61-79 (VH) 
30 mAbB Heavy 61-80 (VH) 
31 mAbB Heavy 62-79 (VH) 
32 mAbB Heavy 63-79 (VH) 
33 mAbB Heavy 63-80 (VH) 
34 mAbB Heavy 64-79 (VH) 
35 mAbB Heavy 64-80 (VH) 
36 mAbB Heavy 66-79 (VH) 
37 mAbB Heavy 66-80 (VH) 
38 mAbB Heavy 69-79 (VH) 
39 mAbB Heavy 69-80 (VH) 
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40 mAbB Heavy 69-83 (VH) 
41 mAbB Heavy 80-83 (VH) 
42 mAbB Heavy 80-86 (VH) 
43 mAbB Heavy 81-86 (VH) 
44 mAbB Heavy 84-90 (VH) 
45 mAbB Heavy 84-93 (VH) 
46 mAbB Heavy 85-93 (VH) 
47 mAbB Heavy 87-104 (VH) 
48 mAbB Heavy 105-114 (VH) 
49 mAbB Heavy 105-118  
50 mAbB Heavy 105-126  
51 mAbB Heavy 124-147 (CH1) 
52 mAbB Heavy 146-174 (CH1) 
53 mAbB Heavy 156-174 (CH1) 
54 mAbB Heavy 159-174 (CH1) 
55 mAbB Heavy 163-174 (CH1) 
56 mAbB Heavy 171-183 (CH1) 
57 mAbB Heavy 180-185 (CH1) 
58 mAbB Heavy 185-193 (CH1) 
59 mAbB Heavy 185-197 (CH1) 
60 mAbB Heavy 186-197 (CH1) 
61 mAbB Heavy 198-220 (CH1) 
62 mAbB Heavy 208-229  
63 mAbB Heavy 235-240  
64 mAbB Heavy 235-252 (CH2) 
65 mAbB Heavy 241-251 (CH2) 
66 mAbB Heavy 241-252 (CH2) 
67 mAbB Heavy 243-252 (CH2) 
68 mAbB Heavy 244-251 (CH2) 
69 mAbB Heavy 263-277 (CH2) 
70 mAbB Heavy 266-277 (CH2) 
71 mAbB Heavy 300-306 (CH2) 
72 mAbB Heavy 301-305 (CH2) 
73 mAbB Heavy 301-306 (CH2) 
74 mAbB Heavy 307-318 (CH2) 
75 mAbB Heavy 334-348  
76 mAbB Heavy 349-364 (CH3) 
77 mAbB Heavy 349-365 (CH3) 
78 mAbB Heavy 355-365 (CH3) 
79 mAbB Heavy 369-376 (CH3) 
80 mAbB Heavy 369-379 (CH3) 
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81 mAbB Heavy 369-380 (CH3) 
82 mAbB Heavy 381-390 (CH3) 
83 mAbB Heavy 379-398 (CH3) 
84 mAbB Heavy 380-398 (CH3) 
85 mAbB Heavy 381-398 (CH3) 
86 mAbB Heavy 382-398 (CH3) 
87 mAbB Heavy 381-404 (CH3) 
88 mAbB Heavy 391-398 (CH3) 
89 mAbB Heavy 392-398 (CH3) 
90 mAbB Heavy 391-404 (CH3) 
91 mAbB Heavy 399-404 (CH3) 
92 mAbB Heavy 406-410 (CH3) 
93 mAbB Heavy 411-423 (CH3) 
94 mAbB Heavy 424-446 (CH3) 
95 mAbB Heavy 429-446 (CH3) 
96 mAbB Heavy 431-446 (CH3) 
97 mAbB Heavy 433-446 (CH3) 
98 mAbB Light 1-4 (VL) 
99 mAbB Light 1-7 (VL) 
100 mAbB Light 1-10 (VL) 
101 mAbB Light 1-11 (VL) 
102 mAbB Light 32-46 (VL) 
103 mAbB Light 33-46 (VL) 
104 mAbB Light 36-46 (VL) 
105 mAbB Light 47-62 (VL) 
106 mAbB Light 47-70 (VL) 
107 mAbB Light 47-74 (VL) 
108 mAbB Light 51-70 (VL) 
109 mAbB Light 71-74 (VL) 
110 mAbB Light 71-83 (VL) 
111 mAbB Light 72-82 (VL) 
112 mAbB Light 74-82 (VL) 
113 mAbB Light 75-82 (VL) 
114 mAbB Light 75-83 (VL) 
115 mAbB Light 80-85 (VL) 
116 mAbB Light 91-103 (VL) 
117 mAbB Light 105-116  
118 mAbB Light 116-122 (CL) 
119 mAbB Light 117-123 (CL) 
120 mAbB Light 116-125 (CL) 
121 mAbB Light 117-125 (CL) 
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122 mAbB Light 116-131 (CL) 
123 mAbB Light 116-132 (CL) 
124 mAbB Light 117-132 (CL) 
125 mAbB Light 136-148 (CL) 
126 mAbB Light 136-161 (CL) 
127 mAbB Light 144-161 (CL) 
128 mAbB Light 149-161 (CL) 
129 mAbB Light 162-172 (CL) 
130 mAbB Light 162-175 (CL) 
131 mAbB Light 162-178 (CL) 
132 mAbB Light 162-179 (CL) 
133 mAbB Light 162-181 (CL) 
134 mAbB Light 172-175 (CL) 
135 mAbB Light 173-179 (CL) 
136 mAbB Light 183-210 (CL) 
137 mAbB Light 186-212 (CL) 
 
 
Ordinal peptide numbers matched to their location identities. 
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Representative DSC thermograms of mAb-B in different formulations (20 mM citrate-phosphate 
buffer, 0.1 M NaCl, pH 6.0) containing the indicated level of excipients. (A) Representative 
curve-fitted DSC thermogram for mAb-B with Tm1, Tm2, and Tm3.  (B) Effect of arginine on 
mAb-B conformational stability.  (C) Effect of sucrose on mAb-B conformational stability. 
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Figure 3.2 
 
SEC analysis of mAb-B samples in different formulations before and after storage at 55 C for 4 
weeks.  (A) Overlay of SEC chromatograms of mAb-B before and after thermal stress:  dotted 
lines correspond to mAb-B samples at time zero (no stress) and solid lines correspond to mAb-B 
samples incubated at 55 C for four weeks.  Samples of mAb-B were prepared in 20 mM citrate-
phosphate buffer, 0.1 M NaCl, pH 6.0 without additional additives (control) (black trace) and 
with 0.5 M sucrose (blue trace) or 0.5 M arginine (red trace).  The bar chart represents the effect 
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of excipients on different forms (monomer, fragment, soluble, and insoluble aggregates) of mAb-
B as measured on (B) day zero and (C) after 4 weeks at 55 C.   
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Figure 3.3   
 
 
 
Effect of sucrose and arginine on accelerated and long term storage stability of mAb-B.  The 
percentage of monomer remaining was measured by SEC. Samples of mAb-B were prepared in 
20 mM citrate-phosphate buffer, 0.1 M NaCl, pH 6.0 without additional additives (control) 
(black trace) or with 0.5 M sucrose (blue trace) or 0.5 M arginine (red trace).  Error bars 
represent one standard deviation with duplicate vials. 
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Figure 3.4  
 
 
Effect of presence and absence of arginine and sucrose on the deuterium uptake of six peptides 
from different regions of mAb-B as measured by H/D-MS.  The domain location and peptide 
identity are provided on each graph. Samples of mAb-B (in a 90% deuterium solution) contain 
20 mM citrate-phosphate buffer at pH 6.0 and 0.1 M sodium chloride without additional 
additives (control) or with 0.5 M arginine or 0.5 M sucrose. The error bars denote one standard 
deviation for three independent replicates.    
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Figure 3.5  
 
Mass difference plots of mAb-B in the presence of 0.5 M arginine and 0.5 M sucrose compared 
to the control as measured by H/D-MS. Mass differences of the average deuterium update were 
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calculated for each of the 137 peptide of mAb-B for four different exchange times (120, 10
3
, 10
4
 
and 10
5
 s) in 90% deuterium solution. Each mass difference data point is an average of three 
independent H/D exchange experiments with mAb-B in 20 mM citrate-phosphate buffer at pH 
6.0 and 0.1 M NaCl without additional additives (control) or with either 0.5 M arginine or 0.5 M 
sucrose added.  The y-axis denotes ΔD(t) = mexcipient(t) – m(t)control where m denotes the mass of 
the peptide as a function of deuterium exposure time, t.  The x-axis denotes the ordinal peptide 
number, a sequential arrangement of 137 peptides of mAb-B by the midpoints in the sequence.  
The black dotted lines at |ΔD(t)| > 0.59 Da represent the 99% confidence limit for significant 
mass differences. The background is colored to represent and differentiate the individual 
domains of mAb-B. Table 3.S1 contains the mAb-B peptide locations and domain information.  
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Figure 3.6   
  
Effect of arginine and sucrose on the local flexibility of mAb-B as measured by H/D-MS.  The 
color code is derived from comparison of mass differences of the average deuterium uptake data 
B
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(Figure 3.5) in the presence of 0.5 M arginine (A) and 0.5 M sucrose (B) compared to the control 
(20 mM citrate-phosphate buffer, pH 6.0, 0.1 M sodium chloride). (A) Arginine caused an 
increase in flexibility in the region of the CH2 and CH1 domain and a decrease in flexibility in the 
VL domain. (B) Sucrose caused decreases in local flexibility across several domains of mAb-B. 
The data are an average of three independent H/D-MS experiments performed on three different 
days. Regions colored in yellow indicate non availability of H/D exchange data (~85% sequence 
coverage in mAb-B). The homology map of mAb-B was constructed from PDB ID 1HZH
43
 (see 
Methods section for more details). 
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Figure 3.S1 
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Deuterium update curves for 137 peptides of mAb-B. The first set of curves is for mAb-B 
labeled in presence of arginine and the second set of curves is for mAb-B labeled in presence of 
sucrose.   
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Figure 3.S2 
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Scatter plots of the mass increase for the 43 peptides of mAb-B with increasing concentration of 
either sucrose or arginine (0.5, 1.0, and 1.35 M) containing 0.1 M NaCl along with the control 
(0.1 M NaCl). 
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Chapter 4 
 
Effects of Salts from the Hofmeister Series on Conformational Stability, Aggregation 
Propensity, and Local Flexibility of an IgG1 Monoclonal Antibody 
 
 
 
 
 
 
 
 
 
 
 
(“Effects of Salts from the Hofmeister Series on Conformational Stability, Aggregation 
Propensity, and Local Flexibility of an IgG1 Monoclonal Antibody.”, Majumdar R., Manikwar 
P., Hickey J.M., Samra H.S., Hasige A.S, Bishop S.M., Middaugh C.R., Volkin D.B., Weis 
D.D., Biochemistry. 2013 May 14;52(19):3376-89.)  
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4.1 Introduction 
Monoclonal antibodies (mAbs) have become successful therapeutic agents due to their high 
binding specificities to biological targets implicated in a wide range of human diseases.  The 
presence of protein aggregates in therapeutic mAb preparations are of particular concern due to 
their potential to cause immune responses that may affect the safety or limit the efficacy of 
therapeutic mAb treatments.
1-3
 Antibodies are multi-domain, homodimeric proteins with a 
molecular weight of ~150 kDa, in which the precise value fluctuates due to post-translational 
modifications such as glycosylation.  Their Y-shaped structure can be classified into the antigen 
binding fragment (Fab) and the crystallizable fragment (Fc) consisting of two heavy (H) and two 
light (L) chains held together by inter- and intra-chain disulfide bonds. The Fab and Fc regions 
consist of multiple domains.  These include the variable (VL and VH ) and constant (CL, CH1) 
domains within the Fab and the constant domains(CH2, and CH3) within the Fc. Antibody 
structures are further defined into different classes (IgA, IgG, IgM, IgE and IgD) and subclasses 
(IgG1, IgG2, IgG3 and IgG4) based on the composition of the constant regions and the number 
of disulfide bonds.
4
  Antibodies exhibit an array of intrinsic internal motions
5
 and can exist as a 
number of conformers with asymmetric structures that exhibit inter-domain flexibility.
6-8
 These 
motions play an important role in their functional activity and biological responses.
9-11
 The effect 
of protein flexibility on overall mAb conformational stability, however, is a more complex 
relationship and an active area of research.
12, 13
 Examining the inter-relationships between 
flexibility and stability is especially important not only to help design more stable antibodies, but 
also to better understand how different excipients and salts predispose, initiate, or delay the 
cascade of events leading to conformational destabilization and aggregation during 
manufacturing, long-term storage, and administration.
14
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Aggregation of mAbs in solution can occur as a result of covalent or non-covalent protein-
protein interactions initiated by changes in pH, temperature, agitation, or interaction with 
solution impurities.
15-18
 These interactions occur due to either conformational changes within 
individual molecules that lead to exposure of nonpolar residues, colloidal effects in solution that 
alter charge-charge repulsion between molecules, or a combination of both conformational and 
colloidal effects.
19
 In other words, different salts may affect aggregation behavior of mAbs in 
solution by decreasing conformational stability and/or charge-charge repulsion between two IgG 
molecules. Protein aggregation has been shown to occur through the formation of partially 
unfolded monomeric states whose population is minimal under stable solution conditions.
19
 With 
increasing stress, the partially unfolded population increases, leading to subsequent multi-order 
aggregation that results in irreversible loss of protein.  For a multi-domain protein like an IgG, 
aggregation-prone segments may also play a key role in the initiation of aggregation
20, 21
 and in 
overall antibody instability.
22
 The flexibility of the aggregation-prone motifs may change in 
response to solution conditions or temperature, which may in turn facilitate conformational 
instability and/or aggregate formation.   
Identification of solution conditions that maintain IgG stability and solubility during long-term 
storage, especially at high protein concentrations, remains a significant challenge in the 
development of mAbs as biotherapeutics. Salts are generally included in antibody formulations 
as buffering agents, tonicity modifiers, or viscosity enhancers.
23
 Salts can also affect the 
solubility and stability of proteins according to their relative position in the Hofmeister series. 
The Hofmeister series of anions, which have more pronounced effects on protein stability than 
cations, is:  SCN
– 
> ClO4
– 
>I
– 
> ClO3
– 
> Br
– 
> NO3
– 
>Cl
– 
> CH3CO2
–
 > HPO4
2– 
> SO4
2–
.
24
 The 
members on the left of the series (e.g., thiocyanate, perchlorate, and iodide) are chaotropes that 
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unfold and solubilize proteins. The members on right (e.g., sulfate and phosphate) are 
kosmotropes that preserve the native structure and decrease solubility, causing proteins to salt-
out of solution.
25
 Chloride is an intermediate member dividing the two groups. The influences of 
salts on the physical properties of proteins in solution including melting temperature 
coefficients,
26
 salting-out coefficients,
27
 and B-viscosity coefficients
28, 29
 can be ranked 
according to the positions of the salts in the Hofmeister series, but other properties such as 
surface tension
29
 do not follow the prescribed order.  Anions have been found to affect protein 
conformational stability
30, 31
 and rates of aggregation
32, 33
 in order of their position in the 
Hofmeister series.  Mechanistic explanation of ion effects on protein stability remains an active 
area of research.
34, 35
 For example, their influence on protein stability can vary by protein and ion 
type, as well as by ion concentration and solution pH, by affecting factors such as the water 
affinity of ions, water structure around proteins, and/or by ions interacting directly with protein 
surfaces.
36-39
 
Flexibility is also a crucial consideration for understanding the physicochemical stability of a 
protein including its aggregation propensity.
40
 Previous work using global measures of 
dynamics, such as red edge excitation shift fluorescence and high resolution ultrasonic 
spectroscopy, has shown that there is a complex relationship between mAb dynamics and 
aggregation.
14, 41, 42
 However, global approaches cannot be used to assign changes in dynamics to 
specific regions that contribute to aggregation. Hydrogen/deuterium exchange coupled to mass 
spectrometry (H/D-MS) can measure backbone flexibility at a resolution of 5-20 residues
43, 44
 
and has been used with mAbs for biopharmaceutical analysis and comparability studies
45, 46
. The 
effects, on monoclonal antibodies, of methionine oxidation, glycan modification or 
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deglycosylation,
47-49
 deamidation and other chemical modifications,
50
 and freeze-thaw cycles
51
 
have all been examined using H/D-MS. 
The purpose of this study was to develop a better understanding of the influence of three 
different anions from the Hofmeister series (sulfate, chloride, and thiocyanate) on the 
conformational stability, aggregation rate, and polypeptide backbone flexibility of an IgG1 mAb 
(mAb-B).  We have correlated the physical stability changes (measured by DSC and SEC) 
induced by the anions with changes observed in local backbone flexibility (measured by H/D-
MS).  In particular, we have identified a potential key role for the local flexibility of two specific 
segments within the CH2 domain in modulating the physical stability of mAb-B.  
4.2 Materials and Methods 
4.2.1 Materials 
Sodium chloride, LC-MS-grade water, acetonitrile, and isopropanol were obtained from Fisher 
Scientific (Fair Lawn, NJ).  LC-grade acetic acid and phosphoric acid were obtained from Fluka 
(St Louis, MO). Formic acid (99+% LC/MS-grade) was obtained from Thermo Scientific 
(Rockford, IL).  Porcine pepsin, tris(2-carboxyethyl)phosphine hydrochloride (TCEP), deuterium 
oxide (99+%D), and guanidine hydrochloride were purchased from Sigma Aldrich (St Louis, 
MO). Citric acid anhydrous (99.5%), sodium phosphate dibasic anhydrous, sodium sulfate 
anhydrous (99%), and sodium thiocyanate (>98%) were purchased from Acros Organics (Fair 
Lawn, NJ).  The IgG1 monoclonal antibody, referred to here as mAb-B, was formulated at 50 mg 
mL
–1
 in 10 mM histidine buffer, pH 6.0 containing 0.005% polysorbate 80.  
4.2.2 Differential Scanning Calorimetry (DSC) 
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Prior to analysis, mAb-B was diluted to 0.5 mg mL
–1
 with 20 mM citrate-phosphate (4 mM 
citrate and 16 mM dibasic sodium phosphate) buffer at pH 6.0 containing NaCl, Na2SO4, or 
NaSCN at concentrations ranging from 0.1 to 1. 5 M. DSC was performed using a VP-Capillary 
differential scanning calorimeter (MicroCal, Northampton, MA). mAb-B samples were analyzed 
in triplicate over a temperature range of 10-100 C with a scan rate of 60 C/hr.  The data were 
processed using MicroCal and Origin software (OriginLab Ltd.). The data were fitted using a 
multi-state model with three transitions.  The onset temperature (Tonset) of the first transition was 
taken as the temperature at which the heat capacity exceeded 500 cal mol
–1
 C
–1
. 
4.2.3 Storage Stability and Analysis by Size Exclusion Chromatography (SEC) 
MAb-B was diluted to 0.5 mg mL
–1
 with 20 mM citrate-phosphate (4 mM citrate and 16 mM 
dibasic sodium phosphate) buffer at pH 6.0 containing either 0.1 M NaCl (control), 0.5 M NaCl, 
0.5 M Na2SO4, or 0.5 M NaSCN. Aliquots of 0.5 mL of mAb-B were sterilized by passing 
through 0.22 μm filters (Millipore, Billerica, MA), dispensed into type I glass vials (West 
Pharmaceutical Services, Exton, PA) in a pre-sterilized laminar flow hood, stoppered, and stored 
at four different temperatures (–70, 4, 25, and 40 C) for a period of up to twelve months. To 
remove insoluble aggregates, each sample was centrifuged at 14,000  g for 5 min prior to 
analysis. SEC was carried out using a 7.8  30 cm
 
TSK-Gel BioAssist G3SWxL column (TOSOH 
Biosciences, King of Prussia, PA) at 0.7 mL/min using a Shimadzu HPLC system equipped with 
a photodiode array detector.  Gel filtration standards (Bio-Rad, Hercules, CA) were used for 
column calibration.  The mobile phase was 200mM sodium phosphate buffer (pH 6.8). The 
resulting chromatograms were analyzed by integrating the area of the monomer peak detected at 
280 nm. The percentage of monomer was measured relative to the total area of all peaks on day 
zero.  
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4.2.4 Deuterated labeling buffer preparation 
The deuterated labeling buffers contained 0.5, 1.0, or 1.5 M salt (sodium chloride, sodium sulfate 
or sodium thiocyanate) and 20 mM citrate-phosphate (4 mM citric acid and 16 mM dibasic 
sodium phosphate) buffer at pH 6.0 in 90 atom% D2O.  The pH values are reported directly from 
the pH meter reading without any further correction for the deuterium isotope effect.  Based on 
the total volume of H2O and D2O, the salts, citric acid, and dibasic sodium phosphate were 
added.  The final volume was noted after adjusting the pH to 6.0.  The final concentrations of the 
salts were within 3% of their target molarities.  The use of 90 atom% D2O was adopted here to 
enable direct comparison with H/D exchange work in a companion study (manuscript in 
preparation) in which some of the buffer components (sucrose and arginine) contributed a non-
negligible amount of exchangeable hydrogen to the labeling buffer. 
4.2.5 H/D-MS 
The antibody was diluted to 10 mg mL
–1
 in 20 mM citrate-phosphate buffer (4 mM citric acid, 16 
mM dibasic sodium phosphate, and 64 mM sodium chloride) at pH 6.0. An H/D-X PAL robot 
(LEAP Technologies, Carrboro, NC) was used for sample preparation and injection.  The protein 
(2 μL) was mixed with labeling buffer (38 μL)  in 1:20 ratio by volume and incubated at 25 °C 
for four exchange times (120, 10
3
, 10
4
 and 10
5
 s). Three independent replicates of each labeling 
condition were prepared.  Following deuterium labeling, the exchange reaction solution (40 μL) 
was quenched at 1 °C with 40 μL of 0.5 M TCEP/ 4 M guanidine hydrochloride / 0.2 M sodium 
phosphate at pH 2.5. 10 μL of the solution (approximately 16 pmol of mAb-B) was analyzed.  
Protein stocks and quench buffers were maintained at 1 °C and the labeling buffers were held at 
25 °C using the two temperature controlled drawers of the H/D-X PAL. LC-MS analysis of the 
deuterated samples were conducted as described previously
52
 with the following differences. The 
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refrigerated compartment of the H/D-X PAL was used to house the columns, traps and valves at 
1 °C during the course of the experiments. Secondly, the immobilized pepsin column was back-
flushed during the gradient elution step. To minimize carry-over, the pepsin column was also 
washed first with acetonitrile (5 %)/ isopropanol (5 %)/ acetic acid (20 %) in water and then with 
2 M guanidine hydrochloride in 100 mM phosphate buffer pH 2.5 and after each injection.
52
   
The typical deuterium recovery achieved with our experimental set-up was 60-90% as 
determined from the deuterium content of fully-deuterated model peptides.  Data are reported as 
relative deuterium content levels without correction for back-exchange. 
4.2.6 MS Data Analysis 
A total of 137 peptides covering 85% of the primary sequence of mAb-B were identified using a 
combination of accurate mass measurement using time-of-flight mass spectrometry and 
collision-induced dissociation-tandem mass spectrometry on a linear quadrupole ion-trap mass 
spectrometer (LTQ-XL; Thermo-Scientific) as described previously.
52
 A coverage map and a 
listing of all mapped peptides can be found in the supporting information (see Fig 4.S1 and Table 
4.S1). H/D exchange data were processed using HDExaminer (Sierra Analytics, Modesto, CA). 
All mass spectra were manually curated after initial processing. To help ensure consistency, the 
charge state for each peptide was kept constant from run to run. To minimize potential biases in 
data interpretation, each replicate was curated by a different analyst.  Most peptide segments 
were detected in all three replicates, but a smaller number were found in only one or two of the 
replicates (see Fig S2). An R script, written in-house, was used to calculate average deuterium 
uptake and standard deviations and generate deuterium uptake plots from the exported data. All 
data with standard deviations exceeding the 95
th
 percentile in the dataset were inspected and 
corrected for data processing errors, if any were found.  A statistical analysis of our replicate 
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data, following Houde et. al
45
 (see Fig S3 and Fig S4) established the 99% confidence limit for a 
deuterium uptake difference as ±0.59 Da. 
4.2.7 Homology modeling of mAb-B 
The primary sequence of the heavy and light chains of mAb-B and human IgG1 b12 (PDB ID: 
1HZH)
53
 were aligned using CLUSTAL W.
54
 The two sequences are approximately 90% 
homologous with the most sequence differences in the complementarity determining region. The 
primary sequence of mAb-B was threaded onto the 1HZH structure using Discovery Studio 3.0 
(Accelrys, San Diego CA) and re-numbered to correct for gaps. The secondary structure of mAb-
B was manually reassigned based on the sequence alignment.  Models were displayed using 
Pymol (Schrödinger, LLC, Portland, OR). 
4.3 Results 
4.3.1 Effect of salts on the conformational stability of mAb-B 
Representative DSC thermograms showing the thermal transitions of mAb-B in presence of each 
of the three salts, are shown in Figure 4.1.  The thermal transitions in the DSC thermograms of 
mAbs have been shown previously to be independent,
55, 56
 sensitive to changes in pH and ionic 
strength, and reflect the multistep unfolding of the CH2,
57
 Fab,
58
 and Fc
59
 domains.  For mAb-B 
formulated in sodium chloride and sodium sulfate, a low temperature shoulder and two distinct 
peaks can be seen (Fig 1A and 1B). DSC analysis of mAb-B in sodium thiocyanate (see Figure 
4.1C) revealed three distinct peaks.  The temperatures of the three conformational transitions 
(Tm1, Tm2, and Tm3) at pH 6.0 are listed in Table 4.1.  Thiocyanate (at 0.5 M and 1.0 M) had 
large destabilizing effects on mAb-B as indicated by decreases in the Tm1, Tm2, and Tm3 values 
compared to control (0.1 M NaCl).  In contrast, 0.5 M and 1.0 M sulfate increased the three Tm 
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values of mAb-B.  Increasing concentrations of chloride (0.1 M to 0.5 M, 1.0 M, and 1.5 M) had 
no notable effect on Tm1 but a small increase in Tm2 and Tm3.   
The onset temperature, Tonset, was also measured to determine the temperature at which the first 
observed structural transition within mAb-B began (see Table 4.1).  Chloride, sulfate, and 
thiocyanate lowered Tonset values compared to the control (0.1 M chloride).  The effect of 0.5 M 
and 1.0 M thiocyanate on the Tonset (Tonset = –14.9 C and –23.8 C, respectively) was notably 
more pronounced than 0.5 M and 1.0 M sulfate (Tonset  = –2.1 C and –1.8 C, respectively) and 
0.5 M, 1.0 M and 1.5 M chloride (Tonset = –3.7 C, –5.7 C, and –7.0 C, respectively).  In 
summary, at pH 6.0, sulfate and thiocyanate showed opposite effects on the thermal transition 
temperatures of mAb-B: sulfate stabilized whereas thiocyanate destabilized mAb-B.  In addition, 
all three anions (sulfate, chloride and thiocyanate) showed titratable effects on the 
conformational stability of mAb-B.  
4.3.2 Effect of salts on aggregation during storage of mAb-B 
MAb-B samples  formulated in a citrate-phosphate buffer containing either 0.1 M sodium 
chloride, 0.5 M sodium chloride, 0.5 M sodium sulfate, or 0.5 M sodium thiocyanate at pH 6.0 
were incubated at various temperatures (–70, 4, 25, and 40 C) in stoppered glass vials.  
Individual vials were analyzed by SEC over a period of twelve months.  An overlay of 
representative chromatograms is shown in Figure 4.2A. The SEC peaks were assigned as 
described previously.
60
 Initially, there were no differences in the composition of mAb-B in the 
different formulations compared to the control (Figure 4.2A, dotted chromatograms).  After 
incubation at 40 C for 60 days, the amount of soluble monomer decreased, the amount of dimer 
remained unchanged, and there was an increase in the abundance of fragments (Figure 4.2A, 
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solid chromatograms).  In addition, multimeric aggregates formed in samples of mAb-B 
containing thiocyanate.  Figure 4.2B shows a plot of the fraction of soluble monomer (relative to 
the total peak area at time zero) over 12 months storage at different temperatures.  It can be seen 
that mAb-B degraded more rapidly in the presence of thiocyanate, and slightly more slowly in 
the presence of sulfate (up to 9 months), relative to the control at 40 C.  At 4C and 25 C, the 
rate of loss of monomer was slower and essentially independent of salt type.  Additional time 
would be required to ascertain if salts cause differences in aggregation rate at lower 
temperatures.  Interestingly, when frozen (–70 C), mAb-B samples containing thiocyanate 
precipitated out of solution, while no differences in the rate of loss of monomer were observed in 
samples formulated with sulfate and chloride, especially during multiple freeze-thaws (data not 
shown). 
4.3.3 Backbone flexibility of mAb-B in 0.1 M NaCl 
Figure 4.3 shows representative deuterium uptake curves for six segments from mAb-B, across 
different IgG1 domains, in 0.1 M sodium chloride (control) and 0.5 M concentration of the three 
different salts.  These six uptake curves are representative of the diverse range of H/D exchange 
kinetics for mAb-B.  (Additional deuterium uptake curves for 137 mAb-B segments covering 
85% of the total sequence are provided in Fig S5 of the Supporting Information.). The 
differences can be used to assess relative local backbone flexibility.  For example, in the CH2 
domain (heavy chain 300-306, peptide 71) deuterium uptake is only apparent after 10
3
 s of 
labeling.  This high level of protection against deuterium exchange indicates that this part of the 
CH2 is relatively rigid.  In contrast, a region between the VL and VH domains in the light chain 
(LC 105-116, peptide 117) was ~75% deuterated within 120 s (relative to the deuterium uptake 
after 27 hours of incubation), indicating that this is a relatively flexible region of mAb-B.  
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To better define a relative backbone flexibility scale, we used the extent of deuteration at 120 s 
relative to the theoretical maximum exchange without correction for back-exchange: 
 
  (1) 
 
where Δm120 s denotes the measured mass increase, N is the number of exchangeable amides, and 
f is mole fraction of deuterium under labeling conditions, here 0.86.  The number of 
exchangeable amides is determined by counting all non-proline residues starting at position 
three.  (After proteolysis, the first amide becomes a rapidly-exchanging amine and the second 
amide also undergoes rapid back-exchange.
61
) Figure 4.4A shows the distribution of local 
flexibility of segments within mAb-B based on this scale.  The segments of mAb-B in the lowest 
quartile on this scale are classified as rigid, segments in the top quartile as flexible, and segments 
in the middle 50% as intermediate.  Figure 4.4B shows the locations of rigid and flexible 
segments projected onto a homology model of mAb-B.  The H/D exchange measurements show 
that several loops and β-strands on the surface of the Fab region and CH3 domain are relatively 
flexible (yellow segments).  Most regions within the CH2 domain as well as some buried β-
strands and loops in other domains of mAb-B are relatively rigid (blue segments).  Similar to 
other studies,
62-64
 we found no strong correlation between the mAb-B flexibilities, measured in 
solution, and segment-averaged B-factor values from the crystal  structure of 1HZH
53
 for 22 
peptides with identical sequences from the constant domains of the two IgG1s (data not shown). 
4.3.4 Identifying the effects of salts on local backbone flexibility of mAb-B 
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In addition to providing information on relative local flexibility of mAb-B in 0.1 M NaCl, we 
can identify regions that undergo changes in H/D exchange kinetics in response to changes in 
salt type or concentration. The representative H/D exchange data in Figure 4.3 show some of the 
effects of the three different salts, at 0.5 M, on the local flexibility of mAb-B.  For each region, 
there was an increase or decrease in deuterium uptake at one or more of the exchange times, 
however, not all of these differences exceed the 99% confidence limit of ±0.59 Da.  These 
individual curves provided a visual representation of salt effects on deuterium uptake for the 
individual segments. To obtain a more quantitative and global view of salt-induced changes in 
deuterium uptake, individual differences in deuterium uptake, i.e., ΔΔm(t) = Δmsalt(t) – 
Δmcontrol(t), for every peptide at every labeling time are plotted in Figure 4.5. This figure shows 
both the magnitudes and signs of the differences and whether the differences exceeded the 99% 
confidence level for significance.  Positive values indicate segments where flexibility increased 
relative to the 0.1 M NaCl control while negative values indicate a decrease in flexibility.  In 
Figure 4.5, the x-axis arranges the peptides in order from the N-terminal end of the heavy chain 
to the C-terminal end of the light chain, similar to the plots described by Houde et al.
47
 The 
domain location for each peptide is denoted by the shading.  Mass difference exceeding 
statistical significance at the 99% confidence level, |ΔΔm| ≥ 0.59 Da (see Experimental section 
and Supporting Information Figures 4.S2, 4.S3 and 4.S4), are indicated by the dashed horizontal 
lines.  mAb-B regions that experienced significant changes in deuterium uptake in the presence 
of 0.5 M chloride, sulfate, and thiocyanate at one or more deuterium exchange times compared to 
the 0.1 M NaCl control are mapped onto a homology model of mAb-B in Figure 4.6.  Regions 
that showed increases in flexibility (positive values in Fig 5) are colored yellow; decreases in 
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flexibility (negative values in Fig 5) are blue.  Unaffected regions are grey and regions without 
H/D exchange data are colored white.  
4.3.5 The effects of 0.5 M chloride 
For the six representative peptide segments shown in Figure 4.3, the only significant effect of 
chloride at 0.5 M was in the light chain 47-70 segment, located in the VL domain of mAb-B 
(peptides 106-108 in Figure 4.5), which experienced an increased protection against H/D 
exchange. For the other five segments shown in Figure 4.3, chloride had no significant effect on 
deuterium uptake relative to the control.  Figures 4.5 and 4.6 show the effect of 0.5 M chloride 
across the entire mAb molecule. The addition of 0.5 M chloride caused only a few significant 
changes in mAb-B local flexibility compared to the 0.1 M chloride control.  In addition to the VL 
segment (47-70), there were also decreases in flexibility in the HC 124-147 segment (peptide 51) 
in the CH1 domain and HC 424-446 segment (peptide 94) in the CH3 domain. Interestingly, there 
was an overall trend of decreased flexibility across mAb-B (defined by slower deuterium uptake 
for most segments in Figure 4.5) in the presence of 0.5 M chloride, but most of the individual 
differences were not significant at the 99%
 
confidence level.   
4.3.6 The effects of 0.5 M sulfate 
Sulfate caused localized changes in the flexibility of mAb-B as summarized in Figure 4.6.  For 
example, data in Figures 4.3 and 4.5 show that 0.5 M sulfate caused substantial increases in 
deuterium uptake in the CH1 domain (HC 156-174 in Figure 4.3; peptides 51-53 in Figure 4.5) 
and in the VL domain (LC 47-70 in Figure 4.3; peptides 106-108 in Figure 4.5). In addition to 
these increases, several other segments (HC 37-80 corresponding to peptides 11, 22, 23, 30 and 
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35; HC 380-404 corresponding to peptides 83-85, 87; and LC 136-161 corresponding to peptide 
126) exchanged slightly faster than the control.   
4.3.7 The effects of 0.5 M thiocyanate 
Thiocyanate caused substantial increases in deuterium uptake in two different segments of the 
CH2 domain, as summarized in Figure 4.6.  Exchange was faster in the HC 241-252 region (120 s 
and 10
3
 s in Figure 4.3; also see peptides 64-68 in Figure 4.5).  In addition, the HC 300-306 
region also exchanged more quickly, but this increase in deuterium uptake was only evident at 
the longest exchange time, 10
5
 s, (see Figure 4.3; see also peptides 71-73 in Figure 4.5). Figure 
4.5 shows that several additional regions in the heavy chain (peptides HC 37-59, 61-80, 124-147, 
198-220, 334-348, 382-398, 429-446) and light chain (peptides LC 47-70, 136-161, 186-212) in 
mAb-B, corresponding to peptides 11, 29-30, 51, 61, 75, 86, 95, 106-107, 126, 136-137 
exchanged faster compared to the control.  
4.3.8 Overlapping effects of anions 
For a few of the peptide segments of mAb-B, the three anions had more complex effects on the 
deuterium exchange kinetics. For example, in the CH1 domain, HC 124-147 (peptide 51) and in 
the VL domain, LC 47-70 (peptide 106), both sulfate and thiocyanate accelerated, while chloride 
slowed H/D exchange (see Figure 4.5).  Similarly, both sulfate and thiocyanate accelerated 
exchange in HC 37-59 in the VH domain (peptide 11) and HC 382-398 in the CH3 domain 
(peptide 86).  Finally, 0.5 M chloride and thiocyanate caused opposite effects on deuterium 
uptake in the HC 429-446 segment of the CH3 domain corresponding to peptide 95 (see Figure 
4.5 and Table 4.S1). 
4.3.9 The effects of salt concentration on mAb-B local flexibility 
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The H/D exchange experiments at 25°C show that the three salts at 0.5 M concentration have 
localized effects on the flexibility of mAb-B. To determine if the magnitudes of these local 
effects were concentration-dependent, we measured H/D exchange at 10
3
 s of labeling for mAb-
B in 1.0 M and 1.5 M sodium chloride as well as in 1.0 M sodium sulfate and 1.0 M sodium 
thiocyanate. A minimized set of 43 mAb-B segments was selected for analysis.  This set 
represented all domains of mAb-B and consisted of both regions that were and were not affected 
by 0.5 M salts.  No significant differences in H/D exchange were noted for any of these 43 
segments in 1.0 M salts compared to 0.5 M salts (plots of deuterium uptake vs. salt concentration 
for each segment are in the Supporting Information Figure 4.S6). These results show that 
changes in local flexibility of mAb-B do not titrate to any appreciable extent beyond 0.5 M salt 
concentration, at least in the citrate-phosphate, pH 6.0 buffer employed in these experiments. 
Since increased ionic strength with 1.0 M or 1.5 M chloride did not have any further significant 
effect on the local flexibility of the mAb, the changes observed with sulfate were not due to 
changes in ionic strength differences but rather are due to the anion. Moreover, since the 
majority of mAb-B segments do not show any perturbation of flexibility in the presence of the 
different salts (see Figure 4.S6 in Supporting Information), intrinsic exchange rates of various 
mAb-B segments were not substantially altered by changes in salt types or ionic strength 
conditions.  
4.3.10 Reproducibility of H/D-MS data  
Figure 4.S3 shows the distribution of standard deviations in measured deuterium uptake for a set 
of H/D exchange experiments performed on mAb-B. This set includes both results presented in 
this work and in a companion study using different labeling buffers (manuscript in preparation). 
With a total of 6473 data points, 74% of the data had a standard deviation less than or equal to 
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±0.1 Da and 90% of the data had a standard deviation of less than ±0.2 Da. 5054 data points 
were obtained in triplicate, 1120 data points were obtained in duplicate and 299 data points were 
obtained as single measurements (Figure 4.S2). The 99
th
 percentile for the standard deviations 
was ±0.42 Da. Propagation of this confidence interval to deuterium uptake differences sets the 99 
percent confidence limit for deuterium uptake differences to ±0.59 Da. We further observed that 
there was no specific trend of standard deviation for different peptide sizes (represented as 
number of exchangeable hydrogens in Figure 4.S4. 
4.4 Discussion 
The purpose of this work was to probe the effects of anions from the extremes of the Hofmeister 
series on the local flexibility of various domains of an IgG1 mAb and examine these results in 
the context of conformational stability and aggregation propensity. Thiocyanate, an extreme 
chaotrope, decreased mAb-B’s thermal stability, as indicated by DSC, and accelerated 
aggregation, as measured by SEC. Sulfate, an extreme kosmotrope, had the opposite effects.  
Chloride, positioned in the middle of the Hofmeister series, had minor effects on both thermal 
and physical stability of mAb-B.  In contrast, the effects of the anions on local flexibility, as 
revealed by H/D exchange, were more complex (see Figures 4.5 and 4.6). Sodium chloride 
induced a small, but nearly-global decrease in flexibility, although most changes in individual 
peptide segments were not statistically significant.  While thiocyanate and sulfate had opposing 
effects on physical stability, both anions increased local flexibility in mAb-B. The increases in 
flexibility were not global; many regions of mAb-B were unaffected by either anion.  While 
thiocyanate and sulfate had similar effects on many regions of mAb-B, notably in the CH1 and 
VL domains, there were notable differences in CH2 domain, where thiocyanate increased 
flexibility, but sulfate had no effect.  We will return to the significance of these findings to the 
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mechanisms by which anions alter physical stability later in the discussion.  First, we address the 
issue of how these anions might directly alter the kinetics of H/D exchange. 
Salts might alter the kinetics of H/D exchange by changing the protein or by changing the 
chemical exchange process.  According to the Linderstrøm-Lang mechanism in the usual EX2 
limit, the rate of H/D exchange depends on both flexibility (kcl/kop) and intrinsic chemical 
exchange (kint).
65, 66
   
 
Changes in intrinsic exchange would lead to altered H/D exchange kinetics even if the flexibility 
of mAb-B was not affected. While base-catalyzed exchange in poly-DL-arginine is highly 
sensitive to changes in ionic strength,
67
 charged side-chains exhibit only moderate ionic strength 
dependence in more realistic peptide models
68
. Similarly, changes in ionic strength have only 
very modest effects on intrinsic exchange by amides in alanine model peptides.
61
 Increasing the 
concentration of NaCl from 0.1 M up to 1.5 M and Na2SO4 and NaSCN from 0.5 to 1.0 M in our 
work with mAb-B did not result in any significant changes in H/D exchange kinetics (see Fig S6 
in Supporting Information). Although sulfate was shown to slow and thiocyanate to increase 
intrinsic exchange in N-acetyl-alanine at pH 4,
69
 in our work we found that H/D exchange was 
not significantly affected by salts in the large majority of peptide segments at pH 6.0.  On the 
whole, we conclude that these anions do not have substantial effects on intrinsic exchange in 
mAb-B.  Thus we attribute the observed effects, instead, to the influence of the anions on the 
backbone flexibility of mAb-B.   
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The pattern of backbone flexibility of mAb-B at pH 6.0, as reported by H/D exchange at 120 s 
(see Figure 4.4), is consistent with several other H/D exchange studies of IgG1 monoclonal 
antibodies.
47-51
 We note in particular, the HC 241-252 (peptide 65, FLFPPKPKDTL) and HC 
300-306 (peptide 71, YRVVSVL) segments, both found in the CH2 domain, which we have 
found to be thiocyanate-sensitive.  H/D exchange kinetic data are available for both of these 
segments in two previous studies
47, 49
 and for HC 241-252 in two others
50, 70
 (the sequence 
numberings are offset slightly). In all of these other works HC 241-252 exchanges with an 
approximate mid-point of ~ 10
3
 sec. All of uptake data, when plotted on a logarithmic scale, 
have the same sigmoidal profile.  In the case of HC 300-306, no deuterium uptake was observed 
because the maximum labeling in previous work was only 3×10
4
 s; in our study, we were able to 
detect H/D exchange by extending D2O exposure to 10
5
 s. The consistency in these results in the 
CH2 domain is a testament to the intra-laboratory repeatability of H/D exchange measurements 
on mAbs.   
Although direct, quantitative comparisons are impeded by slight differences in peptide coverage 
and labeling conditions, domain-scale qualitative comparisons can still be drawn.  On a domain-
by-domain basis, our H/D exchange data for mAb-B, are in good agreement with previous work.  
What emerges is a general picture of backbone flexibility in the conserved regions of IgG1 
mAbs, validated across several different IgG1s examined in different labs. We find that the CH1 
and CH3 domains are relatively more dynamic while the CH2 domain is the most rigid domain.  
(In one of these works, 
47
 exchange in the CH2 appears to be more protected, but this is probably 
because maximum exchange was limited to 240 min.)  
In comparison to the 0.1 M NaCl control, 0.5 M NaCl caused only small changes in the thermal 
melting (Figure 4.1).  Aggregation kinetics, as measured by loss of monomer, were similar in 0.1 
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M and 0.5 M NaCl at 4, 25, and 40 °C over 12 months (Figure 4.2).  0.5 M NaCl caused only a 
few significant decreases in local flexibility in the CH1, VL and CH3 domains of mAb-B, along 
with an overall trend toward reduced flexibility across the molecule (Figure 4.5). This overall 
trend is interesting, although it must be noted that most of these effects are not greater than the 
statistically significant cutoff of 99% confidence (Figure 4.5). Chloride anions decreased the 
local flexibility of EnvZ, an osmolality-sensing inner membrane histidine kinase, but the effect 
was attributed to a change in solution osmolality.
71
 Chloride-protein interactions can occur via 
weak binding of chloride to protein surface residues either through electrostatic or non-specific 
interactions.
72
 For example, the aggregation propensity of three different monoclonal antibodies 
correlated directly with decreases in their net charge (reduced valence) and the apparent Tm1 at 
low salt chloride concentrations (0-160 mM).
73
  
Sulfate anions increased the Tm values of all the three thermal transitions of mAb-B with the 
largest increase observed for Tm2, corresponding to melting of the Fab region
74
 (Figure 4.1).  In 
the accelerated storage stability studies, 0.5 M Na2SO4 protected mAb-B against aggregation to a 
small extent at 40 °C over 12 months of storage (Figure 4.2), with less differences noted at 12 
months. Concomitantly, substantial increases in flexibility were observed in two segments of the 
CH1 and VL domains along with more subtle increases in flexibility in certain regions of the VH, 
CH1 and CH3 domains (Figures 4.5 and 4.6).  Stabilizing effects of sulfate on other proteins
75
 
have been proposed to occur by stabilization of the native folded state,
76, 77
 by the binding of 
sulfate to positively charged residues,
72, 76, 78, 79
 or by increased hydration arising from a higher 
number of dipoles on protein surfaces
80
. Sulfate anions, however, also increase the surface 
tension of aqueous solutions
29, 81-83
 with increasing concentration leading to higher protein 
surface energy (salting-out activity) that may accelerate protein aggregation
37, 84
. Sulfate can also 
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over-charge proteins leading to the increased local flexibility of the CH1 and VL domains via 
charge repulsion between bound sulfate anions.
38
 The interplay of these competing phenomena 
gives rise to the intriguing effects of sulfate anions on the stability and solubility of different 
proteins.
76, 81, 85, 86
 The effect of sulfate anions on stabilizing mAb-B in terms of conformational 
stability, and to a lesser extent against aggregation over time, combined with increases in local 
flexibility in two segments of the CH1 and VL domains, highlight the complex inter-relationships 
between protein stability and flexibility
40
.  
Thiocyanate anions substantially destabilized mAb-B.  The largest effect of thiocyanate was on 
Tm1 (Figure 4.1), corresponding to the unfolding of the CH2 domain
74
.  Thiocyanate also 
dramatically increased aggregation, as measured by monomer loss, at 40 °C over 12 months of 
storage (Figure 4.2). In contrast to sulfate or chloride, only thiocyanate caused substantial 
increases in local flexibility in two separate segments of the CH2 domain (Figure 4.3 and 4.6). 
The mechanism of thiocyanate-induced protein destabilization is thought to involve its 
interaction with both positively charged residues and apolar hydrophobic regions on the surface 
of either native proteins or partially unfolded intermediates,
87-90
 thereby decreasing the overall 
charge on the protein and weakening the electrostatic repulsion
91, 92
 leading to enhanced protein-
protein interactions
93-95
 resulting in aggregation.  The destabilizing effects of thiocyanate on 
protein flexibility are not necessarily observed with all proteins. In the case of recombinant γ-
interferon, no notable differences in H/D exchange kinetics were observed in 0.3 M KSCN vs. 
KCl, although the two salts had different effects on this protein’s solubility and aggregation.
96
  In 
addition to effects on the CH2 domain of mAb-B, additional subtle increases in local flexibility 
were observed across mAb-B (Figure 4.5), indicating thiocyanate may have specific weaker 
interactions with several other segments throughout the mAb. These results also correlate with 
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the decrease in conformational stability of mAb-B as observed for Tm2 (Fab region) and Tm3 
(CH3 domain) caused by thiocyanate. 
The increase in local flexibility (HC 241-252 and 300-306) of the CH2 domain of mAb-B in 
presence of thiocyanate correlates with conformational destabilization of the CH2 domain (Tm1) 
and accelerated aggregation during storage.  Similar effects were observed in a separate study in 
our laboratories where arginine hydrochloride also destabilized mAb-B and increased the 
flexibility of the HC 241-252 segment in the CH2 domain.
97
 At the same time, stabilizing 
additives had no effect on these two regions within the CH2 domain (NaCl and Na2SO4 in the 
present work and sucrose in our companion study).  These observations lead to the conclusion 
that the flexibility of HC 241-252 and 300-306 regions in the CH2 domain is an important factor 
in maintaining the overall physical stability of mAb-B.  We also observed increases in flexibility 
in the N-terminal region of the CH3 domain (HC 379-398, peptide 83). All of these observations 
are consistent with increases in the flexibility in the CH2 and CH3 domains of other IgG1 mAbs 
caused by glycan modifications,
47, 48
 and methionine oxidation
48, 49
. Whether these changes 
merely correlate with loss of stability or actually cause the destabilization cannot be determined 
simply on the basis of the H/D exchange measurements. However, several additional pieces of 
evidence suggest that the CH2 domain plays a causal role in aggregation. Agitation-induced 
aggregation of an Fc was inhibited by the binding of protein A and protein A-derived peptides.
98
  
Since Protein A binds to several residues from the CH2 and CH3 domains of an IgG protein, these 
results further support the idea that the CH2 region is important in mediating IgG aggregation. In 
a separate study, an isolated CH2 domain was stabilized by engineering a L242C and K334C 
double mutant that introduced a stabilizing disulfide bond.
99
 This disulfide bond presumably 
decreased the flexibility of the HC 241-251 region. Hence our results, with an intact IgG1 mAb, 
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further highlights the importance of HC 241-251 segment of the CH2 domain in the physical 
stability of IgG1 mAbs.  
On the other hand, both sulfate and thiocyanate increased the local flexibility in small regions of 
both the Fab and CH3 domains while chloride decreased flexibility in these same regions (see 
Figure 4.6). These changes in local flexibility in mAb-B do not correlate with conformational 
stability or the aggregation propensity of mAb-B.  These results highlight once again the 
complex interrelationships between protein flexibility and stability
40
 as well as the need for local 
measurements of dynamics. Global measurements of dynamics of a mAb may be less 
informative than local measurements because not all increases in flexibility result in decreases in 
stability.  Here, the overall change in dynamics would depend on the balance of effects between 
the relatively flexible Fab and CH3 domains and the comparatively rigid CH2 domain (Figure 4.4). 
Identification of backbone flexibility changes in specific regions within an IgG1 mAb that 
respond to changes in solution conditions (e.g., the presence of various additives) and correlation 
of these changes with conformational stability and physical stability during long term storage 
should provide better mechanistic insight into stabilization and formulation development of 
antibody-based drugs. H/D-MS measurements could complement high-resolution theoretical 
approaches for predicting stability of proteins based on salt-protein interactions.
31, 100
 For 
example, the salt induced effects observed in this work were localized to short segments of the 
mAb-B backbone.  Hence H/D-MS experiments could be designed to screen specific regions of a 
mAb for the effects of different additives to better predict their effects on physical stability. It 
remains to be seen whether the correlations between flexibility and stability persist across 
different subclasses (e.g., IgG1, IgG2, IgG4) or different classes of mAbs (IgG, IgM, IgA).  
Finally, computational studies mapping electrostatic potentials on the surface of the antibody at a 
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specific pH and in presence of various salts may help to further explain the molecular 
mechanism of anion induced changes in local flexibility observed in this study.
101-103
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Table 4.1 
Salt 
Concentration* 
T
onset
 (°C) T
m
1 (°C) T
m
2 (°C) T
m
3 (°C) 
Mean SD Tonset Mean SD ΔTm1 Mean SD ΔTm2 Mean SD ΔTm3 
0.1 M NaCl 
(control) 
57.7 0.2 - 69.3 0.1 - 73.6 <0.1 - 82.4 <0.1 - 
 
0.5 M NaCl 54.0 0.2 –3.7 69.5 <0.1 0.3 73.8 <0.1 0.2 82.7 <0.1 0.3 
1.0 M NaCl 52.1 0.2 –5.7 69.1 0.2 –0.1 74.7 <0.1 1.1 83.6 <0.1 1.2 
1.5 M NaCl 50.7 0.1 –7.0 68.7 0.1 –0.5 75.8 <0.1 2.2 84.7 <0.1 2.3 
 
0.5 M Na
2
SO
4
 55.6 0.7 –2.1 71.1 0.2 1.8 77.7 <0.1 4.1 84.7 <0.1 2.3 
1.0 M Na
2
SO
4
 55.9 0.8 –1.8 70.8 0.4 1.5 80.7 <0.1 7.1 87.8 <0.1 5.4 
 
0.5 M NaSCN 42.8 0.5 –14.9 60.3 0.2 –9.0 67.0 <0.1 –6.6 75.8 <0.1 –6.6 
1.0 M NaSCN 33.9 0.6 –23.8 51.6 0.5 –17.7 62.2 <0.1 –11.4 70.7 <0.1 –11.7 
 
Effect of salt type and concentration on thermal unfolding transitions (Tm) and onset of thermal 
unfolding (Tonset) for mAb-B as measured by DSC.   
*Samples contained 0.5 mg/ml protein in 20 mM citrate-phosphate buffer at pH 6 with salt as 
indicated. The mean and SD are from three separate measurements. 
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Table 4.S1 
Peptide Number Location 
1 mAbB Heavy 4-17 (VH) 
2 mAbB Heavy 5-22 (VH) 
3 mAbB Heavy 30-35 (VH) 
4 mAbB Heavy 33-36 (VH) 
5 mAbB Heavy 36-47 (VH) 
6 mAbB Heavy 37-46 (VH) 
7 mAbB Heavy 36-49 (VH) 
8 mAbB Heavy 36-58 (VH) 
9 mAbB Heavy 36-59 (VH) 
10 mAbB Heavy 37-58 (VH) 
11 mAbB Heavy 37-59 (VH) 
12 mAbB Heavy 36-65 (VH) 
13 mAbB Heavy 47-58 (VH) 
14 mAbB Heavy 47-59 (VH) 
15 mAbB Heavy 47-60 (VH) 
16 mAbB Heavy 47-61 (VH) 
17 mAbB Heavy 47-62 (VH) 
18 mAbB Heavy 48-61 (VH) 
19 mAbB Heavy 47-63 (VH) 
20 mAbB Heavy 47-65 (VH) 
21 mAbB Heavy 47-68 (VH) 
22 mAbB Heavy 48-68 (VH) 
23 mAbB Heavy 50-68 (VH) 
24 mAbB Heavy 59-68 (VH) 
25 mAbB Heavy 60-68 (VH) 
26 mAbB Heavy 61-68 (VH) 
27 mAbB Heavy 62-68 (VH) 
28 mAbB Heavy 64-68 (VH) 
29 mAbB Heavy 61-79 (VH) 
30 mAbB Heavy 61-80 (VH) 
31 mAbB Heavy 62-79 (VH) 
32 mAbB Heavy 63-79 (VH) 
33 mAbB Heavy 63-80 (VH) 
34 mAbB Heavy 64-79 (VH) 
35 mAbB Heavy 64-80 (VH) 
36 mAbB Heavy 66-79 (VH) 
37 mAbB Heavy 66-80 (VH) 
38 mAbB Heavy 69-79 (VH) 
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39 mAbB Heavy 69-80 (VH) 
40 mAbB Heavy 69-83 (VH) 
41 mAbB Heavy 80-83 (VH) 
42 mAbB Heavy 80-86 (VH) 
43 mAbB Heavy 81-86 (VH) 
44 mAbB Heavy 84-90 (VH) 
45 mAbB Heavy 84-93 (VH) 
46 mAbB Heavy 85-93 (VH) 
47 mAbB Heavy 87-104 (VH) 
48 mAbB Heavy 105-114 (VH) 
49 mAbB Heavy 105-118  
50 mAbB Heavy 105-126  
51 mAbB Heavy 124-147 (CH1) 
52 mAbB Heavy 146-174 (CH1) 
53 mAbB Heavy 156-174 (CH1) 
54 mAbB Heavy 159-174 (CH1) 
55 mAbB Heavy 163-174 (CH1) 
56 mAbB Heavy 171-183 (CH1) 
57 mAbB Heavy 180-185 (CH1) 
58 mAbB Heavy 185-193 (CH1) 
59 mAbB Heavy 185-197 (CH1) 
60 mAbB Heavy 186-197 (CH1) 
61 mAbB Heavy 198-220 (CH1) 
62 mAbB Heavy 208-229  
63 mAbB Heavy 235-240  
64 mAbB Heavy 235-252 (CH2) 
65 mAbB Heavy 241-251 (CH2) 
66 mAbB Heavy 241-252 (CH2) 
67 mAbB Heavy 243-252 (CH2) 
68 mAbB Heavy 244-251 (CH2) 
69 mAbB Heavy 263-277 (CH2) 
70 mAbB Heavy 266-277 (CH2) 
71 mAbB Heavy 300-306 (CH2) 
72 mAbB Heavy 301-305 (CH2) 
73 mAbB Heavy 301-306 (CH2) 
74 mAbB Heavy 307-318 (CH2) 
75 mAbB Heavy 334-348  
76 mAbB Heavy 349-364 (CH3) 
77 mAbB Heavy 349-365 (CH3) 
78 mAbB Heavy 355-365 (CH3) 
79 mAbB Heavy 369-376 (CH3) 
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80 mAbB Heavy 369-379 (CH3) 
81 mAbB Heavy 369-380 (CH3) 
82 mAbB Heavy 381-390 (CH3) 
83 mAbB Heavy 379-398 (CH3) 
84 mAbB Heavy 380-398 (CH3) 
85 mAbB Heavy 381-398 (CH3) 
86 mAbB Heavy 382-398 (CH3) 
87 mAbB Heavy 381-404 (CH3) 
88 mAbB Heavy 391-398 (CH3) 
89 mAbB Heavy 392-398 (CH3) 
90 mAbB Heavy 391-404 (CH3) 
91 mAbB Heavy 399-404 (CH3) 
92 mAbB Heavy 406-410 (CH3) 
93 mAbB Heavy 411-423 (CH3) 
94 mAbB Heavy 424-446 (CH3) 
95 mAbB Heavy 429-446 (CH3) 
96 mAbB Heavy 431-446 (CH3) 
97 mAbB Heavy 433-446 (CH3) 
98 mAbB Light 1-4 (VL) 
99 mAbB Light 1-7 (VL) 
100 mAbB Light 1-10 (VL) 
101 mAbB Light 1-11 (VL) 
102 mAbB Light 32-46 (VL) 
103 mAbB Light 33-46 (VL) 
104 mAbB Light 36-46 (VL) 
105 mAbB Light 47-62 (VL) 
106 mAbB Light 47-70 (VL) 
107 mAbB Light 47-74 (VL) 
108 mAbB Light 51-70 (VL) 
109 mAbB Light 71-74 (VL) 
110 mAbB Light 71-83 (VL) 
111 mAbB Light 72-82 (VL) 
112 mAbB Light 74-82 (VL) 
113 mAbB Light 75-82 (VL) 
114 mAbB Light 75-83 (VL) 
115 mAbB Light 80-85 (VL) 
116 mAbB Light 91-103 (VL) 
117 mAbB Light 105-116  
118 mAbB Light 116-122 (CL) 
119 mAbB Light 117-123 (CL) 
120 mAbB Light 116-125 (CL) 
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121 mAbB Light 117-125 (CL) 
122 mAbB Light 116-131 (CL) 
123 mAbB Light 116-132 (CL) 
124 mAbB Light 117-132 (CL) 
125 mAbB Light 136-148 (CL) 
126 mAbB Light 136-161 (CL) 
127 mAbB Light 144-161 (CL) 
128 mAbB Light 149-161 (CL) 
129 mAbB Light 162-172 (CL) 
130 mAbB Light 162-175 (CL) 
131 mAbB Light 162-178 (CL) 
132 mAbB Light 162-179 (CL) 
133 mAbB Light 162-181 (CL) 
134 mAbB Light 172-175 (CL) 
135 mAbB Light 173-179 (CL) 
136 mAbB Light 183-210 (CL) 
137 mAbB Light 186-212 (CL) 
 
 
Locations of peptides based on their ordinal numbers. 
 
 
 
 
 
 
 
 
228 
 
Figure 4.1 
 
229 
 
Representative DSC thermograms of mAb-B in 20 mM citrate-phosphate buffer pH 6.0 
containing indicated concentrations of different salts.  Effect of (A) NaCl, (B) Na2SO4, and (C) 
NaSCN on mAb-B conformational stability along with Tm1, Tm2, and Tm3 are shown.  
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Figure 4.2 
 
MAb-B aggregation during storage at different temperatures as monitored by SE-HPLC. (A) 
Overlay of SEC chromatograms of mAb-B before and after thermal stress: dotted lines 
correspond to mAb-B samples at time zero (no stress) and solid lines correspond to mAb-B 
samples incubated at 40 C for 2 months. (B) Effect of salts (NaCl, Na2SO4, and NaSCN) and 
thermal stress (4, 25, and 40 C) on mAb-B monomer loss. Data were collected in duplicate on 
231 
 
days 0, 28, 60, 90, 180, 260, and 360. Samples of mAb-B were prepared in 20 mM citrate-
phosphate buffer, pH 6.0 with either 0.1 M NaCl (control, black trace), 0.5 M NaCl (red trace), 
0.5 M Na2SO4 (green trace), or 0.5 M NaSCN (blue trace). 
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Figure 4.3 
 
 
Effect of different salts on the deuterium uptake in six segments from different domains of mAb-
B.  The error bars denote one standard deviation. 
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Figure 4.4 
 
 
Local flexibility of mAb-B, as measured by H/D exchange in 0.1 M NaCl at pH 6.0.  (A) 
Flexibility, as obtained from the ratio of the extent of deuteration at 120 s relative to the 
theoretical maximum exchange without correction for back-exchange (equation 1). Colors 
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denote the different domain boundaries. The broken lines denote the top and bottom quartiles. 
The maximum flexibility is 85.5%. (B) Flexibility data plotted on a homology model of mAb-B.  
Peptides representing the bottom quartile are classified as rigid (blue), the middle 50% as 
intermediate (gray), and the top quartile as flexible (yellow). Regions without H/D exchange data 
are colored white. In cases where overlapping segments had different flexibility categories, 
flexible and rigid categories took priority over the intermediate category, and rigid category took 
priority over flexible category (5 amino acids only).   
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Figure 4.5 
 
Relative deuterium uptake differences for all 137 segments of mAb-B in the presence of 0.5 M 
concentration of the salts relative to the control solution (0.1 M sodium chloride) as measured by 
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H/D-MS at each deuterium exposure time. The dashed lines at ±0.59 Da represent the 99% 
confidence limit for the mass difference values. The x-axis denotes the ordinal peptide numbers, 
which are sorted in ascending order based on the midpoint of their sequences. Colors denote the 
different domain boundaries. Positive y-values in these plots denote increased flexibility in the 
particular segment in presence of the particular salt compared to the control (0.1 M sodium 
chloride) and negative y-values denote decreased flexibility. Locations of the mAb domains 
shown in the figure are only approximate because some peptide segments span two different 
domains. See Table 4.S1 for the locations of the peptides in the mAb-B sequence.  
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Figure 4.6 
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Effects of salts on the flexibility of mAb-B relative to the control (0.1 M sodium chloride), as 
measured by H/D-MS plotted onto a homology model of mAb-B. Changes in flexibility are 
colored according to the legend. 
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Figure 4.S1 
 
 
(B) 
(A) 
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Primary sequence coverage map for (A) Heavy chain and (B) Light chain of mAb-B based on  
137 identified peptides. The total coverage was 85% in the heavy chain and 85% in the light 
chain giving a total coverage of 85%. 
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Figure 4.S2 
 
Distribution of number of replicates available across all data points. Here ‘N’ represents the 
number of replicates and the y-axis denoted the number of data points in the experiment. 
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Figure 4.S3 
 
Reproducibility of H/D-MS data from our experimental setup represented by the distribution of 
standard deviations for the mass increase across all time points and peptides of mAb-B from 
triplicate experiments (run on different days, N = 6473). The 99
th
 percentile for standard 
deviations was 0.42 Da. 
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Figure 4.S4 
  
 
Standard deviation of deuterium uptake measurements does not depend on peptide size. 
Distribution of standard deviations (SD) for all data points vs. the number of exchangeable 
hydrogens (representative of peptide size) in all the peptides analyzed for mAb-B. 
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Figure 4.S5  
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Deuterium uptake curves for the 137 segments from mAb-B in formulations containing 0.5 M 
chloride, sulfate or thiocyanate compared to the control (0.1 M chloride). 
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Plots of deuterium uptake vs. salt concentration for 43 segments of mAb-B. 
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Chapter 5 
 
Correlations between changes in conformational dynamics and physical stability in a 
mutant IgG1 mAb engineered for extended serum half-life 
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5.1 Introduction 
The IgG1 framework is the most widely used platform for designing and developing 
therapeutic monoclonal antibodies (mAbs) targeted for treatment of cancer, autoimmune and 
infectious diseases.
1, 2
 The Fc region of IgG1 mAbs, whose sequence is primarily dictated by 
antibody subtype and host, serves a variety of biological functions, the most important of which 
include binding to specific Fcγ receptors to trigger various immunological events (e.g., 
complement activation, ADDC, opsonization),
3-5
 and determining pharmacokinetic properties of 
the mAb through interaction with FcRn receptors.
6
 Recent work has also implicated the Fc region 
in reducing mobility of infectious viruses in the mucosa after antibody binding.
7
 These biological 
properties are often mediated by the glycosylation profile of the N-linked Asn 297 residue within 
the CH2 domain of the IgG1-Fc region.
8
  Thus, engineering specific sequences to improve the 
therapeutic utility of IgG1 mAbs is not limited to the amino acid residues of the complementarity 
determining regions (CDRs) in the Fab to enhance antigen binding specificity and affinity.
9
 The 
constant regions in the Fc can also be engineered to improve mAb-based therapeutics including 
better engagement of the immune system
10, 11
 as well as extension of the circulation half-life. 
12-14
  
Increasing the serum half-life of mAbs is an attractive proposition since it potentially 
results in changes in their pK/pD profiles as well as decreased dosing frequency leading to 
higher patient compliance.
15
 The serum half-life of IgG1 antibodies is known to be regulated by 
the neonatal Fc receptor (FcRn) located primarily in the acidic endosomes of endothelial and 
hematopoietic cells.
16, 17
 Free or antigen-bound antibodies enter these cells through pinocytosis 
or endocytosis, respectively, and are then transported to the endosomes. FcRn interaction then 
marks the antibodies for either recycling or lysosomal degradation. The recycling mechanism is 
based on selective binding of IgG to the FcRn receptor in the relatively more acidic (pH <6.5) 
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environment of endosomes, followed by release from the receptor upon exposure to the more 
basic (pH ~ 7.4) milieu of the bloodstream.
18
 The binding sites of the Fc region of an antibody to 
the FcRn receptor, as well as the amino acid residues responsible for the pH-dependent 
recycling, have been identified and are well documented for human IgGs.
19-21
  The pH-
dependence of this binding within acidic endosomes is driven by positively charged histidine 
residues in human IgG1 antibodies, specifically His 310 and His 436 at pH 6.5 or below, that 
form salt bridges with negatively charged Glu 117 and Asp 137 residues of FcRn.
18, 19, 21
 Under 
the more physiological conditions (pH ~ 7.4) of the bloodstream, however, these histidine 
residues are no longer charged and hence there is little histidine-mediated binding between the 
IgG-Fc region and the FcRn receptor.   
The recycling machinery has been widely targeted through random and specific 
mutations of the IgG primary sequence to increase or decrease the affinity for binding to FcRn 
and thereby extend or reduce the circulation half-life of IgG based therapeutics.
14, 22-28
 For 
example, the increased FcRn binding at pH 6.0 by a YTE triple mutant mAb is mediated by the 
creation of one additional salt bridge between  lu 256 (E) of Fc YTE and  ln 2 (Q) of the β2-
microglobulin chain of FcRn compared to the original IgG1 Fc structure.
29
 The YTE-mutations 
(M252Y/S254T/T256E) in the CH2 domain of an IgG1 mAb resulted in a nearly four-fold higher 
in vivo half-life in cynomolgus monkeys, the largest increase in IgG mAb half-life reported to-
date for non-human primates.
23
  The YTE triple mutation also resulted in ten-fold higher FcRn 
binding, four-fold higher tissue bioavailability, and modulated antibody-dependent cell 
cytotoxicity in non-human primates.
23
 In a recent human clinical trial, the YTE mutant of an 
IgG1 mAb targeted towards RSV (Motavizumab) had two- to four-fold longer in vivo half-life 
compared to the original mAb.
15
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The X-ray crystal structures of the original human IgG1 Fc (PDB ID 3AVE) and the Fc-
YTE (PDB ID 3FJT) mutant reveal no apparent structural differences between the two 
molecules.
14, 30
 A recent study, however, suggested that the YTE mutant has relatively lower 
physical stability in solution than the same mAb without the mutations.
31
  One possibility is that 
these stability differences are mediated by changes in structural dynamics of specific sequences 
in the mAbs due to the YTE mutations. Although the interrelationships between dynamics and 
stability of proteins are complex,
32
 growing evidence suggests that physical destabilization of 
mAbs can, in at least some cases, be mediated by changes in local dynamics of specific 
sequences.
33, 34
 Hydrogen/deuterium exchange coupled to mass spectrometry (H/D-MS) is now a 
well-established technique to explore the local dynamics of the amide backbone of monoclonal 
antibodies (mAbs) with peptide-level resolution.
35, 36
 H/D-MS has been used to study changes in 
mAb conformational dynamics imparted by stabilizing and destabilizing excipients
34
 and salts
33
, 
mutation in the IgG1 CH3 domain,
37
 deglycosylation,
35
 chemical and post-translational 
modifications,
38, 39
 thermal and freeze-thaw stress,
40
 and cytotoxic drug conjugation 
41
 in IgG1 
mAbs.  
This work investigates the nature of the relative differences in physical stability between 
an IgG1 mAb (mAb-A) and its corresponding YTE-mutant (mAb-E) by examining effects of the 
YTE-mutations on amide backbone local dynamics measured by amide H/D exchange, 
conformational stability measured by differential scanning calorimetry (DSC), and aggregation 
propensity measured by size exclusion chromatography (SEC).  Since solution pH plays a very 
important role in the interaction of antibodies with FcRn receptors (i.e., binding at pH 6.0 and 
release at pH 7.4), we explored differences in flexibility and stability between the two mAbs at 
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both pH values. We then correlate the observed changes in physical stability to changes observed 
in the amide backbone dynamics due to the YTE mutations.  
5.2 Materials and Methods 
5.2.1 Materials 
Two highly purified IgG1 mAbs were supplied by MedImmune, Gaithersburg, MD:  mAb-A and 
the corresponding YTE (M255Y/S257T/T259E) mutant of the same IgG1 designated as mAb-E. 
The residue number is slightly different from numbering reported elsewhere
14, 23
 due to the 
presence of three extra amino acids in the sequence of mAb-A/mAb-E. Residue numbers of other 
IgG1 mAbs mentioned in the Discussion section of this report are adjusted according to the 
sequence numbering scheme for mAb-A/mAb-E by adding +3 to the residue numbers. Both 
mAbs were produced in the same cell line and had overall similar N-linked glycosylation 
patterns in the CH2 domain containing primarily G0f and G1f oligosaccharides (see 
Supplemental Figure 5.S4 and Supplemental Table 5.S2). In addition, mAb-E had ~ 50% C-
terminal lysine heterogeneity while mAb-A had little to no C-terminal lysine. The relatively 
elevated levels of C-terminal lysine heterogeneity of mAb-E was not considered while 
interpreting our results, as it has been shown previously to have no effect on the 
pharmacokinetics, stability or conformational dynamics of mAbs.
60, 61
 Both mAb-A and mAb-E 
showed ~99% purity as measured by SDS-PAGE analysis (data not shown), and greater than 
99% monomer content as measured by size exclusion chromatography (see results). The mAbs 
were provided at 100 mg/mL and were buffer exchanged into 50 mM sodium phosphate, 150 
mM sodium chloride at pH 6.0 or 7.4. The protein concentration was adjusted to 10 mg/mL 
based on absorbance at 280 nm measured with an Agilent 8453 UV-visible spectrophotometer.  
Extinction coefficient values of 1.47 (mg/mL)
-1
 cm
-1
 and 1.42 (mg/mL)
-1
 cm
-1
 were used for 
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calculation of concentrations of mAb-A and mAb-E, respectively. Anhydrous sodium phosphate 
dibasic (code number 42437), and monobasic (code number 389870010) were purchased from 
Acros Organics. Sodium chloride (product number M-11628), LC-MS grade water, acetonitrile, 
and isopropanol were purchased from Fisher Scientific. TCEP (Catalogue # C4706), guanidine 
hydrochloride (Catalog # 50933), porcine pepsin, acetic acid, deuterium oxide (99+%D; 
catalogue number 151882) were purchased from Fluka/Sigma Aldrich. All chemicals used were 
of the highest purity grade commercially available from these vendors. 
5.2.2 Differential scanning calorimetry (DSC) 
DSC experiments and corresponding data analysis were performed as described previously.
34
 
The mAb-A and mAb-E samples were diluted to 0.5 mg/mL in buffers containing 50 mM 
sodium phosphate and 150 mM sodium chloride, either at pH 6.0 or 7.4, using the appropriate 
dilution buffer and filtered by 0.22 µm filter before analysis.  All analyses were done in 
triplicate.  
5.2.3 Accelerated storage stability study and analysis by size exclusion chromatography 
(SEC) 
Both mAb-A and mAb-E were prepared at 0.5 mg/mL in 50 mM sodium phosphate, 150 mM 
sodium chloride at both pH 6.0 and 7.4. The stock mAb formulations were filtered by passing 
through 0.22 µm filters (Millipore, Billerica, Massachusetts), aliquoted, 0.5 mL each, into 
separate 3 mL type 1 glass vials (West Pharmaceutical Services, Exton, Pennsylvania), stoppered 
with rubber stoppers (West Pharmaceutical Services, Exton, Pennsylvania), crimped and then 
stored in a 50 °C incubator. Sample filtration, aliquoting, and vial sealing were performed in a 
pre-sanitized laminar flow hood. Samples were taken out of the incubator and analyzed by SEC 
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at days 0, 2, 4, 7, 14, and 28. SEC was performed and data were analyzed in the same manner as 
described in our earlier work 
34
 with the following exception. Duplicate vials were analyzed two 
times each by SEC for each incubation time and condition. Hence the error values for the 
amounts of mAb monomer, soluble aggregates and fragments measured by SEC were derived 
from four different measurements. The error values for insoluble aggregate content were 
calculated by propagating the variances in the measurements of monomers, soluble aggregates 
and fragments. 
5.2.4 Preparation of deuterated labeling buffers 
Calculated weights of anhydrous sodium phosphate monobasic, dibasic and sodium chloride 
were added to 90 atom % D2O to prepare 50 mM sodium phosphate, 150 mM sodium chloride at 
pH 6.0 and 7.4. (90 atom % D was used for consistency with our previous work
33, 34
).  Addition 
of the chemicals did not result in any appreciable change in volume and hence concentrations of 
buffer components are accurate to 1% of their reported molarities.  The pH values reported are 
directly from pH meter readings without correction for the deuterium isotope effect on pH 
measurement 
62
.  
5.2.5 Hydrogen/deuterium-exchange mass spectrometry 
Sample preparation for hydrogen/deuterium exchange experiments followed by LC-MS analyses 
were performed as described in detail elsewhere.
33
  H/D exchange sample preparations were 
performed using the H/DX PAL robot (LEAP Technologies, Carrboro, NC) equipped with 
temperature-controlled sample drawers. The mAb samples at 10 mg/mL in 50 mM sodium 
phosphate and 150 mM sodium chloride at either pH 6.0 or 7.4 were diluted 20-fold in 90% 
deuterated buffer at the same pH at 25 °C to initiate deuterium exchange. Exchange reactions 
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were quenched after 30, 180, 10
3
, 10
4
 and 10
5
 s using quench buffer (0.5 M TCEP, 4 M 
guanidine hydrochloride, and 0.2 M phosphate, pH = 2.4) held at 1 °C resulting in a final pH of ~ 
2.5. Immediately following quench, samples were digested by passing through an immobilized 
pepsin column prepared in-house,
63, 64
 desalted and concentrated on a reversed phase trap 
(Peptide Concentration and Desalting Microtrap; Bruker-Michrom, Auburn, CA, USA), 
separated on a C-18 reversed phase column and mass analyzed (Agilent 6220 time-of-flight LC-
MS system). All the columns and tubing were housed inside a refrigerated compartment 
maintained at 0 °C to minimize back-exchange.  Deuterium recovery measured separately using 
fully deuterated peptides ranged from 64-85 %.  
5.2.6 Mass spectrometry data analysis 
A peptic peptide map shown in Supplemental Figure 5.S1 covering 96 % of the heavy chain and 
92 % of the light chain was constructed from common peptic peptides generated by digestion of 
both mAb-A and mAb-E. Peptide identities were confirmed using a combination of accurate 
mass measurement (±10 ppm) and tandem mass spectrometry data from a time-of-flight mass 
spectrometer and a linear ion trap mass spectrometer respectively.
65
 Three replicate sets of H/D-
exchange data were processed using HDExaminer (Sierra Analytics, California). Each set of data 
was manually curated independently to minimize bias by the analyst.  Deuterium uptake data 
averaging and plotting were achieved using an R script. The 99% confidence interval was 
calculated by combining all of the standard deviations from earlier studies in our laboratories 
with another IgG1 mAb
33, 34
 and from this study with mAb-A and mAb-E. The newly calculated 
value for the 99% confidence levels based on 9580 triplicate measurements, with error 
propagation for the differential measurement, is the same as our previously-established value of 
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± 0.59 Da. (Supplemental Figure 5.S5) All significant differences in deuterium content between 
the two mAbs were mapped onto the homology model of mAb-A. 
5.2.7 Construction of the homology model 
The homology model for the Fab and hinge regions of mAb-A were produced with the in silico 
KOL-Padlan structure
66
 as a template, using Modeller version 9.12 
67
.  The Fc domain was 
derived from PDBID: 3AVE 
30
, which has the same amino acid sequence as mAb-A. Mutations 
were introduced into this model to represent the YTE residues. Very few changes were observed 
in the structure after the mutations. Hence the same homology model was used to represent both 
mAb-A and mAb-E. Of note, the Fc domain of YTE has been crystallized (3FJT), and the 
secondary and tertiary structure folds of 3FJT are highly homologous with 3AVE
14
.  However, 
the 3FJT structure contains two extra residues, not present in mAb-A or mAb-E. Therefore, it 
was not used as a starting structure. The glycan structures in 3AVE were maintained, containing 
homodimeric G0F sequences, which represent a high population of carbohydrate species found 
in mAb-A and mAb-E by intact mass spectrometry measurements (see Figure 5.S4). 
5.3 Results 
5.3.1 YTE mutation decreased the conformational stability of only the CH2 domain 
DSC was used to examine the conformational stability of mAb-A and mAb-E (YTE-
mutant of mAb-A). Representative DSC thermograms comparing the two mAbs are shown in 
Figure 5.1. Both the mAbs display three thermal melting (Tm) transitions at both pH 6.0 and 7.4. 
The Tm1 value (Figure 5.1) has been shown previously to represent the thermal unfolding of the 
CH2 domain.
42
 The Tm2 and Tm3 values (Figure 5.1) have been shown to represent the unfolding 
of either the Fab or the CH3 domain depending on the antibody and solution conditions.
42, 43
 In 
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addition, the Tonset values, marking the temperature at which the first structural transition initiates 
(an important value for formulation stability considerations),
44
 were also determined. A summary 
of the three Tm and Tonset values are listed in Table 5.1. The YTE mutation decreased Tm1 values 
by 6.5 °C and 6.7 °C, at pH 6 and 7.4 respectively, and decreased Tonset values by ~7 °C at both 
pH values. The Tm2 and Tm3 values were not affected by the YTE mutation. Comparing the 
effect of pH 6.0 to 7.4 on protein conformational stability as measured by DSC, both mAbs had 
similar values for Tm1 and Tm2 at the two pH values.  However, both mAb-A and mAb-E had 
~4.7 °C higher values for Tm3 and ~ 1.4 °C lower Tonset values at pH 6.0 compared to 7.4. In 
summary, the YTE mutation decreased conformational stability in the CH2 domain while the 
other domains in the two mAbs were similar in terms of their thermal stability.  
5.3.2 YTE mutation increased the aggregation propensity of mAb-E under accelerated 
storage conditions 
The aggregation propensities of the two mAbs at pH 6.0 and 7.4 under accelerated 
storage conditions were measured by SEC at 50 °C over 28 days. Figure 5.2A shows the loss of 
IgG monomer and formation of fragments, soluble, and insoluble aggregates for the mAb 
samples. Peaks in the SEC chromatograms were assigned based on molecular weight as 
described previously.
34
 Both mAbs had greater than 99% monomer content at time zero and 
small amounts of fragments and soluble aggregates. Quantitation of the various mAb species 
after storage was determined relative to the respective peak areas at time 0. Loss in total 
integrated area of the chromatogram was attributed to formation of insoluble aggregates. The 
YTE mutation caused faster monomer loss at 50 °C at both pH 6.0 and 7.4, but had no effect on 
the rate of fragment formation. In addition, the YTE mutant produced higher amounts of soluble 
aggregates at either pH value which became evident after 14 days at 50 °C. Although minimal 
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amounts were observed until 14 days, the YTE mutant (mAb-E) also produced significantly 
higher amounts of insoluble aggregates (~9-11%) compared to mAb-A (~4-5%) after storage for 
28 days at 50 °C. To better display these differences in soluble, insoluble, and total aggregate 
content after incubation for 28 days, the data are shown as bar charts in Figure 5.2B and 5.2C, 
respectively. Both mAbs produced higher amounts of insoluble aggregates than soluble 
aggregates after 28 days storage. At both pH 6.0 and 7.4, the YTE mutant produced higher 
amounts of soluble and insoluble aggregates. The total aggregate content for the YTE mutant 
after 28 days of storage is roughly 2 fold higher than the original mAb at both pH values. 
5.3.3 Identifying the effects of YTE mutation on the backbone flexibility 
 Amide H/D exchange with mass spectrometric detection was used to measure the effects 
of the YTE mutation on protein amide backbone flexibility.  As an initial step in the analysis of 
both mAbs by H/D-exchange mass spectrometry, a peptic peptide map was developed. A total of 
167 common peptides were reproducibly obtained by pepsin digestion of both mAb-A and mAb-
E resulting in 92% and 96% sequence coverage in the light chain and heavy chain, respectively, 
as shown in Supplemental Figure 5.S1. The two mAbs were incubated in deuterium-containing 
solutions, quenched at various time points and passed through a pepsin column.  The deuterium 
content of the peptides was determined by LC-MS (see Methods section). Examples of 
deuterium uptake plots for six different segments from mAb-A and mAb-E at pH 6.0 and 7.4 are 
shown in Figure 5.3A and 5.3B, respectively. The shapes of the different deuterium uptake 
profiles illustrate the different degrees of flexibility in different regions of the mAb. Similar 
deuterium uptake profiles for all 167 common peptides found in both mAb-A and mAb-E at pH 
6.0 and 7.4 are presented in Supplemental Figures 5.S2 and 5.S3.  Differences in deuterium 
uptake between mAb-A and mAb-E at various exchange times were found in four of the six 
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peptides shown in Figure 5.3 (HC 244-254, HC 255-264, HC 320-332, and LC 179-194) at both 
pH 6.0 and 7.4. However, not all of these differences exceed the 99% confidence interval for 
significance (see below). The segment locations in the primary sequence of mAb-A or mAb-E 
corresponding to peptide numbers are tabulated in Supplemental Table 5.S1.  
 To more clearly display the effects of the YTE mutation on deuterium uptake for all 
peptide segments, the data are presented as differential deuterium uptake as described 
previously.
33
 The differential deuterium uptake i.e. m(t)= mmAb-E(t)−mmAb-A(t) where m 
represents the measured mass increase upon deuteration for each peptide is plotted as a vertical 
bar (Figure 5.4 for pH 6.0 and Figure 5.5 for pH 7.4) and t denotes the labeling time. A positive 
value for m indicates that the YTE mutation caused faster exchange, corresponding to 
increased flexibility, while a negative value indicates slower exchange, corresponding to 
decreased flexibility. The dotted lines denote the 99% confidence interval (±0.59 Da) for a 
statistically significant difference in exchange. The 99% confidence interval was determined by 
pooling all standard deviation values for triplicate measurements in our earlier studies with 
another IgG1 mAb
33, 34
 and this study.  Differential exchange that exceeds the 99% confidence 
interval is mapped onto a homology model for the mAb in Figure 5.6A, and in more detail for 
the Fc portion only in Figure 5.6B. The YTE mutation-induced increases in local flexibility are 
colored in yellow, decreases in blue, and no changes in grey. The absence of H/D exchange data 
is shown in white.  The H/D exchange results are discussed in detail in the next section. 
5.3.4 The YTE mutation caused localized increases in backbone flexibility at pH 6.0  
 At pH 6.0, nearly all of the significant differences in exchange were positive and 
localized to narrow regions indicating that the YTE mutation increases flexibility in only a 
limited number of segments (see Figure 5.4). The highest positive deuterium uptake differences 
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were observed in the HC 244-255 region of the CH2 domain at 10
3 
s followed by 180 s, a region 
covered  by the overlapping peptides HC 238-254, HC 244-254, HC 244-255, HC 245-254, HC 
247-254 and HC 247-255 (corresponding to peptide numbers 52, 54-58 in Figure 5.4). The 
mutation also caused two other segments in the CH1 domain (HC 174-188 corresponding to 
peptide 42 in Figure 5.4) and the CH2-CH3 interface (HC 320-332 corresponding to peptide 81 in 
Figure 5.4) to exchange significantly faster. In addition, the YTE mutation caused several other 
segments (HC 28-46, HC 144-168, HC 159-177, and LC 147-174 corresponding to peptides 12, 
36, 40, and 159 in Figure 5.4) to exchange faster than mAb-A. Only one segment LC 179-194 
(corresponding to peptide 165 in Figure 5.4), exchanged more slowly in the YTE-mutant.  
5.3.5 Mutation-induced differences in local flexibility at pH 7.4 were similar to differences 
at pH 6.0 
 Deuterium uptake by the representative peptides was faster at pH 7.4 than at pH 6.0 (see 
Figure 5.3A vs. 5.3B), as expected from the known pH dependence of intrinsic deuterium 
exchange.
45
 Looking across all of the peptides in Figure 5.5, it can be seen that most of the 
differences in deuterium uptake were at early exchange times (30s and 180s) at pH 7.4 rather 
than later times (180s and 10
3
s) at pH 6.0.  The shift arises from faster intrinsic exchange at pH 
7.4.
45, 46
 Essentially all of the peptide segments that had significant differences in deuterium 
uptake at pH 6.0 also had significant differences at pH 7.4 (Figures 5.4 and 5.5), with only two 
exceptions noted. One segment in the CL domain (LC 147-174 corresponding to peptide 159 in 
Figures 5.4 and 5.5) had increased deuteration at 10
5 
s in the mutant mAb-E at pH 6.0, but not at 
pH 7.4.  Another segment in the CH2 domain (HC 269-280 corresponding to peptide 68 in 
Figures 5.4 and 5.5) had increased deuteration at 10
3
 s at pH 7.4, but not at pH 6.0.  
5.3.6 Backbone flexibility of the peptide segments containing the YTE mutation 
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 Three overlapping peptide segments covering the YTE mutation sites were detected in 
the peptic peptide maps of both mAb-A and mAb-E. The H/D exchange kinetics of one of the 
three segments (HC 255-264) is shown in Figure 5.3 while the two others are shown in 
Supplemental Figures 5.S2 and 5.S3. The point mutations resulted in trends showing slightly 
faster deuterium exchange in these three segments in mAb-E, but observed differences in 
deuterium uptake at every exchange time were less than the 99% confidence interval for a 
significant difference. Under typical exchange conditions (i.e., the EX2 kinetic limit), the 
kinetics of exchange depend on both backbone dynamics and on intrinsic exchange.
47, 48
 When 
comparing homologous backbone segments with different amino acid sequences, the rate of 
intrinsic exchange must be considered.  We used tabulated values for intrinsic exchange
40, 41
 to 
calculate the intrinsic exchange by these segments at pD 6, as shown in Figure 5.7.  All three 
segments in mAb-A have slightly faster intrinsic exchange compared to mAb-E. The differences 
in the calculated intrinsic exchange rates oppose the trend observed experimentally in the two 
mAbs. Therefore, the differences in backbone flexibility in the mutation region are likely 
somewhat larger than they appear in Figure 5.3. Given the complex, multi-exponential nature of 
H/D exchange kinetics, no suitable method has yet been developed to directly correct the 
experimental results for these differences. It remains possible that the small differences in 
backbone flexibility induced by the YTE mutation at the mutation sites would be statistically 
significant if they could be corrected for intrinsic exchange effects. 
5.4 Discussion 
Previous work has shown that the YTE mutations in the CH2 domain of IgG1 mAbs 
resulted in ten-fold higher FcRn binding and four-fold longer serum half-life in animal models.
23
 
In-house formulation work (data not shown) and characterization studies,
31
 however, have shown 
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a relative decrease in physical stability of various mAbs containing the YTE mutations. The 
purpose of this study was to probe the potential mechanisms of this destabilization by examining 
the YTE mutation induced changes in backbone flexibility of an IgG1 mAb and correlating 
results to DSC and SEC analysis of physical stability. To accomplish this purpose, two IgG1 
mAbs were generated with identical primary sequences in the Fab domains, one molecule 
containing the YTE triple mutations in the Fc domain (mAb-E), while the other molecule had the 
native IgG1 sequence for the Fc domain (mAb-A).  The N-linked glycosylation patterns in the Fc 
region of mAb-A and mAb-E were overall similar containing primarily G0f and G1f 
oligosaccharides (see Supplemental Figure 5.S4 and Supplemental Table 5.S2).  
DSC is a robust and widely utilized technique to assess the thermal stability of mAbs.
49
 
The endothermic unfolding transitions have been found to be independent of each other and 
generally irreversible for mAbs.
50
 In the case of three distinct transitions, the peaks can be 
attributed to unfolding of the CH2 domain followed by the Fab and then the CH3 domain in order 
of increasing melting temperatures.
42
 Although both mAbs displayed high thermal stability as 
measured by DSC, typical for IgG molecules, the mutant mAb-E had relatively lower Tm1 values 
at both pH 6.0 and 7.4 (Figure 5.1 and Table 5.1). The YTE mutant had ~ 7 °C lower Tonset value 
and ~ 6.7 °C lower Tm1 value compared to mAb-A.  There were no differences in the other 
thermal melting transition temperatures (Tm2 and Tm3) between mAb-A and mAb-E.  In 
addition, accelerated stability studies monitoring mAb dimer and multimer formation by SEC 
analysis showed that the YTE mutant has a higher aggregation propensity (Figure 5.2).  Despite 
these observed relative differences in physical stability, the YTE molecules can be formulated as 
biopharmaceuticals to be sufficiently stable during manufacturing and long-term storage by 
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appropriate design of formulation conditions including solution pH, excipients, and dosage form 
selection.  
An examination of the X-ray crystal structures of Fc-YTE of mAb-E (PDB ID 3FJT) and 
the Fc of mAb-A (PDB ID 3AVE) indicated that there is little structural difference between the 
two.
14, 30
 However several adjacent as well as distant segments from the mutation site in the CH2 
domain were shown in the current work to have increased flexibility due to the YTE mutations. 
Earlier reports indicated that single as well as concerted mutations far from the Fc binding 
epitopes in the Fc region enhanced the IgG1/FcRn binding.
25, 27
 Using the residue numbering 
scheme of mAb-A or mAb-E, these mutations are P233S/T, F244L, T253Q, V267A/E, N318D, 
A333V, N364D, A381V/T, M431L).
25, 27
 Several of these previously reported mutations (e.g., 
F244L, T253Q, V267A/E, N318D, and A333V) are in the peptide segments (HC 244-255, HC 
269-280, HC 320-332) that showed increased local flexibility due to the YTE-mutations in our 
work.  Hence, it can be inferred that residue/s in the segments with increased flexibility in the 
CH2 domain and the CH2-CH3 interface may have indirect interactions with the conformation of 
the 255-259 segment which is the location for YTE-mutations as well as one of the FcRn binding 
epitopes of Fc.     
Additional segments in the Fab region (HC 28-46, HC 144-168, HC 159-177, HC 174-
188, and LC 147-174 corresponding to peptide 9, 36, 40, 42 and 158 in Figures 5.4 and 5.5) had 
increased flexibility in the YTE mutant and the LC 179-194 had decreased flexibility.  It is 
surprising that the YTE mutations in the CH2 domain caused flexibility changes at distant sites in 
different domains. Molecular dynamics simulations have shown that the two arms of the Fab can 
have polar and non-specific interactions with regions of the Fc not far from the FcRn binding 
sites.
51
 Furthermore, recent studies have shown that mAbs with identical Fc but differing Fab 
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sequences, 
52
 as well as mAbs and Fc fusion proteins with the same Fc sequences,
53
 can bind 
FcRn differentially with varying pharmacokinetic properties. The H/D exchange data in our 
study further support the notion that certain segments of the Fab sequence may have some yet-to-
be-defined indirect interactions with the 255-259 region in the CH2 domain of the Fc, one of the 
FcRn binding epitopes. At the same time, the YTE mutation did not cause any changes in the 
thermal unfolding temperatures of the Fab region measured by DSC (Figure 5.1 and Table 5.1). 
These results further highlight the complex interrelationships between protein flexibility and 
conformational stability.
32
 
The YTE mutation increased the flexibility of the 244-255 region of the CH2 domain at 
both pH 6.0 and 7.4. This region, covered by six overlapping segments (peptide numbers 52, 54-
58 in Figures 5.4 and 5.5), had the largest magnitude of increase among all differences detected 
by H/D-MS. This segment is adjacent to the 255-259 segment containing the YTE mutations. A 
visual comparison of the deuterium uptake kinetic profiles of segments covering the 244-255 
region at pH 6.0 show very similar overall shapes across three different IgG1 mAbs (mAbs A 
and E in this study and mAb-B in previous studies) examined in our laboratories with the 
midpoint of deuterium uptake at ~ 10
3
 s.
33, 34
 Moreover, similar kinetic profiles are evident in 
H/D-MS studies at pH ~ 6 with other IgG1 mAbs in other laboratories. 
35, 38, 54
 Hence it can be 
concluded that this region has similar dynamic behavior across all of these distinct IgG1 mAbs.  
Increased flexibility of the 244-255 sequence caused by the YTE mutation (mAb-E vs. 
mAb-A) correlates with decreased thermal stability of the CH2 domain and increased aggregation 
propensity. Significant increases in flexibility of this same segment have been correlated 
previously in our labs in another IgG1 mAb with arginine and sodium thiocyanate-induced 
decreases in conformational stability, and concomitant increases in the aggregation propensity.
33, 
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34
  Furthermore, several reports by others have correlated increased flexibility of this same 
primary sequence segment in the CH2 domain with methionine oxidation,
38, 39, 54
 destabilization 
by deglycosylation,
35
 changes in glycosylation
38
 and even decreased stability due to drug 
conjugation to free cysteine residues
41
. The 244-255 segment in the CH2 domain is relatively 
apolar in nature with two valine residues and two phenylalanine residues and whose phenyl rings 
pack closely with the glycans in crystal structures.
30
 It is possible that the increased flexibility of 
the peptide backbone disrupts the packing interactions between the peptide backbone and the 
glycan chains leading to unfolding of this hydrophobic segment. This unfolded apolar segment, 
in turn, may act as a hotspot for subsequent structural alterations that could lead to irreversible 
aggregation in IgG1 mAbs,
55-57
 for example, as observed by SEC analysis. 
 Limiting the flexibility of this particular segment may therefore serve as a good indicator 
for designing mAbs (and mAb-related products such as IgG-Fc, fusion proteins, or antibody drug 
conjugates) with higher thermostability and resistance to aggregation. In fact, it has been 
reported that engineering an additional disulfide bond at the Leu (L) 245 residue between two 
Phe (F) residues in this segment (L245C mutation), and the Lys (K) 337 residue to Cys (C) 
residues (K337C mutation) in an isolated IgG1 CH2 domain results in an ~ 20 °C increase in 
thermal stability possibly by limiting the flexibility of the segment.
58
 Furthermore soluble IgG1 
CH2 and CH3 domains with engineered disulfides have been shown to have increased 
thermostability and binding to FcRn.
59
 Therefore it appears that this particular segment in the 
CH2 domain, whose sequence is conserved across all human IgG1 mAbs, can act as a 
destabilizing motif or aggregation hotspot and thus can play a crucial role in modulating the 
overall physical stability in many IgG1 mAbs. 
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Table 5.1  
 
 
 
Thermal stability of mAb-A and mAb-E at pH 6.0 and pH 7.4 indicated by the melting onset 
temperature (Tonset) and the melting transitions (Tm1, Tm2, and Tm3) as measured by DSC. 
Formulations contained 50 mM sodium phosphate, 150 mM sodium chloride with 0.5 mg ml
-1
 of
 
mAb-A or mAb-E. The mean and standard deviations are based on three independent 
measurements. 
 
 
 
 
Proteins pH
Tonset
( °C)
Tm1
( °C)
Tm2
( °C)
Tm3
( °C)
Mean SD Mean SD Mean SD Mean SD
mAb-A
6.0
62.1 0.9 69.6 <0.1 82.9 <0.1 91.9 <0.1
mAb-E 55.2 0.4 63.1 <0.1 83.1 <0.1 91.8 <0.1
 (mAb-A – mAb-E) 6.9 6.5 - 0.2 0.1
mAb-A
7.4
63.5 0.2 70.3 <0.1 83.1 <0.1 87.2 <0.1
mAb-E 56.5 0.2 63.6 <0.1 83.0 <0.1 87.2 <0.1
 (mAb-A – mAb-E) 7.0 6.7 0.1 0.0
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Table 5.S1 
Peptide 
Number Location 
1 Heavy 4-19 (VH) 
2 Heavy 5-19 (VH) 
3 Heavy 5-20 (VH) 
4 Heavy 18-22 (VH) 
5 Heavy 9-32 (VH) 
6 Heavy 16-39 (VH) 
7 Heavy 27-30 (VH) 
8 Heavy 27-45 (VH) 
9 Heavy 28-46 (VH) 
10 Heavy 28-47 (VH) 
11 Heavy 27-50 (VH) 
12 Heavy 28-50 (VH) 
13 Heavy 35-44 (VH) 
14 Heavy 35-50 (VH) 
15 Heavy 35-52 (VH) 
16 Heavy 37-52 (VH) 
17 Heavy 41-52 (VH) 
18 Heavy 51-62 (VH) 
19 Heavy 51-69 (VH) 
20 Heavy 53-82 (VH) 
21 Heavy 63-73 (VH) 
22 Heavy 63-77 (VH) 
23 Heavy 66-82 (VH) 
24 Heavy 70-82 (VH) 
25 Heavy 78-81 (VH) 
26 Heavy 83-94 (VH) 
27 Heavy 79-103 (VH) 
28 Heavy 91-112 (VH) 
29 Heavy 106-119 (VH) 
30 Heavy 112-119 (VH) 
31 Heavy 108-124 (VH) 
32 Heavy 113-125 (VH) 
33 Heavy 115-130  
34 Heavy 136-143 (CH1) 
35 Heavy 147-154 (CH1) 
36 Heavy 144-168 (CH1) 
37 Heavy 151-168 (CH1) 
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38 Heavy 158-163 (CH1) 
39 Heavy 149-177 (CH1) 
40 Heavy 159-177 (CH1) 
41 Heavy 166-172 (CH1) 
42 Heavy 174-188 (CH1) 
43 Heavy 183-188 (CH1) 
44 Heavy 183-200 (CH1) 
45 Heavy 188-200 (CH1) 
46 Heavy 189-200 (CH1) 
47 Heavy 195-205 (CH1) 
48 Heavy 201-212 (CH1) 
49 Heavy 214-219 (CH1) 
50 Heavy 220-238  
51 Heavy 238-243 (CH2) 
52 Heavy 238-254 (CH2) 
53 Heavy 245-251 (CH2) 
54 Heavy 244-254 (CH2) 
55 Heavy 244-255 (CH2) 
56 Heavy 245-254 (CH2) 
57 Heavy 247-254 (CH2) 
58 Heavy 247-255 (CH2) 
59 Heavy 255-263 (CH2) 
60 Heavy 255-264 (CH2) 
61 Heavy 256-263 (CH2) 
62 Heavy 261-269 (CH2) 
63 Heavy 266-271 (CH2) 
64 Heavy 267-271 (CH2) 
65 Heavy 264-280 (CH2) 
66 Heavy 265-280 (CH2) 
67 Heavy 266-280 (CH2) 
68 Heavy 269-280 (CH2) 
69 Heavy 272-290 (CH2) 
70 Heavy 273-290 (CH2) 
71 Heavy 279-294 (CH2) 
72 Heavy 303-309 (CH2) 
73 Heavy 304-309 (CH2) 
74 Heavy 309-312 (CH2) 
75 Heavy 312-318 (CH2) 
76 Heavy 310-321 (CH2) 
77 Heavy 311-327 (CH2) 
78 Heavy 314-327  
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79 Heavy 320-327  
80 Heavy 315-337  
81 Heavy 320-332  
82 Heavy 328-336  
83 Heavy 337-351 (CH3) 
84 Heavy 346-349 (CH3) 
85 Heavy 337-359 (CH3) 
86 Heavy 338-362 (CH3) 
87 Heavy 352-358 (CH3) 
88 Heavy 352-359 (CH3) 
89 Heavy 352-361 (CH3) 
90 Heavy 352-367 (CH3) 
91 Heavy 352-370 (CH3) 
92 Heavy 360-367 (CH3) 
93 Heavy 360-369 (CH3) 
94 Heavy 371-379 (CH3) 
95 Heavy 372-379 (CH3) 
96 Heavy 369-383 (CH3) 
97 Heavy 371-382 (CH3) 
98 Heavy 372-381 (CH3) 
99 Heavy 372-382 (CH3) 
100 Heavy 372-383 (CH3) 
101 Heavy 372-401 (CH3) 
102 Heavy 380-393 (CH3) 
103 Heavy 384-393 (CH3) 
104 Heavy 380-401 (CH3) 
105 Heavy 382-401 (CH3) 
106 Heavy 383-401 (CH3) 
107 Heavy 384-401 (CH3) 
108 Heavy 380-407 (CH3) 
109 Heavy 383-407 (CH3) 
110 Heavy 384-407 (CH3) 
111 Heavy 394-401 (CH3) 
112 Heavy 392-409 (CH3) 
113 Heavy 394-407 (CH3) 
114 Heavy 402-407 (CH3) 
115 Heavy 394-416 (CH3) 
116 Heavy 402-408 (CH3) 
117 Heavy 408-413 (CH3) 
118 Heavy 409-413 (CH3) 
119 Heavy 408-425 (CH3) 
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120 Heavy 408-426 (CH3) 
121 Heavy 409-426 (CH3) 
122 Heavy 410-426 (CH3) 
123 Heavy 408-429 (CH3) 
124 Heavy 414-425 (CH3) 
125 Heavy 414-426 (CH3) 
126 Heavy 428-433 (CH3) 
127 Heavy 427-449 (CH3) 
128 Heavy 429-449 (CH3) 
129 Heavy 430-449 (CH3) 
130 Heavy 432-449 (CH3) 
131 Heavy 434-449 (CH3) 
132 Heavy 436-449 (CH3) 
133 Light 21-25 (VL) 
134 Light 17-34 (VL) 
135 Light 20-37 (VL) 
136 Light 35-45 (VL) 
137 Light 46-53 (VL) 
138 Light 43-60 (VL) 
139 Light 46-71 (VL) 
140 Light 60-81 (VL) 
141 Light 73-79 (VL) 
142 Light 67-90 (VL) 
143 Light 95-102 (VL) 
144 Light 90-108 (VL) 
145 Light 106-118 (CL) 
146 Light 115-124 (CL) 
147 Light 115-130 (CL) 
148 Light 116-129 (CL) 
149 Light 115-131 (CL) 
150 Light 116-130 (CL) 
151 Light 116-131 (CL) 
152 Light 125-142 (CL) 
153 Light 128-147 (CL) 
154 Light 135-160 (CL) 
155 Light 143-160 (CL) 
156 Light 148-160 (CL) 
157 Light 152-163 (CL) 
158 Light 147-174 (CL) 
159 Light 151-171 (CL) 
160 Light 161-177 (CL) 
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161 Light 161-178 (CL) 
162 Light 172-178 (CL) 
163 Light 178-194 (CL) 
164 Light 179-194 (CL) 
165 Light 185-195 (CL) 
166 Light 195-213 (CL) 
167 Light 203-209 (CL) 
 
 
Segment location in the primary sequence of mAb-A or mAb-E corresponding to peptide 
numbers assigned based on segment midpoint calculated in ascending order from N-to-C termini 
of the heavy followed by the light chain of mAb-A/mAb-E. 
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Table 5.S2 
Protein Observed MS peaks Theoretical mass (Da) Possible glycans 
Error 
(Da) 
mAb-A 
148040.50 148038.20 G0f/G0f 2.30 
148202.12 148200.36 G0f/G1f 1.76 
148364.04 148362.51 G1f/G1f 1.53 
mAb-E 
148188.55 148186.30 G0f/G0f 2.25 
148350.82 148348.40 G0f/G1f 2.42 
148513.43 148510.50 G1f/G1f 2.93 
 
Possible glycoforms of mAb-A and mAb-E are shown according to the intact mass spectra of 
both the mAbs. The mass difference between the two mAbs is due to the YTE mutations. These 
results were further confirmed using FabRICATOR protease digestion and accurate mass 
measurement of the glycosylated fragments (results not shown). 
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Figure 5.1 
 
Representative overlay of DSC thermograms of mAb-A and mAb-E at (A) pH 6.0 and (B) pH 
7.4. The Tm1, Tm2, and Tm3 values indicate the first, second, and third thermal melting 
transitions for the two mAbs.  
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Figure 5.2 
 
Accelerated storage stability of mAb-A and mAb-E after incubation at 50 C for up to 28 days as 
measured by SEC. The mAbs were formulated in 50 mM sodium phosphate and 150 mM sodium 
chloride at pH 6.0 and 7.4. (A) The percentage of monomer, fragments, soluble aggregates, and 
insoluble aggregates of mAb-A and mAb-E analyzed by SEC after incubation at 50 C for 0, 2, 
4, 7, 14, and 28 days relative to day zero. Error bars represent one standard deviation for 
duplicate analyses of duplicate vials. Bar charts representing the percentage of soluble, insoluble, 
and total aggregate content in mAb-A and mAb-E after incubation for 28 days at 50 C are 
shown at (B) pH 6.0 and at (C) pH 7.4. 
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Figure 5.3 
 
Effect of the YTE triple mutation on deuterium uptake of six peptide segments from mAb-A and 
mAb-E at (A) pH 6.0, and (B) pH 7.4. Domain location and peptide number of the segment are 
shown in parentheses. The error bars represent one standard deviation from three independent 
experiments.   
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Figure 5.4 
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Differential deuterium uptake at five exposure times for 167 common peptide segments of mAb-
E relative to mAb-A at pH 6.0. Average mass corresponding to each exposure time for each 
segment is calculated based on three independent measurements. The horizontal axes denote the 
ordinal peptide numbers assigned based on peptide midpoints spread in ascending order from the 
N-to-C termini of the heavy chain followed by the light chain of mAb-A or mAb-E. Positive and 
negative vertical bars imply increased or decreased deuterium uptake respectively for a segment 
in mAb-E compared to mAb-A. The dashed lines at ±0.59 Da indicate the 99% confidence limits 
for significant differences. Domain locations shown on the top of the figure are approximate as 
some segments span two neighboring domains. Alternate shades of white and grey in the 
background demarcate domain boundaries. Shades in pink demarcate segments with residues of 
Fc epitopes of Fc-FcRn binding interfaces. The red circles denote segments that contain the YTE 
mutations. Segment locations in the mAb-A/mAb-E sequence corresponding to peptide numbers 
can be found in the Table S1 in the supporting information. 
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Figure 5.5 
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Differential deuterium uptake at five exposure times for 167 common peptide segments of mAb-
E relative to mAb-A at pH 7.4. Refer to the legend for Figure 5.4 for description of the figure.  
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Figure 5.6 
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Effect of the YTE mutation (mAb-E) on the local flexibility of the native mAb (mAb-A) at pH 
6.0 as measured by H/D-MS plotted on the homology models of (A) intact mAb-A and (B) Fc 
domain of mAb-A. Changes in flexibility of particular peptide segments are colored as shown in 
the legend and are derived from the differential exchange data shown in Figure 5.4.  
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Figure 5.7 
 
Calculated intrinsic deuterium exchange rates of three peptide segments of mAb-A and mAb-E 
at pD 6.0 at 25 °C. The segment identity and domain location are shown on top of each graph. 
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Figure 5.S1 
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Peptide map of the (A) Heavy chain and (B) Light chain of mAb-A/mAb-E composed of 167 
common segments covering the primary sequence of 96% of the HC and 92% of the LC. 
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Figure 5.S2 
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Deuterium uptake plots of 167 common segments between mAb-A and mAb-E at pH 6.0. 
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Figure 5.S3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
373 
 
 
 
374 
 
 
 
375 
 
 
 
376 
 
 
 
377 
 
 
 
378 
 
 
 
379 
 
 
 
380 
 
 
 
381 
 
 
 
382 
 
 
 
383 
 
 
 
384 
 
 
 
385 
 
 
 
386 
 
 
 
387 
 
 
 
388 
 
 
 
389 
 
 
 
390 
 
 
 
391 
 
 
 
392 
 
 
 
393 
 
 
Deuterium uptake plots of 167 common segments between mAb-A and mAb-E at pH 7.4. 
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Figure 5.S4  
 
 
Overlaid mass spectra of the two intact mAbs. The black and red traces correspond to mAb-A 
and mAb-E respectively. Both the mAbs were incubated with carboxypeptidase B for two hours 
at room temperature prior to injection into the mass spectrometer. The difference in mass 
between the two mAbs as seen in the figure is due to the YTE mutations. Possible glycosylation 
profiles for both mAbs corresponding to the mass values detected are shown in Table 5.S2. 
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Figure 5.S5 
 
 
Reproducibility of H/D-MS data from our experimental setup as measured from standard 
deviations for the mass increase across all time points and peptides of mAb-B (chapters 3 and 4) 
and mAb-A (chapter 5) from triplicate experiments (run on different days, months and year, N = 
9580). The 99
th
 percentile for standard deviations was 0.42 Da. 
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Chapter 6 
 
Conclusion and future work 
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6.1 Overview 
Monoclonal antibodies (mAbs) and related antibody-based drugs are the largest class of 
biopharmaceuticals in clinical development. These protein drugs experience various types of 
stress during production, processing, shipping and administration and hence are susceptible to 
physical instability ranging from conformational instability, aggregation, low solubility and 
precipitation. Changes in stability of mAbs due to particular types of stress are generally 
monitored by long-term (18-24 months), accelerated and stressed stability studies. Approaches to 
predict the long-term storage stability of proteins have relied on integration of large amounts of 
short term stability data with some success but with certain limitations.
1
 Recent work has shown 
that structural dynamics of mAbs are important for maintaining their stability.
2-5
 Hence changes 
in dynamics may potentially serve as indicators for changes in long term storage stability of 
mAbs. Furthermore, excipients may differentially alter the structural dynamics and physical 
stability of mAbs, as was shown with two different mAbs from the same IgG1 subclass in 
presence of excipients.
6,7
 However, the relation between dynamics and stability of proteins is 
complex,
3
 and not all changes in dynamics will correspond to changes in stability for all mAbs. 
This dissertation explored potential mechanisms of changes in physical stability of IgG1 mAbs 
by examining changes in local backbone dynamics of IgG1 mAbs and correlating the results to 
physical stability changes. Changes in protein physical stability were monitored by biophysical 
techniques such as differential scanning calorimetry (DSC) and aggregation measuring 
techniques such as size exclusion chromatography (SEC). Changes in protein backbone 
dynamics were monitored by hydrogen-deuterium exchange mass spectrometry (H/D-MS). 
6.2 Chapter summaries and future work 
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6.2.1 Chapter 2 
As part of initial H/D-MS method development work for an IgG1 mAb, significant amounts of 
carry-over were observed. Here carry-over indicated elution of peptides in subsequent blank LC-
MS injections after the mAb sample injection. Carry-over arises due to the large number of 
peptides generated by online pepsin digestion of the mAb that are rapidly separated (~ 5 min) at 
low pH (~ 2.5) and 0 °C prior to mass analyses. Carry-over is particularly problematic due to 
back-exchange of deuterated peptides which, when elute during subsequent sample injections, 
give rise to bimodal isotopic distribution, falsely indicating EX1 kinetics.
8
 We identified the 
online pepsin digestion step as the major source of carry-over. An online wash protocol 
consisting of subsequent injections of two wash cocktails was designed that significantly reduced 
carry-over, but at the same time, did not harm the enzymatic activity of the protease. Analysis of 
the physicochemical properties such as mass, pI, hydrophobicity, and MS response could not 
distinguish between carried-over and non-carried over peptides. 
Other acidic proteases
9
 may also give rise to carry-over during H/D-MS experiments if 
immobilized on a column. Hence similar studies as described in this chapter may be required to 
explore carry-over in other protease columns for H/D-MS. Moreover, it will be interesting to 
explore if other IgG1 mAbs and other classes of IgG mAbs (IgG 2 or IgG4) are also prone to 
carry-over problems during typical H/D-MS experiments. 
6.2.2 Chapter 3 
This chapter explores the effects of two excipients (arginine and sucrose) on the thermal stability 
(Tonset and Tm by DSC), aggregation propensity under accelerated as well as long-term storage 
conditions (SEC), and local backbone dynamics (H/D-MS) of an IgG1 mAb. Changes in 
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physical stability were then compared with changes in dynamics of local segments of the mAb. 
Sucrose increased the thermal stability of the mAb, decreased mAb monomer loss, and caused a 
global trend of small decreases in backbone dynamics. Although most of the decreases in 
backbone dynamics were less than significant, these overall trends are consistent with earlier 
observations on the preferential hydration mechanism of sucrose induced stabilization of 
proteins.
10
 Arginine decreased the thermal stability of the mAb most notably for the CH2 domain, 
accelerated the loss of mAb monomer and formation of soluble and insoluble aggregates during 
storage at elevated temperature, and increased backbone dynamics of few specific segments of 
the mAb most notably in the CH2 domain. Results from Chapter 4 below also showed physical 
destabilization of the same IgG1 mAb as well as significantly increased dynamics of specific 
segments (241-252 and 300-306) in the CH2 domain caused by sodium thiocyanate. Hence, 
decreased conformational stability of the CH2 domain in presence of arginine correlated with 
increased dynamics of a specific aggregation hotspot segment, 241-252 of the heavy chain in the 
CH2 domain of the mAb. However, sucrose had no effect on the dynamics of this segment of the 
CH2 domain. These results indicate that change in dynamics of specific sequences in the CH2 
domain of a mAb induced by destabilizing excipients may dictate its overall physical stability of 
at least some percentage of IgG1 mAbs.  
Arginine is generally included in protein formulations to improve efficiency of protein refolding 
and to decrease aggregation.
11,12
 Although in this study, arginine caused increased aggregation of 
the mAb stored at a high temperature, it will be interesting to explore arginine effects on a mAb 
due to other forms of stress such as agitation, freeze-thaw, etc. It will also be interesting to 
confirm if arginine cause similar effects in terms of changes in dynamics and stability of the 
constant domains in other IgG1 mAbs under heat stress.  
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No significant changes were observed in local dynamics of the IgG1 mAb at three different 
concentrations (0.5, 1.0, and 1.35 M) of arginine and sucrose compared to a 0.1 M sodium 
chloride control as described in chapters 3 and 4.  It will be interesting to repeat this experiment 
with arginine and sucrose concentration in the 0 - 0.5 M concentration range, to explore if the 
results are similar or different than what are discussed in Chapter 3. 
Experiments to explore the effects of a wide variety of additives, selected from the different 
classes of pharmaceutical excipients, on the local dynamics of key segments in the CH2 domain 
and the variable domains including the CDR motifs, of an IgG1 mAb using pulsed H/D exchange 
mass spectrometry experiments (at one or two exchange times in a high throughput fashion) is in 
progress in the laboratory. The results will be compared with changes in conformational stability, 
aggregation propensity and types of aggregates formed under identical formulation conditions. 
Such experiments can potentially indicate if H/D-MS can be used a predictive tool in a high 
throughput manner to screen for stabilizing excipients for specific mAbs. 
This work explored changes in only the physical stability of the mAb. However, mAbs are also 
known to degrade due to various different types of chemical degradation pathways. Hence, 
changes in chemical stability of monoclonal antibodies may be explored upon long-term storage 
and/or stressed conditions in a variety of excipient and salt containing liquid formulations. The 
observed changes in chemical stability of specific amino acid residues may be compared with 
changes in local dynamics of the same residues within the intact mAb using H/D-MS in the same 
formulation conditions. This future work may help better explain and understand the inter-
relationships between changes in protein higher order structure and protein instability from a 
local dynamics, chemical and physical stability perspective. 
6.2.3 Chapter 4 
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This chapter explores the effects of three sodium salts from the Hofmeister series (sulfate, 
chloride, and thiocyanate) on the physical stability and backbone dynamics of an IgG1 mAb. 
Physical stability of the mAb was tested in formulations containing 0.5 M of the different salts. 
Sulfate increased the thermal stability of the mAb as measured by DSC, decreased mAb 
monomer loss, and increased local dynamics of several segments in the Fab and the CH3 domain 
compared to 0.1 M sodium chloride control. In comparison to the control, 0.5 M chloride caused 
similar changes in physical stability, and small, uniform decreases in dynamics across all 
segments of the mAb. The small decreases in dynamics in presence of 0.5 M sodium chloride 
were not statistically significant, but showed a global trend similar to what was observed with 
sucrose as described above. In contrast, thiocyanate decreased the thermal stability of the mAb, 
accelerated mAb monomer loss, resulted in formation of insoluble aggregates, and increased 
local dynamics of multiple segments across all domains of the mAb. Effects of thiocyanate were 
most pronounced on the CH2 domain. Thiocyanate decreased the thermal unfolding transition 
temperature of the CH2 domain by 9 °C, and caused the highest increases in dynamics in two 
segments HC 241-252 and HC 300-306 of the CH2 domain. As discussed in Chapter 3, physical 
destabilization of the IgG1 mAb induced by arginine correlated with increased dynamics of the 
241-252 segment of the heavy chain in the CH2 domain. Hence, thiocyanate induced 
destabilization of the IgG1 mAb correlated with increased dynamics of the same apolar segment 
HC 241-252, further supporting that this segment may act as a hotspot initiating aggregation 
events in this IgG1 mAb. On the contrary, sulfate induced changes in local dynamics had no 
similarities with changes in dynamics observed in presence of sucrose as outlined in Chapter 3. 
Moreover, sulfate and thiocyanate increased the backbone dynamics of several common 
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segments in the Fab and CH3 domains. Such observations further highlight the complex 
interrelationships between stability and dynamics of proteins.
3
   
These results indicate that dynamics of specific segments may dictate overall physical stability of 
a multi-domain protein such as a mAb. Correlation between physical stability of the mAb and 
dynamics for specific segments may not only help to better understand how salts may destabilize 
proteins, but may help predict changes in long-term stability induced by various salts depending 
upon their effects on local dynamics of hotspot sequences.  
Molecular dynamics simulations of an IgG1 mAb in presence of the different anions may 
provide further mechanistic insights into anion induced stability changes in mAbs and thus could 
complement the experimental results from H/D-MS experiments as discussed in this work. 
Moreover, anion induced effects on the dynamics and stability of other IgG1 mAbs as well as 
other subclasses of mAbs (IgG2, and IgG4) may further unravel the universality of sequence 
specificity of aggregation hotspots across different mAbs.  
6.2.4 Chapter 5 
YTE mutations (S255Y/S257T/T259E) in the CH2 domain of an IgG1 mAb  have been shown 
previously to increase in-vivo half-life by 4 fold, FcRn binding by 10 fold, and tissue 
bioavailability by 4 fold in non-human primates,
13
 but marginally decreased the physical stability 
of the mAb.
14
 This chapter explored the nature of relative differences in physical stability 
between an IgG1 mAb and its YTE mutant by examining changes in thermal stability by DSC, 
changes in aggregation propensity under accelerated conditions measured by SEC, and changes 
in backbone dynamics measured by H/D-MS at pH 6.0 and 7.4. The YTE mutation decreased the 
thermal unfolding temperature of the CH2 domain only, and increased aggregation propensity of 
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the mAb when tested under accelerated storage conditions. The YTE mutation induced changes 
in backbone dynamics at few local segments away from the mutation sites as well as away from 
the FcRn binding sites. The highest magnitude of increase in local backbone dynamics was 
detected for the 244-255 segment of the heavy chain in the CH2 domain. Increased dynamics of 
this particular segment has been shown to correlate with arginine and thiocyanate induced 
destabilization of an IgG1 mAb in Chapters 3 and 4 respectively of this thesis, as well as 
destabilization of IgG1 mAbs due to deglycosylation,
15
 and methionine oxidation
16-18
. In this 
study, increased dynamics of the 244-255 segment in the CH2 domain correlates with decreased 
thermal stability of the CH2 domain, and higher aggregation propensity induced by the YTE 
mutation. Hence this study provides mechanistic insights on the physical destabilization of an 
IgG1 mAb due to YTE mutations.  
The results from this chapter as well as Chapters 3 and 4 suggest that the possible mechanism for 
changes in physical stability of the mAbs examined in this thesis is by disruption in packing of 
the heterogeneous glycan structures within a key hydrophobic segment in the CH2 domain of the 
mAb. As a continuation of this research, the nature of interactions between glycan chains and 
segments of the CH2 domain can be explored to gain more mechanistic insights into changes in 
physical stability of mAbs. To serve this purpose, Fc proteins with well-defined homogenous 
glycan structures are being produced in various ways by enzymatic treatments. The changes in 
local dynamics due to changes in glycan structures can then be explored using H/D exchange 
mass spectrometry and compared to changes in physical stability of the Fc glycoproteins. This 
approach is currently being tested in our laboratory. 
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